MAPK/ERK Pathway Protein Tyrosine Kinase/RTK Autophagy Apoptosis Stem Cell/Wnt JAK/STAT Signaling PI3K/Akt/mTOR Metabolic Enzyme/Protease Cytoskeleton Epigenetics Cell Cycle/DNA Damage
Raf VEGFR FLT3 Autophagy Apoptosis STAT Akt MMP Cadherin p38 MAPK ERK MEK PI3K PARP Bcl-2 Family
Sorafenib

Art. -Nr.: HY-10201

Sorafenib

(Synonyms: Bay 43-9006)

292 Cited Publications

Kundenbewertung

Based on 292 publication(s) in Google Scholar

Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.84%
CAS. Nr.: 284461-73-0
Formel: C₂₁H₁₆ClF₃N₄O₃
Molecular Weight:464.83

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Sorafenib Chemical Structure

CAS. Nr.: 284461-73-0

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (292)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]^[3]^[5]

VEGFR3

20 nM (IC₅₀)

Braf

22 nM (IC₅₀)

Raf-1

6 nM (IC₅₀)

VEGFR2

15 nM (IC₅₀)

Braf^V599E

38 nM (IC₅₀)

STAT3

MMP2

Bcl-xL

Bcl-2

Alle Raf Isoform-spezifische Produkte anzeigen :

Alle VEGFR Isoform-spezifische Produkte anzeigen :

Alle STAT Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

Alle MMP Isoform-spezifische Produkte anzeigen :

Alle p38 MAPK Isoform-spezifische Produkte anzeigen :

Alle ERK Isoform-spezifische Produkte anzeigen :

Alle MEK Isoform-spezifische Produkte anzeigen :

Alle PI3K Isoform-spezifische Produkte anzeigen :

Alle PARP Isoform-spezifische Produkte anzeigen :

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	GI₅₀	3.16 μM Compound: 1	Cytotoxicity against human 786-0 cells after 48 hrs by SRB method Cytotoxicity against human 786-0 cells after 48 hrs by SRB method	[PMID: 26590508]
786-0	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
786-0	GI₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
786-0	IC₅₀	4.9 μM Compound: Sorafenib	Cytotoxicity against human 786-O cells after 72 hrs by CCK8 assay Cytotoxicity against human 786-O cells after 72 hrs by CCK8 assay	[PMID: 29297688]
786-0	IC₅₀	4.9 μM Compound: Sorafenib	Cytotoxicity against human 786-O cells after 72 hrs by CCK-8 assay Cytotoxicity against human 786-O cells after 72 hrs by CCK-8 assay	[PMID: 29517908]
786-0	IC₅₀	5.3 μM Compound: Sorafenib	Cytotoxicity against human 786-O cells after 72 hrs by CCK8 assay Cytotoxicity against human 786-O cells after 72 hrs by CCK8 assay	[PMID: 29786436]
786-0	IC₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
786-0	IC₅₀	13 μM Compound: Sora	Cytotoxicity against human 786-O cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay Cytotoxicity against human 786-O cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay	[PMID: 31298537]
786-0	IC₅₀	15.62 μM Compound: Sorafenib	Cytotoxicity against human 786-0 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human 786-0 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
786-0	GI₅₀	3.16 μM Compound: Sorafenib	Anticancer activity against human 786-0 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human 786-0 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
786-0	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human 786-0 cells measured after 48 hrs by SRB assay Antiproliferative activity against human 786-0 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
786-0	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human 786-0 cells assessed as cell growth inhibition Antiproliferative activity against human 786-0 cells assessed as cell growth inhibition	[PMID: 38850857]
8505C	IC₅₀	4.7 μM Compound: Sorafenib	Antiproliferative activity against human 8505C cells after 48 hrs by MTT assay Antiproliferative activity against human 8505C cells after 48 hrs by MTT assay	[PMID: 29032031]
A2058	IC₅₀	3.8 μM Compound: sorafenib	Cytotoxicity against human A2058 cells after 48 hrs by MTT assay Cytotoxicity against human A2058 cells after 48 hrs by MTT assay	[PMID: 22708987]
A-375	IC₅₀	5.4 μM Compound: sorafenib	Antiproliferative activity against human A375 cells after 48 hrs by SRB assay Antiproliferative activity against human A375 cells after 48 hrs by SRB assay	[PMID: 18477505]
A-375	IC₅₀	5.58 μM Compound: Sorafenib	Antiproliferative activity against human A375 cells by MTT assay Antiproliferative activity against human A375 cells by MTT assay	[PMID: 19464887]
A-375	IC₅₀	2200 nM Compound: Sorafenib	Toxicity against human A375 cells after 72 hrs by cell titer-blue assay Toxicity against human A375 cells after 72 hrs by cell titer-blue assay	[PMID: 19654408]
A-375	IC₅₀	5.4 μM Compound: Sorafenib	Antiproliferative activity against human A375 cells after 48 hrs by SRB assay Antiproliferative activity against human A375 cells after 48 hrs by SRB assay	[PMID: 20056548]
A-375	IC₅₀	5.6 μM Compound: Sorafenib, Nexavar	Antiproliferation activity against human A375P cells after 48 hrs by MTT assay in presence of fetal bovine serum Antiproliferation activity against human A375P cells after 48 hrs by MTT assay in presence of fetal bovine serum	[PMID: 21592628]
A-375	IC₅₀	6599 nM Compound: 1, Nexavar	Inhibition of BRAF V600E mutant-dependent MEK phosphorylation in A375 cells Inhibition of BRAF V600E mutant-dependent MEK phosphorylation in A375 cells	[PMID: 21807507]
A-375	IC₅₀	2.4 μM Compound: 1	Antiproliferative activity against human A375 cells expressing B-Raf V600E mutant and wild type Ras Antiproliferative activity against human A375 cells expressing B-Raf V600E mutant and wild type Ras	[PMID: 22808911]
A-375	IC₅₀	7.56 μM Compound: Sorafenib	Cytotoxicity against human A375 cells after 72 hrs by MTT assay Cytotoxicity against human A375 cells after 72 hrs by MTT assay	[PMID: 24215818]
A-375	IC₅₀	9.17 μM Compound: Sorafenib	Cytotoxicity against human A375 cells assessed as growth inhibition after 120 hrs by MTT assay Cytotoxicity against human A375 cells assessed as growth inhibition after 120 hrs by MTT assay	[PMID: 24675135]
A-375	IC₅₀	16.24 μM Compound: Sorafenib	Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 25461318]
A-375	IC₅₀	13.64 μM Compound: 3	Antiproliferative activity against human A375 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A375 cells after 72 hrs by CCK8 assay	[PMID: 25462267]
A-375	IC₅₀	13.64 μM Compound: Sorafenib	Antiproliferative activity human A375 cells after 72 hrs by cell titer-glo luminescence assay Antiproliferative activity human A375 cells after 72 hrs by cell titer-glo luminescence assay	[PMID: 28242553]
A-375	IC₅₀	3.36 μM Compound: Sorafenib	Antiproliferative activity against human A375 cells harboring BRAF V600E mutant after 48 hrs by MTT assay Antiproliferative activity against human A375 cells harboring BRAF V600E mutant after 48 hrs by MTT assay	[PMID: 29602674]
A-375	IC₅₀	8.33 μM Compound: Sorafenib	Antiproliferative activity against human A375 cells harboring BRAF V600E mutant after 72 hrs by MTT assay Antiproliferative activity against human A375 cells harboring BRAF V600E mutant after 72 hrs by MTT assay	[PMID: 29886324]
A-375	IC₅₀	8.27 μM Compound: 1	Antiproliferative activity against human A375 cells Antiproliferative activity against human A375 cells	[PMID: 30216849]
A-375	IC₅₀	13.6 μM Compound: Sorafenib	Antiproliferative activity against human A375 cells after 72 hrs by Cell-Titer Glo assay Antiproliferative activity against human A375 cells after 72 hrs by Cell-Titer Glo assay	[PMID: 30529543]
A-375	IC₅₀	7.88 μM Compound: Sorafenib	Cytotoxicity against human A-375 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A-375 cells assessed as reduction in cell viability by MTT assay	[PMID: 30955995]
A-375	IC₅₀	1.95 μM Compound: Sorafenib	Antiproliferative activity against human A375 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A375 cells measured after 48 hrs by MTT assay	[PMID: 33316752]
A-375	IC₅₀	10.28 μM Compound: Sorafenib	Cytotoxicity against human A-375 cells by MTT assay Cytotoxicity against human A-375 cells by MTT assay	[PMID: 33316752]
A-375	IC₅₀	1.8 μM Compound: Sorafenib	Cytotoxicity against human A-375 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human A-375 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38354306]
A375P	IC₅₀	95 nM Compound: Sorafenib	Cytotoxicity against human A375P cells Cytotoxicity against human A375P cells	[PMID: 31923860]
A375P	IC₅₀	5.6 μM Compound: Sorafenib	Antiproliferative activity against human A375P cells Antiproliferative activity against human A375P cells	[PMID: 31926469]
A-431	IC₅₀	10.46 μM Compound: Sorafenib	Antiproliferative activity against human A431 cells after 48 hrs by MTT assay Antiproliferative activity against human A431 cells after 48 hrs by MTT assay	[PMID: 29032031]
A-431	IC₅₀	0.12 μM Compound: Sorafenib	Antiproliferative activity against human A431 cells Antiproliferative activity against human A431 cells	[PMID: 30503935]
A-431	IC₅₀	3.32 μM Compound: Sorafenib	Antiproliferative activity against human A431 cells after 48 hrs by MTT assay Antiproliferative activity against human A431 cells after 48 hrs by MTT assay	[PMID: 30616052]
A498	GI₅₀	2.51 μM Compound: 1	Cytotoxicity against human A498 cells after 48 hrs by SRB method Cytotoxicity against human A498 cells after 48 hrs by SRB method	[PMID: 26590508]
A498	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human A498 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human A498 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
A498	GI₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
A498	IC₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
A498	GI₅₀	2.51 μM Compound: Sorafenib	Anticancer activity against human A498 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human A498 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
A498	IC₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human A498 cells measured after 48 hrs by SRB assay Antiproliferative activity against human A498 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
A549	IC₅₀	5.21 μM Compound: Sorafenib	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT based WST-8 assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT based WST-8 assay	[PMID: 20181414]
A549	IC₅₀	4.5 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells assessed as growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 23260578]
A549	IC₅₀	4 μM Compound: Sorafenib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 23454017]
A549	IC₅₀	12.54 μM Compound: Sorafenib, BAY 43-9006	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 23644219]
A549	IC₅₀	27.71 μM Compound: Sorafenib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 23871909]
A549	IC₅₀	1.92 μM Compound: Sorafenib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 24826815]
A549	IC₅₀	3.19 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay	[PMID: 25778995]
A549	IC₅₀	0.63 μM Compound: Sorafenib	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25982075]
A549	IC₅₀	1.45 μM Compound: BAY-43-9006	Antiproliferative activity against human A549 cells assessed as cell growth inhibition after after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition after after 48 hrs by MTT assay	[PMID: 26342134]
A549	IC₅₀	13.64 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 26560049]
A549	GI₅₀	3.16 μM Compound: 1	Cytotoxicity against human A549 cells after 48 hrs by SRB method Cytotoxicity against human A549 cells after 48 hrs by SRB method	[PMID: 26590508]
A549	IC₅₀	2.02 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26753815]
A549	EC₅₀	>1000 nM Compound: Sorafenib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 27010810]
A549	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human A549/ATCC cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human A549/ATCC cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
A549	IC₅₀	6.53 μM Compound: Sorafenib	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27043268]
A549	IC₅₀	19.54 μM Compound: Sorafenib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 27162123]
A549	IC₅₀	2.92 μM Compound: Sorafenib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 27777009]
A549	GI₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
A549	IC₅₀	6.53 μM Compound: Sorafenib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 28340913]
A549	IC₅₀	6.7 μM Compound: Sorafenib	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 28865276]
A549	IC₅₀	2.92 μM Compound: Sorafenib	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28927801]
A549	IC₅₀	3.1 μM Compound: Sorafenib	Growth inhibition of human A549 cells after 48 hrs by MTT assay Growth inhibition of human A549 cells after 48 hrs by MTT assay	[PMID: 29102175]
A549	IC₅₀	3.779 μg/mL Compound: Sorafenib	Antiproliferative activity against human A549 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 96 hrs by MTT assay	[PMID: 29395969]
A549	IC₅₀	6.21 μM Compound: Sorafenib	Anticancer activity against human A549 cells assessed as reduction in cell viability after 96 hrs by MTT assay Anticancer activity against human A549 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 29549841]
A549	IC₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
A549	IC₅₀	19.3 μM Compound: Sorafenib	Antiproliferative activity against VEGF-stimulated human A549 cells after 48 hrs by CCK8 assay Antiproliferative activity against VEGF-stimulated human A549 cells after 48 hrs by CCK8 assay	[PMID: 30108994]
A549	IC₅₀	27 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 30502686]
A549	IC₅₀	0.08 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 30503935]
A549	IC₅₀	6.11 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 30503942]
A549	IC₅₀	3.88 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30616052]
A549	IC₅₀	0.75 μM Compound: Sorafenib	Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30826508]
A549	IC₅₀	180 nM Compound: Sorafenib	Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method	[PMID: 30826508]
A549	IC₅₀	5.53 μM Compound: Sorafenib	Induction of apoptosis in human A549 cells assessed as reduction in MCL-1 protein level after 2 hrs by sandwich ELISA method Induction of apoptosis in human A549 cells assessed as reduction in MCL-1 protein level after 2 hrs by sandwich ELISA method	[PMID: 30826508]
A549	IC₅₀	27 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells incubated for 2 days by MTT assay Antiproliferative activity against human A549 cells incubated for 2 days by MTT assay	[PMID: 30878834]
A549	IC₅₀	7.62 μM Compound: C1	Antiproliferative activity against human A549 cells expressing EGFR assessed as reduction in cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells expressing EGFR assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 31252306]
A549	IC₅₀	25.671 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 31488358]
A549	IC₅₀	8.1 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells expressing EGFR assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells expressing EGFR assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31668972]
A549	IC₅₀	7.43 μM Compound: Sorafenib	Antiproliferative activity against human A549 assessed as inhibition of cell growth measured after 72 hrs by plate reader assay Antiproliferative activity against human A549 assessed as inhibition of cell growth measured after 72 hrs by plate reader assay	[PMID: 32422489]
A549	IC₅₀	11.24 mM Compound: Sorafenib	Anticancer activity against human A549 cells after 48 hrs by MTT assay Anticancer activity against human A549 cells after 48 hrs by MTT assay	[PMID: 32631569]
A549	IC₅₀	5.62 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 32663641]
A549	IC₅₀	4.47 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32739648]
A549	IC₅₀	1.25 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 33129590]
A549	IC₅₀	6.83 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 33423463]
A549	IC₅₀	5.13 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 33493829]
A549	GI₅₀	4.1 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay	[PMID: 34147745]
A549	IC₅₀	10.7 μM Compound: Sorafenib	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
A549	IC₅₀	5 μM Compound: 1	Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34634618]
A549	IC₅₀	64.9 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
A549	GI₅₀	3.16 μM Compound: Sorafenib	Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
A549	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells measured after 48 hrs by SRB assay Antiproliferative activity against human A549 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
A549	IC₅₀	2.9 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36324492]
A549	IC₅₀	8.26 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 37216813]
A549	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human A549 cells assessed as cell growth inhibition Antiproliferative activity against human A549 cells assessed as cell growth inhibition	[PMID: 38850857]
A549	IC₅₀	7.46 μM Compound: Sorafenib	Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 38894896]
A549	IC₅₀	6.08 μM Compound: Sorafenib	Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition after 48 hr by MTT assay	10.1007/s00044-012-0398-y
A549	IC₅₀	5.231 μM Compound: Sorafenib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	10.1039/C2MD20275A
A549	IC₅₀	3.36 μM Compound: BAY-93-4006	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	10.1039/C3MD00192J
ACHN	GI₅₀	3.16 μM Compound: 1	Cytotoxicity against human ACHN cells after 48 hrs by SRB method Cytotoxicity against human ACHN cells after 48 hrs by SRB method	[PMID: 26590508]
ACHN	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human ACHN cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human ACHN cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
ACHN	GI₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
ACHN	IC₅₀	3.4 μM Compound: Sorafenib	Cytotoxicity against human ACHN cells after 72 hrs by CCK8 assay Cytotoxicity against human ACHN cells after 72 hrs by CCK8 assay	[PMID: 29297688]
ACHN	IC₅₀	3.4 μM Compound: Sorafenib	Cytotoxicity against human ACHN cells after 72 hrs by CCK-8 assay Cytotoxicity against human ACHN cells after 72 hrs by CCK-8 assay	[PMID: 29517908]
ACHN	IC₅₀	3.5 μM Compound: Sorafenib	Cytotoxicity against human ACHN cells after 72 hrs by CCK8 assay Cytotoxicity against human ACHN cells after 72 hrs by CCK8 assay	[PMID: 29786436]
ACHN	IC₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
ACHN	IC₅₀	3.3 μM Compound: Sora	Cytotoxicity against human ACHN cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay Cytotoxicity against human ACHN cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay	[PMID: 31298537]
ACHN	GI₅₀	2.51 μM Compound: Sorafenib	Anticancer activity against human ACHN cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human ACHN cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
ACHN	IC₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human ACHN cells measured after 48 hrs by SRB assay Antiproliferative activity against human ACHN cells measured after 48 hrs by SRB assay	[PMID: 35764033]
B16	IC₅₀	9.29 μM Compound: Sorafenib	Antiproliferative activity against mouse B16 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against mouse B16 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37453330]
B16-BL6	IC₅₀	36.48 μM Compound: Sorafenib	Cytotoxicity against mouse B16-BL6 cells after 48 hrs by MTT assay Cytotoxicity against mouse B16-BL6 cells after 48 hrs by MTT assay	[PMID: 29631788]
B16-F1	IC₅₀	4.9 μM Compound: sorafenib	Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay	[PMID: 18477505]
B16-F1	IC₅₀	4.9 μM Compound: Sorafenib	Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay	[PMID: 20056548]
BaF3	IC₅₀	>10 μM Compound: Sorafenib	Antiproliferative activity against mouse BaF3 cells assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	IC₅₀	0.012 μM Compound: Sorafenib	Antiproliferative activity against mouse BaF3 cells expressing FLT3-ITD assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing FLT3-ITD assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	IC₅₀	0.013 μM Compound: Sorafenib	Antiproliferative activity against mouse BaF3 cells expressing Tel-PDGFRbeta assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing Tel-PDGFRbeta assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	IC₅₀	0.014 μM Compound: Sorafenib	Antiproliferative activity against mouse BaF3 cells expressing Tel-KDR-myc1.3 assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing Tel-KDR-myc1.3 assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	IC₅₀	0.078 μM Compound: Sorafenib	Antiproliferative activity against mouse BaF3 cells expressing PTC3-RET assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing PTC3-RET assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	IC₅₀	1.015 μM Compound: Sorafenib	Antiproliferative activity against mouse BaF3 cells expressing NPM-ALK assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing NPM-ALK assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	IC₅₀	2.458 μM Compound: Sorafenib	Antiproliferative activity against mouse BaF3 cells expressing Tel-FGFR3 assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing Tel-FGFR3 assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	IC₅₀	2.804 μM Compound: Sorafenib	Antiproliferative activity against mouse BaF3 cells expressing KIT D816V mutant assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing KIT D816V mutant assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	IC₅₀	3.681 μM Compound: Sorafenib	Antiproliferative activity against mouse BaF3 cells expressing Tel-IGF-1R assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing Tel-IGF-1R assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	IC₅₀	4.208 μM Compound: Sorafenib	Antiproliferative activity against mouse BaF3 cells expressing ERBB2 V659E mutant assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing ERBB2 V659E mutant assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	IC₅₀	5.82 μM Compound: Sorafenib	Antiproliferative activity against mouse BaF3 cells expressing Bcr-ABL assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing Bcr-ABL assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	IC₅₀	7.4 μM Compound: Sorafenib	Antiproliferative activity against mouse BaF3 cells expressing Trp-MET assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing Trp-MET assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	GI₅₀	0.23 μM Compound: Sorafenib	Growth inhibition of mouse BaF3 cells over expressing wild type RET incubated for 3 days by MTT assay Growth inhibition of mouse BaF3 cells over expressing wild type RET incubated for 3 days by MTT assay	[PMID: 29133048]
BaF3	GI₅₀	1.1 μM Compound: Sorafenib	Growth inhibition of mouse BaF3 cells harboring RET V804M mutant incubated for 3 days by MTT assay Growth inhibition of mouse BaF3 cells harboring RET V804M mutant incubated for 3 days by MTT assay	[PMID: 29133048]
BaF3	GI₅₀	1.28 μM Compound: Sorafenib	Growth inhibition of mouse BaF3 cells harboring RET M918T mutant incubated for 3 days by MTT assay Growth inhibition of mouse BaF3 cells harboring RET M918T mutant incubated for 3 days by MTT assay	[PMID: 29133048]
BaF3	GI₅₀	1.8 μM Compound: Sorafenib	Growth inhibition of mouse BaF3 cells harboring RET V804L mutant incubated for 3 days by MTT assay Growth inhibition of mouse BaF3 cells harboring RET V804L mutant incubated for 3 days by MTT assay	[PMID: 29133048]
BaF3	GI₅₀	6.36 μM Compound: Sorafenib	Growth inhibition of mouse BaF3 cells incubated for 3 days by MTT assay Growth inhibition of mouse BaF3 cells incubated for 3 days by MTT assay	[PMID: 29133048]
BaF3	IC₅₀	0.006 μM Compound: Sorafenib	Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD mutant measured after 72 hrs by Celltiter-Glo assay Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD mutant measured after 72 hrs by Celltiter-Glo assay	[PMID: 31103903]
BaF3	IC₅₀	1.112 μM Compound: Sorafenib	Growth inhibition of mouse BAF3 cells transformed with FLT3 D835V mutant measured after 72 hrs by Celltiter-Glo assay Growth inhibition of mouse BAF3 cells transformed with FLT3 D835V mutant measured after 72 hrs by Celltiter-Glo assay	[PMID: 31103903]
BaF3	IC₅₀	1.348 μM Compound: Sorafenib	Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD/F691L double mutant measured after 72 hrs by Celltiter-Glo assay Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD/F691L double mutant measured after 72 hrs by Celltiter-Glo assay	[PMID: 31103903]
BaF3	IC₅₀	1.454 μM Compound: Sorafenib	Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD/D835V double mutant measured after 72 hrs by Celltiter-Glo assay Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD/D835V double mutant measured after 72 hrs by Celltiter-Glo assay	[PMID: 31103903]
BaF3	IC₅₀	7.997 μM Compound: Sorafenib	Growth inhibition of mouse BAF3 cells measured after 72 hrs by Celltiter-Glo assay Growth inhibition of mouse BAF3 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31103903]
BaF3	GI₅₀	1542 nM Compound: Sorafenib	Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691L mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691L mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
BaF3	GI₅₀	2.8 nM Compound: Sorafenib	Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
BaF3	GI₅₀	206.2 nM Compound: Sorafenib	Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
BaF3	GI₅₀	2637 nM Compound: Sorafenib	Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691I mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691I mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
BaF3	GI₅₀	5417 nM Compound: Sorafenib	Antiproliferative activity against mouse Ba/F3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse Ba/F3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
BaF3	GI₅₀	56.5 nM Compound: Sorafenib	Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
BCPAP	IC₅₀	6.7 μM Compound: Sorafenib	Antiproliferative activity against human BCPAP cells after 48 hrs by MTT assay Antiproliferative activity against human BCPAP cells after 48 hrs by MTT assay	[PMID: 29032031]
BEAS-2B	IC₅₀	31.6 μM Compound: Sorafenib	Cytotoxicity against human BEAS-2B cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human BEAS-2B cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38354306]
Bel-7402	IC₅₀	10.26 μM Compound: sorafenib	Cytotoxicity against human Bel7402 cells after 48 hrs by MTT based ELISA Cytotoxicity against human Bel7402 cells after 48 hrs by MTT based ELISA	[PMID: 21504204]
Bel-7402	IC₅₀	5.8 μM Compound: Sorafenib	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 23454017]
Bel-7402	IC₅₀	10.31 μM Compound: Sorafenib	Growth inhibition of human Bel7402 cells after 48 hrs by MTT assay Growth inhibition of human Bel7402 cells after 48 hrs by MTT assay	[PMID: 29102175]
Bel-7402	IC₅₀	10.87 μM Compound: Cpd S	Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32827851]
Bel-7402	IC₅₀	6.03 μM Compound: Sorafenib	Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35525080]
Bel-7402	IC₅₀	4.2 μM Compound: Sorafenib	Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36324492]
Bel7402/5-FU	IC₅₀	13.31 μM Compound: Sorafenib	Antiproliferative activity against human BEL-7402/5-FU cells overexpressing 14-3-3 eta assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human BEL-7402/5-FU cells overexpressing 14-3-3 eta assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35525080]
BEL-7404 tumor cell line	IC₅₀	92 μM Compound: Sorafenib	Antiproliferative activity against human BEL-7404 tumor cell line assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human BEL-7404 tumor cell line assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 30114660]
BGC-823	IC₅₀	10.91 μM Compound: Sorafenib	Antiproliferative activity against human BGC823 cells after 72 hrs by MTT assay Antiproliferative activity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 22721924]
BGC-823	IC₅₀	3 μM Compound: Sorafenib	Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36324492]
BMDM	IC₅₀	164 nM Compound: Sorafenib	Inhibition of CSF-1-induced C57BL6 mouse BMDM cell growth preincubated for 1 hr followed by CSF-1 addition and measured after 5 hrs by alamar blue assay Inhibition of CSF-1-induced C57BL6 mouse BMDM cell growth preincubated for 1 hr followed by CSF-1 addition and measured after 5 hrs by alamar blue assay	[PMID: 38850857]
BT-549	GI₅₀	3.16 μM Compound: 1	Cytotoxicity against human BT549 cells after 48 hrs by SRB method Cytotoxicity against human BT549 cells after 48 hrs by SRB method	[PMID: 26590508]
BT-549	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human BT549 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human BT549 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
BT-549	GI₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
BT-549	IC₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
BT-549	GI₅₀	3.16 μM Compound: Sorafenib	Anticancer activity against human BT-549 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human BT-549 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
BT-549	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human BT-549 cells measured after 48 hrs by SRB assay Antiproliferative activity against human BT-549 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
BXPC-3	EC₅₀	>1000 nM Compound: Sorafenib	Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 27010810]
C6	IC₅₀	8.17 μM Compound: Sorafenib	Antiproliferative activity against human C6 cells measured after 72 hrs by MTT assay Antiproliferative activity against human C6 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
Caco-2	IC₅₀	1.3 μM Compound: Sorafenib	Cytotoxicity against human Caco-2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human Caco-2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38354306]
CAKI-1	GI₅₀	3.16 μM Compound: 1	Cytotoxicity against human Caki1 cells after 48 hrs by SRB method Cytotoxicity against human Caki1 cells after 48 hrs by SRB method	[PMID: 26590508]
CAKI-1	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human Caki1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human Caki1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
CAKI-1	GI₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
CAKI-1	IC₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
CAKI-1	GI₅₀	3.16 μM Compound: Sorafenib	Anticancer activity against human CAKI-1 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human CAKI-1 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
CAKI-1	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human CAKI-1 cells measured after 48 hrs by SRB assay Antiproliferative activity against human CAKI-1 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
CAKI-1	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human CAKI-1 cells assessed as cell growth inhibition Antiproliferative activity against human CAKI-1 cells assessed as cell growth inhibition	[PMID: 38850857]
CAKI-2	EC₅₀	>1000 nM Compound: Sorafenib	Antiproliferative activity against human Caki2 cells after 72 hrs by MTT assay Antiproliferative activity against human Caki2 cells after 72 hrs by MTT assay	[PMID: 27010810]
CCRF-CEM	GI₅₀	2 μM Compound: 1	Cytotoxicity against human CCRF-CEM cells after 48 hrs by SRB method Cytotoxicity against human CCRF-CEM cells after 48 hrs by SRB method	[PMID: 26590508]
CCRF-CEM	GI₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human CCRF-CEM cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human CCRF-CEM cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
CCRF-CEM	GI₅₀	2 μM Compound: Sorafenib	Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
CCRF-CEM	IC₅₀	2 μM Compound: Sorafenib	Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
CCRF-CEM	GI₅₀	2 μM Compound: Sorafenib	Anticancer activity against human CCRF-CEM cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human CCRF-CEM cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
CCRF-CEM	IC₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human CCRF-CEM cells measured after 48 hrs by SRB assay Antiproliferative activity against human CCRF-CEM cells measured after 48 hrs by SRB assay	[PMID: 35764033]
CCRF-CEM	GI₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition	[PMID: 38850857]
COLO 205	IC₅₀	>3 μM Compound: Sorafenib	Antiproliferative activity against Rb-positive human COLO205 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis Antiproliferative activity against Rb-positive human COLO205 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis	[PMID: 24641103]
COLO 205	IC₅₀	0.87 μM Compound: Sorafenib	Antiproliferative activity against human COLO205 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay Antiproliferative activity against human COLO205 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay	[PMID: 25778995]
COLO 205	GI₅₀	2 μM Compound: 1	Cytotoxicity against human COLO205 cells after 48 hrs by SRB method Cytotoxicity against human COLO205 cells after 48 hrs by SRB method	[PMID: 26590508]
COLO 205	GI₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human COLO205 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human COLO205 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
COLO 205	GI₅₀	1.99 μM Compound: Sorafenib	Antiproliferative activity against human COLO 205 cells assessed as reduction in cell growth Antiproliferative activity against human COLO 205 cells assessed as reduction in cell growth	[PMID: 27155467]
COLO 205	GI₅₀	2 μM Compound: Sorafenib	Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
COLO 205	IC₅₀	7.04 μM Compound: Sorafenib	Antiproliferative activity human COLO205 cells after 72 hrs by cell titer-glo luminescence assay Antiproliferative activity human COLO205 cells after 72 hrs by cell titer-glo luminescence assay	[PMID: 28242553]
COLO 205	IC₅₀	2 μM Compound: Sorafenib	Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
COLO 205	GI₅₀	2 μM Compound: Sorafenib	Anticancer activity against human COLO 205 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human COLO 205 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
COLO 205	IC₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human COLO 205 cells measured after 48 hrs by SRB assay Antiproliferative activity against human COLO 205 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
COLO 205	GI₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human COLO 205 cells assessed as cell growth inhibition Antiproliferative activity against human COLO 205 cells assessed as cell growth inhibition	[PMID: 38850857]
CT26	GI₅₀	14.7 μM Compound: Sorafenib	Antiproliferative activity against mouse CT26 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against mouse CT26 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 36068975]
CT26	GI₅₀	30.2 μM Compound: Sorafenib	Antiproliferative activity against human CT26 cells assessed as cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human CT26 cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 36126227]
CT26	IC₅₀	2.1 μM Compound: Sorafenib	Antiproliferative activity against mouse CT26 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against mouse CT26 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36324492]
DU-145	IC₅₀	5.1 μM Compound: sorafenib	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 22708987]
DU-145	IC₅₀	24.91 μM Compound: Sorafenib	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 23871909]
DU-145	GI₅₀	3.16 μM Compound: 1	Cytotoxicity against human DU145 cells after 48 hrs by SRB method Cytotoxicity against human DU145 cells after 48 hrs by SRB method	[PMID: 26590508]
DU-145	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human DU145 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human DU145 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
DU-145	IC₅₀	24.91 μM Compound: Sorafenib	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 27162123]
DU-145	GI₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
DU-145	IC₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
DU-145	IC₅₀	83.736 μM Compound: Sorafenib	Antiproliferative activity against human DU145 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human DU145 cells incubated for 72 hrs by MTT assay	[PMID: 31488358]
DU-145	IC₅₀	3.16 μM Compound: Sorafenib	Cytotoxicity against human DU-145 cells assessed as reduction in cell viability Cytotoxicity against human DU-145 cells assessed as reduction in cell viability	[PMID: 33316752]
DU-145	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34237622]
DU-145	GI₅₀	3.16 μM Compound: Sorafenib	Anticancer activity against human DU-145 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human DU-145 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
DU-145	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human DU-145 cells measured after 48 hrs by SRB assay Antiproliferative activity against human DU-145 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
DU-145	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition	[PMID: 38850857]
EA.hy 926	IC₅₀	24.36 μM Compound: Sorafenib	Antiproliferative activity against human EAhy926 cells after 48 hrs by MTT assay Antiproliferative activity against human EAhy926 cells after 48 hrs by MTT assay	[PMID: 28068599]
EA.hy 926	IC₅₀	18.52 μM Compound: Sorafenib	Antiangiogenic activity against human EAhy926 cells after 24 hrs by CCK8 assay Antiangiogenic activity against human EAhy926 cells after 24 hrs by CCK8 assay	[PMID: 29032031]
EA.hy 926	IC₅₀	24.36 μM Compound: Sorafenib	Anti-angiogenic activity in human EAhy926 cells as growth inhibition after 24 hrs by CCK-8 assay Anti-angiogenic activity in human EAhy926 cells as growth inhibition after 24 hrs by CCK-8 assay	[PMID: 29102175]
EA.hy 926	IC₅₀	11.74 μM Compound: Sorafenib	Anti-angiogenic activity against human EAhy926 after 24 hrs by CCK-8 assay Anti-angiogenic activity against human EAhy926 after 24 hrs by CCK-8 assay	[PMID: 30503935]
EA.hy 926	IC₅₀	11.74 μM Compound: Sorafenib	Antiproliferative activity against human EAhy926 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay Antiproliferative activity against human EAhy926 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	[PMID: 30616052]
EA.hy 926	IC₅₀	11.02 μM Compound: Sorafenib	Antiproliferative activity against human EA.hy 926 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human EA.hy 926 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36508995]
EJ	IC₅₀	22.9 μM Compound: Sorafenib	Cytotoxicity against human EJ cells after 48 hrs by MTT assay Cytotoxicity against human EJ cells after 48 hrs by MTT assay	[PMID: 24300920]
EKVX	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human EKVX cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human EKVX cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
EKVX	GI₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
EKVX	GI₅₀	2.51 μM Compound: Sorafenib	Anticancer activity against human EKVX cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human EKVX cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
EKVX	IC₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human EKVX cells measured after 48 hrs by SRB assay Antiproliferative activity against human EKVX cells measured after 48 hrs by SRB assay	[PMID: 35764033]
EOL1	IC₅₀	2.3 nM Compound: 4	Antiproliferative activity against human EOL-1 cells by CellTiterGlo assay Antiproliferative activity against human EOL-1 cells by CellTiterGlo assay	10.1039/C1MD00175B
Fibroblast	IC₅₀	15.1 μM Compound: sorafenib, velcade	Antiproliferative activity against human fibroblasts after 48 hrs by SRB assay Antiproliferative activity against human fibroblasts after 48 hrs by SRB assay	[PMID: 17561392]
Fibroblast	IC₅₀	15.1 μM Compound: sorafenib	Antiproliferative activity against fibroblast cells after 48 hrs by SRB assay Antiproliferative activity against fibroblast cells after 48 hrs by SRB assay	[PMID: 18477505]
Fibroblast	IC₅₀	15.1 μM Compound: Sorafenib	Cytotoxicity against human fibroblasts after 48 hrs by SRB assay Cytotoxicity against human fibroblasts after 48 hrs by SRB assay	[PMID: 20056548]
GES1	IC₅₀	15.8 μM Compound: Sorafenib	Cytotoxicity against human GES-1 cells after 48 hrs by MTT assay Cytotoxicity against human GES-1 cells after 48 hrs by MTT assay	[PMID: 23871909]
GES1	IC₅₀	10.68 μM Compound: Sorafenib	Cytotoxicity against human GES-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human GES-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27162123]
GES1	IC₅₀	9.59 μM Compound: Sorafenib	Cytotoxicity against human GES-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human GES-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 33493829]
GES1	GI₅₀	15.9 μM Compound: Sorafenib	Cytotoxicity against human GES1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human GES1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 36068975]
GES1	GI₅₀	28.9 μM Compound: Sorafenib	Cytotoxicity against human GES1 cells assessed as cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human GES1 cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 36126227]
GES1	IC₅₀	9.47 μM Compound: Sorafenib	Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36242985]
H22	IC₅₀	10.72 μM Compound: Sorafenib	Antiproliferative activity against mouse H22 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 method Antiproliferative activity against mouse H22 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 method	[PMID: 38224754]
HCC 2998	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human HCC2998 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HCC2998 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
HCC 2998	GI₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
HCC 2998	IC₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
HCC 2998	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human HCC 2998 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human HCC 2998 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34237622]
HCC 2998	GI₅₀	3.16 μM Compound: Sorafenib	Anticancer activity against human HCC 2998 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human HCC 2998 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
HCC 2998	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human HCC 2998 cells measured after 48 hrs by SRB assay Antiproliferative activity against human HCC 2998 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
HCCLM3	IC₅₀	6.3 μM Compound: Sora	Antiproliferative activity against human HCCLM3 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human HCCLM3 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 38905539]
HCCLM9	IC₅₀	21.07 μM Compound: Sorafenib	Antiproliferative activity against human HCCLM9 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HCCLM9 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
HCCLM9	IC₅₀	3.15 μM Compound: sorafenib	Antiproliferative activity against human HCCLM9 cells treated for 72 hrs by MTT assay Antiproliferative activity against human HCCLM9 cells treated for 72 hrs by MTT assay	[PMID: 35639640]
HCCLM9	IC₅₀	9.21 μM Compound: Sorafenib	Antiproliferative activity against human HCCLM9 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human HCCLM9 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 37182331]
HCT-116	GI₅₀	5.4 μM Compound: BAY-439006	Antiproliferative activity was evaluated using HCT116 cells in WST-1 assay Antiproliferative activity was evaluated using HCT116 cells in WST-1 assay	[PMID: 15225706]
HCT-116	GI₅₀	6.6 μM Compound: BAY-439006	Ability of compound to inhibit anchorage independent colony formation (soft agar growth assay) in HCT116 cells Ability of compound to inhibit anchorage independent colony formation (soft agar growth assay) in HCT116 cells	[PMID: 15225706]
HCT-116	IC₅₀	7.8 μM Compound: Sorafenib	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 22483592]
HCT-116	IC₅₀	2 μM Compound: 1	Antiproliferative activity against human HCT116 cells expressing wild type b-Raf and KRAS mutant Antiproliferative activity against human HCT116 cells expressing wild type b-Raf and KRAS mutant	[PMID: 22808911]
HCT-116	IC₅₀	2.3 μM Compound: Sorafenib	Antiproliferative activity against human HCT116 cells assessed as growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 23260578]
HCT-116	IC₅₀	8.08 μM Compound: Sorafenib, BAY 43-9006	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 23644219]
HCT-116	IC₅₀	5.65 μM Compound: Sorafenib	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 24215818]
HCT-116	IC₅₀	8.08 μM Compound: Sorafenib	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 24440479]
HCT-116	GI₅₀	1.58 μM Compound: 1	Cytotoxicity against human HCT116 cells after 48 hrs by SRB method Cytotoxicity against human HCT116 cells after 48 hrs by SRB method	[PMID: 26590508]
HCT-116	GI₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
HCT-116	GI₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
HCT-116	IC₅₀	23.31 μM Compound: Sorafenib	Antiproliferative activity against wild type BRAF expressing human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against wild type BRAF expressing human HCT116 cells after 48 hrs by MTT assay	[PMID: 29602674]
HCT-116	IC₅₀	8.41 μM Compound: Sorafenib	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29631788]
HCT-116	IC₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
HCT-116	IC₅₀	9.4 μM Compound: 1; BAY-43-9006	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33214036]
HCT-116	GI₅₀	5.42 μM Compound: Sorafenib	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34147745]
HCT-116	IC₅₀	168 μM Compound: Sorafenib	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
HCT-116	IC₅₀	16.12 μM Compound: Sorafenib	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
HCT-116	GI₅₀	1.58 μM Compound: Sorafenib	Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
HCT-116	IC₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human HCT-116 cells measured after 48 hrs by SRB assay Antiproliferative activity against human HCT-116 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
HCT-116	IC₅₀	5.47 μM Compound: SOR	Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay	[PMID: 35964425]
HCT-116	GI₅₀	9 μM Compound: Sorafenib	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 36068975]
HCT-116	GI₅₀	19.8 μM Compound: Sorafenib	Antiproliferative activity against human HCT-116 cells assessed as cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 36126227]
HCT-116	IC₅₀	10.55 μM Compound: Sorafenib	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37453330]
HCT-116	IC₅₀	6.82 μM Compound: Sorafenib	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition	[PMID: 37453330]
HCT-116	GI₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition	[PMID: 38850857]
HCT-116	IC₅₀	7.75 μM Compound: Sorafenib	Cytotoxicity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by MTT assay	10.1007/s00044-012-0400-8
HCT-116	IC₅₀	8.41 μM Compound: Sorafenib	Antiproliferative activity against human HCT116 cells by MTT assay Antiproliferative activity against human HCT116 cells by MTT assay	10.1039/C4MD00536H
HCT-15	GI₅₀	2.51 μM Compound: 1	Cytotoxicity against human HCT15 cells after 48 hrs by SRB method Cytotoxicity against human HCT15 cells after 48 hrs by SRB method	[PMID: 26590508]
HCT-15	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human HCT15 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HCT15 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
HCT-15	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human HCT-15 cells assessed as reduction in cell growth Antiproliferative activity against human HCT-15 cells assessed as reduction in cell growth	[PMID: 27155467]
HCT-15	GI₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
HCT-15	IC₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
HCT-15	GI₅₀	2.51 μM Compound: Sorafenib	Anticancer activity against human HCT-15 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human HCT-15 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
HCT-15	IC₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human HCT-15 cells measured after 48 hrs by SRB assay Antiproliferative activity against human HCT-15 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
HCT-15	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human HCT-15 cells assessed as cell growth inhibition Antiproliferative activity against human HCT-15 cells assessed as cell growth inhibition	[PMID: 38850857]
HEK293	IC₅₀	0.12 μM Compound: Sorafenib	Competitive inhibition of recombinant B-Raf (unknown origin) expressed in HEK293 cells by FRET analysis in presence of ATP Competitive inhibition of recombinant B-Raf (unknown origin) expressed in HEK293 cells by FRET analysis in presence of ATP	[PMID: 26318998]
HEK293	IC₅₀	5 μM Compound: Sorafenib	Antiproliferative activity against HEK293 cells by MTT assay Antiproliferative activity against HEK293 cells by MTT assay	[PMID: 30502686]
HEK293	IC₅₀	5 μM Compound: Sorafenib	Antiproliferative activity against HEK293 cells incubated for 2 days by MTT assay Antiproliferative activity against HEK293 cells incubated for 2 days by MTT assay	[PMID: 30878834]
HEK293	IC₅₀	2.95 μM Compound: Sorafenib	Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 35635929]
HEK-293T	IC₅₀	6.38 μM Compound: Sorafenib	Cytotoxicity against HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36242985]
HeLa	IC₅₀	3.3 μM Compound: BAY-439006	Inhibition of EGF-stimulated Elk1-luciferase reporter assay in HeLa cells Inhibition of EGF-stimulated Elk1-luciferase reporter assay in HeLa cells	[PMID: 15225706]
HeLa	IC₅₀	4.163 μM Compound: Sorafenib	Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23362959]
HeLa	IC₅₀	5.23 μM Compound: Sorafenib	Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26342867]
HeLa	IC₅₀	2.44 μM Compound: Sorafenib	Growth inhibition of human HeLa cells after 48 hrs by MTT assay Growth inhibition of human HeLa cells after 48 hrs by MTT assay	[PMID: 29102175]
HeLa	IC₅₀	12.01 μM Compound: Sorafenib	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29103873]
HeLa	IC₅₀	0.64 μM Compound: Sorafenib	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 30015070]
HeLa	IC₅₀	4.59 μM Compound: Sorafenib	Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay	[PMID: 30108964]
HeLa	IC₅₀	6.1 μM Compound: Sorafenib	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 30502686]
HeLa	IC₅₀	0.27 μM Compound: Sorafenib	Antiproliferative activity against human HeLa cells Antiproliferative activity against human HeLa cells	[PMID: 30503935]
HeLa	IC₅₀	8.74 μM Compound: Sorafenib	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30616052]
HeLa	IC₅₀	6.1 μM Compound: Sorafenib	Antiproliferative activity against human HeLa cells incubated for 2 days by MTT assay Antiproliferative activity against human HeLa cells incubated for 2 days by MTT assay	[PMID: 30878834]
HeLa	IC₅₀	8.04 μM Compound: SOR	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 35964425]
HeLa	IC₅₀	3.31 μM Compound: SFN	Cytotoxicity against human HeLa cells by SRB assay Cytotoxicity against human HeLa cells by SRB assay	[PMID: 36067930]
HeLa	IC₅₀	10.26 μM Compound: Sorafenib	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38422700]
HeLa	IC₅₀	7.68 μM Compound: BAY-93-4006	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	10.1039/C3MD00192J
Hep 3B2	IC₅₀	14.08 μM Compound: sorafenib	Cytotoxicity against human Hep3B cells after 48 hrs by MTT based ELISA Cytotoxicity against human Hep3B cells after 48 hrs by MTT based ELISA	[PMID: 21504204]
Hep 3B2	IC₅₀	11.2 μM Compound: Sorafenib	Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay	[PMID: 28342400]
Hep 3B2	IC₅₀	9.4 μM Compound: Sorafenib	Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay	[PMID: 28865276]
Hep 3B2	IC₅₀	2.63 μM Compound: Sorafenib	Growth inhibition of human Hep3B cells after 48 hrs by MTT assay Growth inhibition of human Hep3B cells after 48 hrs by MTT assay	[PMID: 29102175]
Hep 3B2	IC₅₀	4.33 μM Compound: Sor	Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
Hep 3B2	IC₅₀	5.2 μM Compound: Sorafenib	Anti-hepatoma activity against human Hep3B cells assessed as cell growth inhibition by MTT assay Anti-hepatoma activity against human Hep3B cells assessed as cell growth inhibition by MTT assay	[PMID: 32371334]
Hep 3B2	IC₅₀	8.62 μM Compound: Sorafenib	Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33310290]
Hep 3B2	IC₅₀	5.49 μM Compound: Sorafenib	Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35525080]
Hep 3B2	IC₅₀	4.01 μM Compound: Sorafenib	Antiproliferative activity against human Hep3B cells measured by MTT assay Antiproliferative activity against human Hep3B cells measured by MTT assay	[PMID: 35764033]
Hep 3B2	IC₅₀	5.2 μM Compound: Sorafenib	Cytotoxicity against human Hep3B cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human Hep3B cells assessed as inhibition of cell growth by MTT assay	[PMID: 36223633]
Hep 3B2	IC₅₀	<10 μM Compound: 1; BAY 43-9006	Antitumor activity against human Hep3B cells assessed as inhibition of cell viability Antitumor activity against human Hep3B cells assessed as inhibition of cell viability	[PMID: 36332549]
Hep 3B2	IC₅₀	12.4 μM Compound: Sorafenib	Antiproliferative activity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay	[PMID: 36461923]
Hep 3B2	IC₅₀	8.55 μM Compound: Sorafenib	Cytotoxicity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Cytotoxicity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 36549116]
Hep 3B2	IC₅₀	7.7 μM Compound: Sorafenib	Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36745506]
Hep 3B2	IC₅₀	4.01 μM Compound: Sorafenib	Antiproliferative activity against human Hep3B cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human Hep3B cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 38850857]
Hepatocyte	IC₅₀	16.55 μM Compound: Sorafenib	Cytotoxicity against rat hepatocytes assessed as reduction in cell growth for 4 hrs by MTT assay Cytotoxicity against rat hepatocytes assessed as reduction in cell growth for 4 hrs by MTT assay	[PMID: 34479065]
HepG2	IC₅₀	11.49 μM Compound: sorafenib	Cytotoxicity against human HepG2 cells after 48 hrs by MTT based ELISA Cytotoxicity against human HepG2 cells after 48 hrs by MTT based ELISA	[PMID: 21504204]
HepG2	IC₅₀	5 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 23260578]
HepG2	IC₅₀	4 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 23454017]
HepG2	GI₅₀	4.5 μM Compound: BAY 43-9006, Nexavar	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 23726028]
HepG2	IC₅₀	8.42 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 23871909]
HepG2	IC₅₀	5 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23932071]
HepG2	IC₅₀	6.3 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 23932071]
HepG2	IC₅₀	8.67 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 120 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 120 hrs by MTT assay	[PMID: 24675135]
HepG2	IC₅₀	5.74 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 25461318]
HepG2	IC₅₀	3.5 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay	[PMID: 25462265]
HepG2	IC₅₀	3.4 μM Compound: Sorafenib	Inhibition of human HepG2cells assessed as inhibition of cell growth after 72 hrs by SRB method Inhibition of human HepG2cells assessed as inhibition of cell growth after 72 hrs by SRB method	[PMID: 26071861]
HepG2	IC₅₀	6.7 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 26159483]
HepG2	IC₅₀	9.14 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 26560049]
HepG2	EC₅₀	302 nM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 27010810]
HepG2	IC₅₀	8.42 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 27162123]
HepG2	IC₅₀	12 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 48 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 48 hrs by MTS assay	[PMID: 27422336]
HepG2	IC₅₀	3.44 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 27777009]
HepG2	IC₅₀	2.84 μM Compound: Sorafenib	Antiproliferative activity human HepG2 cells after 72 hrs by cell titer-glo luminescence assay Antiproliferative activity human HepG2 cells after 72 hrs by cell titer-glo luminescence assay	[PMID: 28242553]
HepG2	IC₅₀	6.2 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28865276]
HepG2	IC₅₀	3.44 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28927801]
HepG2	IC₅₀	12.54 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29032031]
HepG2	IC₅₀	12.4 μg/mL Compound: Sorafenib	Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 29103873]
HepG2	IC₅₀	15 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29103873]
HepG2	IC₅₀	3.66 μM Compound: Sor	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
HepG2	IC₅₀	1.06 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 29628325]
HepG2	IC₅₀	29 μM Compound: Sorafenib	Antiproliferative activity against VEGF-stimulated human HepG2 cells after 48 hrs by CCK8 assay Antiproliferative activity against VEGF-stimulated human HepG2 cells after 48 hrs by CCK8 assay	[PMID: 30108994]
HepG2	IC₅₀	16.3 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT spectrophotometric assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT spectrophotometric assay	[PMID: 30114660]
HepG2	IC₅₀	8.27 μM Compound: 1	Antiproliferative activity against human HepG2 cells Antiproliferative activity against human HepG2 cells	[PMID: 30216849]
HepG2	IC₅₀	5.23 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells after 48 hrs by SRB assay Antiproliferative activity against human HepG2 cells after 48 hrs by SRB assay	[PMID: 30503942]
HepG2	IC₅₀	2.8 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells after 72 hrs by Cell-Titer Glo assay Antiproliferative activity against human HepG2 cells after 72 hrs by Cell-Titer Glo assay	[PMID: 30529543]
HepG2	IC₅₀	3.04 μM Compound: 1	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 31053508]
HepG2	IC₅₀	2.41 μM Compound: C1	Antiproliferative activity against human HepG2 cells expressing VEGFR2 assessed as reduction in cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells expressing VEGFR2 assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 31252306]
HepG2	IC₅₀	3.5 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells by sulforhodamine B assay Cytotoxicity against human HepG2 cells by sulforhodamine B assay	[PMID: 31401008]
HepG2	IC₅₀	7.839 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 31488358]
HepG2	IC₅₀	3.6 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells expressing VEGFR2 assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells expressing VEGFR2 assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31668972]
HepG2	IC₅₀	5.2 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 31926469]
HepG2	GI₅₀	2.5 μM Compound: 3	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by WST assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by WST assay	[PMID: 32272419]
HepG2	IC₅₀	5.5 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 32323991]
HepG2	IC₅₀	9.75 μM Compound: Sorafenib	Anti-hepatoma activity against human HepG2 cells assessed as cell growth inhibition by MTT assay Anti-hepatoma activity against human HepG2 cells assessed as cell growth inhibition by MTT assay	[PMID: 32371334]
HepG2	IC₅₀	5.78 μM Compound: Sorafenib	Antiproliferative activity against human HEPG2 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay Antiproliferative activity against human HEPG2 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay	[PMID: 32422489]
HepG2	IC₅₀	9.64 mM Compound: Sorafenib	Anticancer activity against human HepG2 cells after 48 hrs by MTT assay Anticancer activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 32631569]
HepG2	IC₅₀	7.67 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 32791397]
HepG2	IC₅₀	0.001 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
HepG2	IC₅₀	8 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32842729]
HepG2	IC₅₀	7.31 μM Compound: 1; BAY-43-9006	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33214036]
HepG2	IC₅₀	7.22 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33310290]
HepG2	IC₅₀	29.6 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 33328104]
HepG2	IC₅₀	6.7 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells Antiproliferative activity against human HepG2 cells	[PMID: 33421712]
HepG2	IC₅₀	5.06 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 33423463]
HepG2	IC₅₀	6.5 μM Compound: 1	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 33460739]
HepG2	IC₅₀	6.18 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 33493829]
HepG2	IC₅₀	6.4 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 34128674]
HepG2	IC₅₀	2.17 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay	[PMID: 34479065]
HepG2	IC₅₀	29.35 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
HepG2	IC₅₀	3.3 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35525080]
HepG2	IC₅₀	2.1 μM Compound: sorafenib	Antiproliferative activity against human HepG2 cells treated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells treated for 72 hrs by MTT assay	[PMID: 35639640]
HepG2	IC₅₀	2.86 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells measured by MTT assay Antiproliferative activity against human HepG2 cells measured by MTT assay	[PMID: 35764033]
HepG2	IC₅₀	9.18 μM Compound: SOR	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 35964425]
HepG2	IC₅₀	6.54 μM Compound: SFN	Cytotoxicity against human HepG2 cells by SRB assay Cytotoxicity against human HepG2 cells by SRB assay	[PMID: 36067930]
HepG2	IC₅₀	9.7 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by MTT assay	[PMID: 36223633]
HepG2	IC₅₀	5.06 μM Compound: 1	Anticancer activity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 36270111]
HepG2	IC₅₀	<10 μM Compound: 1; BAY 43-9006	Antitumor activity against human HepG2 cells assessed as inhibition of cell viability Antitumor activity against human HepG2 cells assessed as inhibition of cell viability	[PMID: 36332549]
HepG2	IC₅₀	16.6 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay	[PMID: 36461923]
HepG2	IC₅₀	2.69 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36508995]
HepG2	IC₅₀	6.422 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 36549116]
HepG2	IC₅₀	5.5 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36745506]
HepG2	IC₅₀	9.03 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 37182331]
HepG2	IC₅₀	19.33 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition Cytotoxicity against human HepG2 cells assessed as cell growth inhibition	[PMID: 37453330]
HepG2	IC₅₀	3.1 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by MTT based colorimetric analysis Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by MTT based colorimetric analysis	[PMID: 37453330]
HepG2	IC₅₀	11.2 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38422700]
HepG2	IC₅₀	12.8 μM Compound: Sorafenib	Anti-hepatoma activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs Anti-hepatoma activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs	[PMID: 38521176]
HepG2	IC₅₀	14 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 38536967]
HepG2	IC₅₀	12.33 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 38784474]
HepG2	IC₅₀	2.86 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 38850857]
HepG2	IC₅₀	12.669 μM Compound: Sorafenib	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	10.1039/C2MD20275A
HepG2	IC₅₀	10.48 μM Compound: Sorafenib	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	10.1039/C4MD00536H
HGC-27	IC₅₀	5.22 μM Compound: Sorafenib	Antiproliferative activity against human HGC-27 cells assessed as cell growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human HGC-27 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 33493829]
HGC-27	IC₅₀	>150 μM Compound: Sorafenib	Antiproliferative activity against human HGC-27 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HGC-27 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
HGC-27	IC₅₀	5.15 μM Compound: Sorafenib	Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36242985]
HK-2	IC₅₀	2.6 μM Compound: Sora	Cytotoxicity against human HK2 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay Cytotoxicity against human HK2 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay	[PMID: 31298537]
HL-60	IC₅₀	1.68 μM Compound: Nexavar, Sorafenib	Cytotoxicity against human HL60 cells after 72 hrs by Alamar Blue assay Cytotoxicity against human HL60 cells after 72 hrs by Alamar Blue assay	[PMID: 24858546]
HL-60	IC₅₀	2.59 μM Compound: Sorafenib	Cytotoxicity against human HL60 cells after 72 hrs by alamar blue assay Cytotoxicity against human HL60 cells after 72 hrs by alamar blue assay	[PMID: 30108964]
HL-60	IC₅₀	5 μM Compound: Sorafenib	Antiproliferative activity against human HL60 cells by MTT assay Antiproliferative activity against human HL60 cells by MTT assay	[PMID: 30502686]
HL-60	IC₅₀	0.5 μM Compound: Sorafenib	Antiproliferative activity against human HL-60 cells expressing wild type FLT3 assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against human HL-60 cells expressing wild type FLT3 assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 35148084]
HL-60	GI₅₀	1.58 μM Compound: Sorafenib	Anticancer activity against human HL-60 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human HL-60 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
HL-60(TB)	GI₅₀	1.58 μM Compound: 1	Cytotoxicity against human HL-60(TB) cells after 48 hrs by SRB method Cytotoxicity against human HL-60(TB) cells after 48 hrs by SRB method	[PMID: 26590508]
HL-60(TB)	GI₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human HL-60(TB) cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HL-60(TB) cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
HL-60(TB)	GI₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
HL-60(TB)	IC₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
HL-60(TB)	IC₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human HL-60(TB) cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human HL-60(TB) cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34237622]
HL-60(TB)	IC₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human HL-60(TB) cells measured after 48 hrs by SRB assay Antiproliferative activity against human HL-60(TB) cells measured after 48 hrs by SRB assay	[PMID: 35764033]
HMEC-1	IC₅₀	34 μM Compound: Sorafenib	Antiangiogenic activity against HMEC1 cells after 20 hrs by tube formation assay Antiangiogenic activity against HMEC1 cells after 20 hrs by tube formation assay	[PMID: 30502686]
HMEC-1	IC₅₀	34 μM Compound: Sorafenib	Antiproliferative activity against HMEC1 cells by MTT assay Antiproliferative activity against HMEC1 cells by MTT assay	[PMID: 30502686]
HMEC-1	IC₅₀	34 μM Compound: Sorafenib	Antiproliferative activity against HMEC1 cells incubated for 2 days by MTT assay Antiproliferative activity against HMEC1 cells incubated for 2 days by MTT assay	[PMID: 30878834]
HOP-62	GI₅₀	2 μM Compound: 1	Cytotoxicity against human HOP62 cells after 48 hrs by SRB method Cytotoxicity against human HOP62 cells after 48 hrs by SRB method	[PMID: 26590508]
HOP-62	GI₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human HOP62 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HOP62 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
HOP-62	GI₅₀	2 μM Compound: Sorafenib	Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
HOP-62	IC₅₀	2 μM Compound: Sorafenib	Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
HOP-62	GI₅₀	2 μM Compound: Sorafenib	Anticancer activity against human HOP-62 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human HOP-62 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
HOP-62	IC₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human HOP-62 cells measured after 48 hrs by SRB assay Antiproliferative activity against human HOP-62 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
HOP-92	GI₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human HOP92 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HOP92 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
HOP-92	GI₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human HOP-92 cells assessed as reduction in cell growth Antiproliferative activity against human HOP-92 cells assessed as reduction in cell growth	[PMID: 27155467]
HOP-92	GI₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
HOP-92	IC₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
HOP-92	GI₅₀	1.58 μM Compound: Sorafenib	Anticancer activity against human HOP-92 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human HOP-92 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
HOP-92	IC₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human HOP-92 cells measured after 48 hrs by SRB assay Antiproliferative activity against human HOP-92 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
HOS-TE85	IC₅₀	4.814 μM Compound: Sorafenib	Antiproliferative activity against human MNNG/HOS cells assessed as inhibition of cell growth incubated for 24 to 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human MNNG/HOS cells assessed as inhibition of cell growth incubated for 24 to 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 38232462]
HS27	IC₅₀	7.85 μM Compound: Sorafenib	Antiproliferative activity against human HS27 cells Antiproliferative activity against human HS27 cells	[PMID: 19464887]
HS27	IC₅₀	7.8 μM Compound: sorafenib	Antiproliferative activity against human HS27 cells after 24 hrs by MTT assay Antiproliferative activity against human HS27 cells after 24 hrs by MTT assay	[PMID: 19857963]
HS27	IC₅₀	7.8 μM Compound: Sorafenib	Cytotoxicity against human HS27 cells by MTT assay Cytotoxicity against human HS27 cells by MTT assay	[PMID: 19897366]
HS27	GI₅₀	7.85 μM Compound: Sorafenib	Antiproliferative activity against human HS27 cells assessed as growth inhibition after 24 hrs by MTT assay Antiproliferative activity against human HS27 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 21353571]
HS27	GI₅₀	>30 μM Compound: Sorafenib	Cytotoxicity against human HS27 cells after 24 hrs by MTT assay Cytotoxicity against human HS27 cells after 24 hrs by MTT assay	[PMID: 26318067]
HS27	IC₅₀	7.8 μM Compound: Sorafenib	Cytotoxicity against human HS27 cells Cytotoxicity against human HS27 cells	[PMID: 31923860]
HS27	IC₅₀	8.3 μM Compound: Sorafenib	Cytotoxicity against human HS27 cells assessed as reduction in cell growth measured after 48 hrs by MTT assay Cytotoxicity against human HS27 cells assessed as reduction in cell growth measured after 48 hrs by MTT assay	[PMID: 38850857]
Hs-578T	GI₅₀	2.51 μM Compound: 1	Cytotoxicity against human Hs578T cells after 48 hrs by SRB method Cytotoxicity against human Hs578T cells after 48 hrs by SRB method	[PMID: 26590508]
Hs-578T	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human Hs 578T cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human Hs 578T cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
Hs-578T	GI₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human Hs 578T cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Hs 578T cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
Hs-578T	IC₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human Hs578T cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Hs578T cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
Hs-578T	GI₅₀	2.51 μM Compound: Sorafenib	Anticancer activity against human Hs-578T cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human Hs-578T cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
Hs-578T	IC₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human Hs-578T cells measured after 48 hrs by SRB assay Antiproliferative activity against human Hs-578T cells measured after 48 hrs by SRB assay	[PMID: 35764033]
Hs-578T	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human Hs-578T cells assessed as cell growth inhibition Antiproliferative activity against human Hs-578T cells assessed as cell growth inhibition	[PMID: 38850857]
HT-1080	IC₅₀	<10 μM Compound: 1; BAY 43-9006	Antitumor activity against human HT-1080 cells assessed as inhibition of cell viability Antitumor activity against human HT-1080 cells assessed as inhibition of cell viability	[PMID: 36332549]
HT-29	IC₅₀	4 μM Compound: Sorafenib	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 23454017]
HT-29	IC₅₀	15.2 μM Compound: Sorafenib	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 120 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 120 hrs by MTT assay	[PMID: 24675135]
HT-29	IC₅₀	3.61 μM Compound: Sorafenib	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 24826815]
HT-29	IC₅₀	3.61 μM Compound: 5	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 25086238]
HT-29	IC₅₀	3.61 μM Compound: 5	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 25440879]
HT-29	IC₅₀	0.39 μM Compound: Sorafenib	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay	[PMID: 25778995]
HT-29	GI₅₀	2 μM Compound: 1	Cytotoxicity against human HT-29 cells after 48 hrs by SRB method Cytotoxicity against human HT-29 cells after 48 hrs by SRB method	[PMID: 26590508]
HT-29	IC₅₀	3.37 μM Compound: Sorafenib	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 26991938]
HT-29	EC₅₀	>1000 nM Compound: Sorafenib	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 27010810]
HT-29	GI₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
HT-29	GI₅₀	2 μM Compound: Sorafenib	Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
HT-29	IC₅₀	5.9 μM Compound: Sorafenib	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 28865276]
HT-29	IC₅₀	3.97 μM Compound: Sorafenib	Anticancer activity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by MTT assay Anticancer activity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 29549841]
HT-29	IC₅₀	8.44 μM Compound: Sorafenib	Antiproliferative activity against human HT-29 cells harboring BRAF V600E mutant after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells harboring BRAF V600E mutant after 48 hrs by MTT assay	[PMID: 29602674]
HT-29	IC₅₀	2.58 μM Compound: Sorafenib	Antiproliferative activity against human HT-29 cells harboring BRAF V600E mutant after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells harboring BRAF V600E mutant after 72 hrs by MTT assay	[PMID: 29886324]
HT-29	IC₅₀	2 μM Compound: Sorafenib	Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
HT-29	IC₅₀	3.61 μM Compound: 1	Antiproliferative activity against human HT-29 cells Antiproliferative activity against human HT-29 cells	[PMID: 30216849]
HT-29	IC₅₀	17 μM Compound: Sorafenib	Antiproliferative activity against human HT-29 cells by MTT assay Antiproliferative activity against human HT-29 cells by MTT assay	[PMID: 30502686]
HT-29	IC₅₀	6.6 μM Compound: Sorafenib	Antiproliferative activity against human HT-29 cells after 72 hrs by Cell-Titer Glo assay Antiproliferative activity against human HT-29 cells after 72 hrs by Cell-Titer Glo assay	[PMID: 30529543]
HT-29	IC₅₀	10 μM Compound: Sorafenib	Anticancer activity against human HT-29 assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human HT-29 assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30826508]
HT-29	IC₅₀	17 μM Compound: Sorafenib	Antiproliferative activity against human HT-29 cells incubated for 2 days by MTT assay Antiproliferative activity against human HT-29 cells incubated for 2 days by MTT assay	[PMID: 30878834]
HT-29	IC₅₀	5.29 μM Compound: Sorafenib	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31546197]
HT-29	IC₅₀	10.05 mM Compound: Sorafenib	Anticancer activity against human HT-29 cells after 48 hrs by MTT assay Anticancer activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 32631569]
HT-29	IC₅₀	17.28 μM Compound: Sorafenib	Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 32663641]
HT-29	IC₅₀	5.57 μM Compound: Sorafenib	Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 33493829]
HT-29	IC₅₀	>150 μM Compound: Sorafenib	Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
HT-29	GI₅₀	2 μM Compound: Sorafenib	Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
HT-29	IC₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human HT-29 cells measured after 48 hrs by SRB assay Antiproliferative activity against human HT-29 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
HT-29	GI₅₀	25.4 μM Compound: Sorafenib	Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 36068975]
HT-29	GI₅₀	25.6 μM Compound: Sorafenib	Antiproliferative activity against human HT-29 cells assessed as cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 36126227]
HT-29	IC₅₀	11.51 μM Compound: 14	Anti-necroptic activity in TNF induced cell death in human HT-29 cells pretreated with compound for 1 hr followed by hTNF/BV6/zVAD stimulation for 6 hrs by PI satining based flow cytometry analysis Anti-necroptic activity in TNF induced cell death in human HT-29 cells pretreated with compound for 1 hr followed by hTNF/BV6/zVAD stimulation for 6 hrs by PI satining based flow cytometry analysis	[PMID: 36346971]
HT-29	IC₅₀	3.56 μM Compound: Sorafenib	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38422700]
HT-29	GI₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition	[PMID: 38850857]
Huh-7	GI₅₀	4 μM Compound: BAY 43-9006, Nexavar	Cytotoxicity against human HuH7 cells by MTT assay Cytotoxicity against human HuH7 cells by MTT assay	[PMID: 23726028]
Huh-7	IC₅₀	7.1 μM Compound: Sorafenib	Cytotoxicity against human HuH7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human HuH7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 26159483]
Huh-7	IC₅₀	11.3 μM Compound: Sorafenib	Cytotoxicity against human HuH7 cells assessed as reduction in cell growth after 48 hrs by MTS assay Cytotoxicity against human HuH7 cells assessed as reduction in cell growth after 48 hrs by MTS assay	[PMID: 27422336]
Huh-7	IC₅₀	2.68 μM Compound: Sor	Antiproliferative activity against human HuH-7 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human HuH-7 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
Huh-7	IC₅₀	7.92 μM Compound: Sorafenib	Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 32791397]
Huh-7	IC₅₀	0.001 μM Compound: Sorafenib	Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
Huh-7	IC₅₀	10.1 μM Compound: Sorafenib	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32842729]
Huh-7	IC₅₀	7.55 μM Compound: Sorafenib	Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33310290]
Huh-7	IC₅₀	7.1 μM Compound: Sorafenib	Antiproliferative activity against human Huh-7 cells Antiproliferative activity against human Huh-7 cells	[PMID: 33421712]
Huh-7	IC₅₀	4.25 μM Compound: Sorafenib	Antiproliferative activity against human Huh-7 cells by MTT assay Antiproliferative activity against human Huh-7 cells by MTT assay	[PMID: 34128674]
Huh-7	IC₅₀	10.94 μM Compound: Sorafenib	Antiproliferative activity against human Huh-7 cells measured after 72 hrs by MTT assay Antiproliferative activity against human Huh-7 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
Huh-7	IC₅₀	2.6 μM Compound: sorafenib	Antiproliferative activity against human Huh-7 cells treated for 72 hrs by MTT assay Antiproliferative activity against human Huh-7 cells treated for 72 hrs by MTT assay	[PMID: 35639640]
Huh-7	IC₅₀	<10 μM Compound: 1; BAY 43-9006	Antitumor activity against human Huh-7 cells assessed as inhibition of cell viability Antitumor activity against human Huh-7 cells assessed as inhibition of cell viability	[PMID: 36332549]
Huh-7	IC₅₀	9.7 μM Compound: Sorafenib	Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay	[PMID: 36461923]
Huh-7	IC₅₀	9.48 μM Compound: Sorafenib	Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 37182331]
Huh-7	IC₅₀	14.66 μM Compound: Sorafenib	Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 method Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 method	[PMID: 38224754]
Huh-7	IC₅₀	8.8 μM Compound: Sorafenib	Anti-hepatoma activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs Anti-hepatoma activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs	[PMID: 38521176]
Huh-7.5	CC₅₀	>20 μM Compound: 25	Cytotoxicity against human Huh7.5 cells Cytotoxicity against human Huh7.5 cells	[PMID: 33539089]
HUVEC	IC₅₀	0.59 nM Compound: sorafenib	Antiangiogenic activity against HUVEC after 24 hrs by calcein AM staining-based fluorescent microscopy Antiangiogenic activity against HUVEC after 24 hrs by calcein AM staining-based fluorescent microscopy	[PMID: 18849971]
HUVEC	IC₅₀	4 μM Compound: sorafenib	Cytotoxicity against HUVEC by MTT assay Cytotoxicity against HUVEC by MTT assay	[PMID: 23562241]
HUVEC	IC₅₀	6.42 μM Compound: Sorafenib, BAY 43-9006	Antiproliferative activity against human HUVEC cells after 48 hrs by MTT assay Antiproliferative activity against human HUVEC cells after 48 hrs by MTT assay	[PMID: 23644219]
HUVEC	GI₅₀	6 μM Compound: BAY 43-9006, Nexavar	Antiproliferative activity against HUVEC after 72 hrs by MTT assay Antiproliferative activity against HUVEC after 72 hrs by MTT assay	[PMID: 23726028]
HUVEC	IC₅₀	6.42 μM Compound: Sorafenib	Antiproliferative activity against HUVEC after 48 hrs by MTT assay Antiproliferative activity against HUVEC after 48 hrs by MTT assay	[PMID: 24440479]
HUVEC	EC₅₀	718 nM Compound: Sorafenib	Antiangiogenic activity in HUVEC after 72 hrs by MTT assay Antiangiogenic activity in HUVEC after 72 hrs by MTT assay	[PMID: 27010810]
HUVEC	IC₅₀	40.6 μM Compound: Sorafenib	Cytotoxicity against HUVEC after 48 hrs by MTT assay Cytotoxicity against HUVEC after 48 hrs by MTT assay	[PMID: 28342400]
HUVEC	IC₅₀	1.49 μM Compound: Sorafenib	Growth inhibition of HUVEC after 72 hrs by CellTiter-Glo assay Growth inhibition of HUVEC after 72 hrs by CellTiter-Glo assay	[PMID: 29189002]
HUVEC	IC₅₀	2.69 μM Compound: Sorafenib	Antiproliferative activity against HUVEC harboring VEGFR2 after 72 hrs by MTT assay Antiproliferative activity against HUVEC harboring VEGFR2 after 72 hrs by MTT assay	[PMID: 29886324]
HUVEC	IC₅₀	5.35 μM Compound: C1	Antiproliferative activity against human HUVEC cells expressing VEGFR2 assessed as reduction in cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HUVEC cells expressing VEGFR2 assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 31252306]
HUVEC	IC₅₀	4.1 μM Compound: Sorafenib	Antiproliferative activity against human HUVEC cells expressing VEGFR2 assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human HUVEC cells expressing VEGFR2 assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31668972]
HUVEC	IC₅₀	2.8 μM Compound: Sorafenib	Antiproliferative activity against HUVEC incubated for 48 hrs by MTT assay Antiproliferative activity against HUVEC incubated for 48 hrs by MTT assay	[PMID: 33328104]
HUVEC	IC₅₀	8.33 μM Compound: Sorafenib	Cytotoxicity against human HUVEC cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human HUVEC cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 33493829]
HUVEC	IC₅₀	9.66 μM Compound: Sorafenib	Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36242985]
HUVEC	IC₅₀	18.24 μM Compound: Sorafenib	Cytotoxicity against HUVEC cells assessed as reduction in cell viability and measured after 24 hrs by MTT assay Cytotoxicity against HUVEC cells assessed as reduction in cell viability and measured after 24 hrs by MTT assay	[PMID: 37484562]
HUVEC	IC₅₀	73.16 μM Compound: Sorafenib	Anti-angiogenesis activity in HUVEC cells Anti-angiogenesis activity in HUVEC cells	[PMID: 37484562]
HUVEC	IC₅₀	89.77 μM Compound: Sorafenib	Cytotoxicity against HUVECs incubated for 72 hrs by MTT assay Cytotoxicity against HUVECs incubated for 72 hrs by MTT assay	[PMID: 38894896]
IGROV-1	GI₅₀	2.51 μM Compound: 1	Cytotoxicity against human IGROV1 cells after 48 hrs by SRB method Cytotoxicity against human IGROV1 cells after 48 hrs by SRB method	[PMID: 26590508]
IGROV-1	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
IGROV-1	GI₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
IGROV-1	IC₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
IGROV-1	GI₅₀	2.51 μM Compound: Sorafenib	Anticancer activity against human IGROV-1 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human IGROV-1 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
IGROV-1	IC₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human IGROV-1 cells measured after 48 hrs by SRB assay Antiproliferative activity against human IGROV-1 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
JeKo-1	IC₅₀	1070 nM Compound: 12; Sor	Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 36399923]
Jurkat	IC₅₀	14.37 μM Compound: 14	Anti-necroptic activity in TNF alpha stimulated FADD-deficient human Jurkat cells pretreated with compound for 1 hr followed by hTNF stimulation for 10 hrs by PI satining based flow cytometry analysis Anti-necroptic activity in TNF alpha stimulated FADD-deficient human Jurkat cells pretreated with compound for 1 hr followed by hTNF stimulation for 10 hrs by PI satining based flow cytometry analysis	[PMID: 36346971]
K562	GI₅₀	6.2 μM Compound: BAY-439006, 3	Antiproliferation activity against human K562 cells expressing wild type BCR/ABL after 72 hrs by MTS method Antiproliferation activity against human K562 cells expressing wild type BCR/ABL after 72 hrs by MTS method	[PMID: 21708468]
K562	GI₅₀	7.3 μM Compound: 2, BAY-43-9006	Cytotoxicity against human FLT3-negative K562 cells harboring wild type BCR/ABL after 72 hrs by MTS assay Cytotoxicity against human FLT3-negative K562 cells harboring wild type BCR/ABL after 72 hrs by MTS assay	[PMID: 23618709]
K562	IC₅₀	13.85 μM Compound: Sorafenib, BAY 43-9006	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 23644219]
K562	IC₅₀	0.86 μM Compound: Sorafenib	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 24315192]
K562	IC₅₀	1.22 μM Compound: Sorafenib	Antiproliferative activity against human K562 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay	[PMID: 25778995]
K562	GI₅₀	7.3 μM Compound: 2	Inhibition of wild type BCR/ABL in FLT3 deficient human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay Inhibition of wild type BCR/ABL in FLT3 deficient human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 26081023]
K562	GI₅₀	3.16 μM Compound: 1	Cytotoxicity against human K562 cells after 48 hrs by SRB method Cytotoxicity against human K562 cells after 48 hrs by SRB method	[PMID: 26590508]
K562	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
K562	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human K562 cells assessed as reduction in cell growth Antiproliferative activity against human K562 cells assessed as reduction in cell growth	[PMID: 27155467]
K562	GI₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
K562	IC₅₀	5.08 μM Compound: Sor	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
K562	IC₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
K562	IC₅₀	17.23 μM Compound: 1	Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay	[PMID: 31053508]
K562	GI₅₀	0.612 μM Compound: 3	Antiproliferative activity against human K562 cells assessed as cell growth inhibition by WST assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition by WST assay	[PMID: 32272419]
K562	IC₅₀	2.81 μM Compound: Sorafenib	Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32739648]
K562	IC₅₀	0.001 μM Compound: Sorafenib	Cytotoxicity against human K562 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human K562 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
K562	GI₅₀	3.16 μM Compound: Sorafenib	Anticancer activity against human K562 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human K562 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
K562	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human K562 cells measured after 48 hrs by SRB assay Antiproliferative activity against human K562 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
K562	IC₅₀	7740 nM Compound: 12; Sor	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 36399923]
K562	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human K562 cells assessed as cell growth inhibition Antiproliferative activity against human K562 cells assessed as cell growth inhibition	[PMID: 38850857]
K562	IC₅₀	0.86 μM Compound: BAY-93-4006	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	10.1039/C3MD00192J
Kasumi 1	IC₅₀	0.015 μM Compound: 2	Antiproliferative activity against human Kasumi-1 cells after 72 hrs by MTT assay Antiproliferative activity against human Kasumi-1 cells after 72 hrs by MTT assay	[PMID: 20570526]
KB	GI₅₀	5.43 μM Compound: Sorafenib	Antiproliferative activity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay Antiproliferative activity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay	[PMID: 34147745]
KETR3	IC₅₀	18.8 μM Compound: Sorafenib	Cytotoxicity against human Ketr3 cells assessed as growth inhibition after 120 hrs by MTT assay Cytotoxicity against human Ketr3 cells assessed as growth inhibition after 120 hrs by MTT assay	[PMID: 24675135]
KETR3	IC₅₀	8.27 μM Compound: 1	Antiproliferative activity against human Ketr3 cells Antiproliferative activity against human Ketr3 cells	[PMID: 30216849]
KM12	GI₅₀	1.58 μM Compound: 1	Cytotoxicity against human KM12 cells after 48 hrs by SRB method Cytotoxicity against human KM12 cells after 48 hrs by SRB method	[PMID: 26590508]
KM12	GI₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human KM12 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human KM12 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
KM12	GI₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
KM12	IC₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
KM12	GI₅₀	1.58 μM Compound: Sorafenib	Anticancer activity against human KM12 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human KM12 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
KM12	IC₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human KM12 cells measured after 48 hrs by SRB assay Antiproliferative activity against human KM12 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
L02	IC₅₀	72.9 μM Compound: Sorafenib	Cytotoxicity against human LO2 cells Cytotoxicity against human LO2 cells	[PMID: 31668972]
L02	IC₅₀	9.1 μM Compound: Sorafenib	Cytotoxicity against human LO2 cells after 48 hrs by MTT assay Cytotoxicity against human LO2 cells after 48 hrs by MTT assay	[PMID: 32323991]
L02	IC₅₀	52.87 μM Compound: Sorafenib	Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
L02	IC₅₀	5.98 μM Compound: sorafenib	Antiproliferative activity against human L02 cells treated for 72 hrs by MTT assay Antiproliferative activity against human L02 cells treated for 72 hrs by MTT assay	[PMID: 35639640]
LC-2-ad	GI₅₀	3224.13 nM Compound: Sorafenib	Antiproliferative activity against human LC-2-ad cells expressing CCDC6-RET fusion protein assessed as growth inhibition after 72 hrs by resazurin assay Antiproliferative activity against human LC-2-ad cells expressing CCDC6-RET fusion protein assessed as growth inhibition after 72 hrs by resazurin assay	[PMID: 35081714]
LoVo	IC₅₀	3.3 μM Compound: Sorafenib	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 23454017]
LoVo	IC₅₀	6.56 μM Compound: Sorafenib	Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay	[PMID: 24315192]
LoVo	IC₅₀	9.47 μM Compound: Sorafenib	Growth inhibition of human LoVo cells after 48 hrs by MTT assay Growth inhibition of human LoVo cells after 48 hrs by MTT assay	[PMID: 29102175]
LoVo	IC₅₀	0.25 μM Compound: Sorafenib	Antiproliferative activity against human LoVo cells Antiproliferative activity against human LoVo cells	[PMID: 30503935]
LoVo	IC₅₀	2.52 μM Compound: Sorafenib	Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay	[PMID: 30616052]
LoVo	IC₅₀	14.57 μM Compound: Sorafenib	Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 33423463]
LoVo	IC₅₀	6.56 μM Compound: BAY-93-4006	Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay	10.1039/C3MD00192J
LOX IMVI	IC₅₀	4.25 μM Compound: Sorafenib	Antiproliferative activity against human LOXIMVI cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay Antiproliferative activity against human LOXIMVI cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay	[PMID: 25778995]
LOX IMVI	GI₅₀	1.58 μM Compound: 1	Cytotoxicity against human LOXIMVI cells after 48 hrs by SRB method Cytotoxicity against human LOXIMVI cells after 48 hrs by SRB method	[PMID: 26590508]
LOX IMVI	GI₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human LOXIMVI cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human LOXIMVI cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
LOX IMVI	GI₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
LOX IMVI	GI₅₀	1.58 μM Compound: Sorafenib	Anticancer activity against human LOX IMVI cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human LOX IMVI cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
M14	GI₅₀	2 μM Compound: 1	Cytotoxicity against human M14 cells after 48 hrs by SRB method Cytotoxicity against human M14 cells after 48 hrs by SRB method	[PMID: 26590508]
M14	GI₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human M14 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human M14 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
M14	GI₅₀	2 μM Compound: Sorafenib	Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
M14	IC₅₀	2 μM Compound: Sorafenib	Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
M14	GI₅₀	2 μM Compound: Sorafenib	Anticancer activity against human M14 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human M14 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
M14	IC₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human M14 cells measured after 48 hrs by SRB assay Antiproliferative activity against human M14 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
M14	GI₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human M14 cells assessed as cell growth inhibition Antiproliferative activity against human M14 cells assessed as cell growth inhibition	[PMID: 38850857]
Mahlavu	IC₅₀	13.4 μM Compound: Sorafenib	Cytotoxicity against human human Mahlavu cells assessed as inhibition of cell viability incubated upto 72 hrs by MTT assay Cytotoxicity against human human Mahlavu cells assessed as inhibition of cell viability incubated upto 72 hrs by MTT assay	[PMID: 36018000]
Malme-3M	GI₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human MALME-3M cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MALME-3M cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
Malme-3M	GI₅₀	2 μM Compound: Sorafenib	Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
Malme-3M	IC₅₀	2 μM Compound: Sorafenib	Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
Malme-3M	GI₅₀	2 μM Compound: Sorafenib	Anticancer activity against human Malme-3M cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human Malme-3M cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
Malme-3M	IC₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human Malme-3M cells measured after 48 hrs by SRB assay Antiproliferative activity against human Malme-3M cells measured after 48 hrs by SRB assay	[PMID: 35764033]
Malme-3M	GI₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human Malme-3M cells assessed as cell growth inhibition Antiproliferative activity against human Malme-3M cells assessed as cell growth inhibition	[PMID: 38850857]
MCF7	IC₅₀	8.83 μM Compound: Sorafenib	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20435479]
MCF7	IC₅₀	7.33 μM Compound: Sorafenib, BAY 43-9006	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23644219]
MCF7	IC₅₀	11.34 μM Compound: Sorafenib	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 23871909]
MCF7	IC₅₀	9.12 μM Compound: Sorafenib	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24300920]
MCF7	IC₅₀	0.19 μM Compound: Sorafenib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25496804]
MCF7	IC₅₀	1.88 μM Compound: Sorafenib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25637123]
MCF7	IC₅₀	0.78 μM Compound: Sorafenib	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay	[PMID: 25778995]
MCF7	IC₅₀	5.5 μM Compound: Sorafenib	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 26159483]
MCF7	GI₅₀	2.51 μM Compound: 1	Cytotoxicity against human MCF7 cells after 48 hrs by SRB method Cytotoxicity against human MCF7 cells after 48 hrs by SRB method	[PMID: 26590508]
MCF7	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
MCF7	IC₅₀	4.21 μM Compound: Sorafenib	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27043268]
MCF7	IC₅₀	11.34 μM Compound: Sorafenib	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27162123]
MCF7	IC₅₀	3.18 μM Compound: Sorafenib	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27777009]
MCF7	GI₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
MCF7	IC₅₀	4.21 μM Compound: Sorafenib	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 28340913]
MCF7	IC₅₀	4.33 μg/mL Compound: Sorafenib	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 28505536]
MCF7	IC₅₀	3.18 μM Compound: Sorafenib	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28927801]
MCF7	IC₅₀	2.78 μM Compound: Sorafenib	Growth inhibition of human MCF7 cells after 48 hrs by MTT assay Growth inhibition of human MCF7 cells after 48 hrs by MTT assay	[PMID: 29102175]
MCF7	IC₅₀	3.64 μM Compound: Sorafenib	Anticancer activity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 29549841]
MCF7	IC₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
MCF7	IC₅₀	3.07 μM Compound: Sorafenib	Cytotoxicity against human MCF7 cells after 72 hrs by alamar blue assay Cytotoxicity against human MCF7 cells after 72 hrs by alamar blue assay	[PMID: 30108964]
MCF7	IC₅₀	2.51 μM Compound: 1	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 30216849]
MCF7	IC₅₀	14 μM Compound: Sorafenib	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 30502686]
MCF7	IC₅₀	0.09 μM Compound: Sorafenib	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 30503935]
MCF7	IC₅₀	4.27 μM Compound: Sorafenib	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 30503942]
MCF7	IC₅₀	3.47 μM Compound: Sorafenib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30616052]
MCF7	IC₅₀	14 μM Compound: Sorafenib	Antiproliferative activity against human MCF7 cells incubated for 2 days by MTT assay Antiproliferative activity against human MCF7 cells incubated for 2 days by MTT assay	[PMID: 30878834]
MCF7	IC₅₀	4.33 μM Compound: I; BAY 43-9006	Cytotoxicity against human MCF7 cells expressing VEGFR2 and wild type BRAF measured after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells expressing VEGFR2 and wild type BRAF measured after 48 hrs by sulforhodamine B assay	[PMID: 31284081]
MCF7	IC₅₀	38.168 μM Compound: Sorafenib	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 31488358]
MCF7	IC₅₀	43.3 μM Compound: Sorafenib	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31546197]
MCF7	IC₅₀	10.87 mM Compound: Sorafenib	Anticancer activity against human MCF7 cells after 48 hrs by MTT assay Anticancer activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 32631569]
MCF7	IC₅₀	2.5 μM Compound: Sorafenib	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32739648]
MCF7	IC₅₀	0.001 μM Compound: Sorafenib	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
MCF7	IC₅₀	7.21 μM Compound: 1; BAY-43-9006	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33214036]
MCF7	IC₅₀	5.5 μM Compound: Sorafenib	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 33421712]
MCF7	IC₅₀	15 μM Compound: 1	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 33460739]
MCF7	GI₅₀	4.98 μM Compound: Sorafenib	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay	[PMID: 34147745]
MCF7	IC₅₀	3.51 μM Compound: Sorafenib	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay	[PMID: 34479065]
MCF7	GI₅₀	2.51 μM Compound: Sorafenib	Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
MCF7	IC₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human MCF7 cells measured after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
MCF7	IC₅₀	7.26 μM Compound: SOR	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 35964425]
MCF7	IC₅₀	5.6 μM Compound: Sorafenib	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36324492]
MCF7	IC₅₀	17.87 μM Compound: Sorafenib	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37453330]
MCF7	IC₅₀	5.1 μM Compound: Sorafenib	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 38283214]
MCF7	IC₅₀	9.81 μM Compound: Sorafenib	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38422700]
MCF7	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition	[PMID: 38850857]
MCF7	IC₅₀	4.88 μM Compound: Sorafenib	Cytotoxicity against human MCF7 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 38894896]
MDA-MB-231	IC₅₀	7.62 μM Compound: Sorafenib	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT based WST-8 assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT based WST-8 assay	[PMID: 20181414]
MDA-MB-231	IC₅₀	4.77 μM Compound: Sorafenib	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 20435479]
MDA-MB-231	IC₅₀	2.5 μM Compound: Sorafenib	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 22414612]
MDA-MB-231	IC₅₀	36 μM Compound: Sorafenib	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 22483592]
MDA-MB-231	IC₅₀	7.18 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 22721924]
MDA-MB-231	IC₅₀	2 μM Compound: Sorafenib	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 23454017]
MDA-MB-231	IC₅₀	14.62 μM Compound: Sorafenib, BAY 43-9006	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 23644219]
MDA-MB-231	IC₅₀	35 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 24315192]
MDA-MB-231	IC₅₀	14.62 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 24440479]
MDA-MB-231	IC₅₀	0.94 μM Compound: 5	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 25086238]
MDA-MB-231	IC₅₀	0.94 μM Compound: 5	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 25440879]
MDA-MB-231	IC₅₀	5.1 μM Compound: Sorafenib	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 26159483]
MDA-MB-231	GI₅₀	1.26 μM Compound: 1	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB method Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB method	[PMID: 26590508]
MDA-MB-231	IC₅₀	3.08 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 26991938]
MDA-MB-231	EC₅₀	>1000 nM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 27010810]
MDA-MB-231	GI₅₀	1.26 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
MDA-MB-231	GI₅₀	1.26 μM Compound: Sorafenib	Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
MDA-MB-231	IC₅₀	2.8 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 29202403]
MDA-MB-231	IC₅₀	1.26 μM Compound: Sorafenib	Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
MDA-MB-231	IC₅₀	17.38 μM Compound: C1	Antiproliferative activity against human MDA-MB-231 cells expressing EGFR assessed as reduction in cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells expressing EGFR assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 31252306]
MDA-MB-231	IC₅₀	15.8 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-231 cells expressing EGFR assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells expressing EGFR assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31668972]
MDA-MB-231	IC₅₀	11.84 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay	[PMID: 32422489]
MDA-MB-231	IC₅₀	3.81 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32739648]
MDA-MB-231	IC₅₀	5.1 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-231 cells Antiproliferative activity against human MDA-MB-231 cells	[PMID: 33421712]
MDA-MB-231	GI₅₀	4.13 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay	[PMID: 34147745]
MDA-MB-231	IC₅₀	8.52 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34536673]
MDA-MB-231	GI₅₀	1.26 μM Compound: Sorafenib	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
MDA-MB-231	IC₅₀	1.26 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
MDA-MB-231	GI₅₀	1.26 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition	[PMID: 38850857]
MDA-MB-231	IC₅₀	36.6 μM Compound: Sorafenib	Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition after 48 hr by MTT assay	10.1007/s00044-012-0400-8
MDA-MB-231	IC₅₀	35 μM Compound: BAY-93-4006	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	10.1039/C3MD00192J
MDA-MB-231	IC₅₀	17.84 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-231 cells by MTT assay Antiproliferative activity against human MDA-MB-231 cells by MTT assay	10.1039/C4MD00536H
MDA-MB-435	IC₅₀	1.67 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay	[PMID: 25778995]
MDA-MB-435	GI₅₀	1.58 μM Compound: 1	Cytotoxicity against human MDA-MB-435 cells after 48 hrs by SRB method Cytotoxicity against human MDA-MB-435 cells after 48 hrs by SRB method	[PMID: 26590508]
MDA-MB-435	GI₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
MDA-MB-435	GI₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
MDA-MB-435	IC₅₀	2.11 μM Compound: Sorafenib	Growth inhibition of human MDA-MB-435 cells after 72 hrs by CellTiter-Glo assay Growth inhibition of human MDA-MB-435 cells after 72 hrs by CellTiter-Glo assay	[PMID: 29189002]
MDA-MB-435	IC₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
MDA-MB-435	IC₅₀	1.95 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-435 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-435 cells measured after 48 hrs by MTT assay	[PMID: 33316752]
MDA-MB-435	GI₅₀	1.58 μM Compound: Sorafenib	Anticancer activity against human MDA-MB-435 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human MDA-MB-435 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
MDA-MB-435	IC₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-435 cells measured after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-435 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
MDA-MB-435	GI₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth inhibition Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth inhibition	[PMID: 38850857]
MDA-MB-436	IC₅₀	4.2 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-436 cells assessed as decrease in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-436 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 29202403]
MDA-MB-468	IC₅₀	4.9 μM Compound: Sorafenib	Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 26159483]
MDA-MB-468	GI₅₀	2 μM Compound: 1	Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB method Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB method	[PMID: 26590508]
MDA-MB-468	GI₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
MDA-MB-468	GI₅₀	1.99 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell growth Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell growth	[PMID: 27155467]
MDA-MB-468	GI₅₀	2 μM Compound: Sorafenib	Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
MDA-MB-468	IC₅₀	2 μM Compound: Sorafenib	Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
MDA-MB-468	IC₅₀	12.17 μM Compound: 1	Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay	[PMID: 31053508]
MDA-MB-468	IC₅₀	4.9 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-468 cells Antiproliferative activity against human MDA-MB-468 cells	[PMID: 33421712]
MDA-MB-468	IC₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34237622]
MDA-MB-468	GI₅₀	3.16 μM Compound: Sorafenib	Anticancer activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
MDA-MB-468	IC₅₀	7.31 μM Compound: Sorafenib	Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 35635929]
MDA-MB-468	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
MDA-MB-468	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition	[PMID: 38850857]
MGC-803	IC₅₀	7.99 μM Compound: Sorafenib	Antiproliferative activity against human MGC803 cells by MTT assay Antiproliferative activity against human MGC803 cells by MTT assay	[PMID: 26560049]
MGC-803	IC₅₀	9.2 μM Compound: Sorafenib	Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 29032031]
MGC-803	IC₅₀	19.92 μM Compound: Sorafenib	Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 29103873]
MGC-803	IC₅₀	7.99 μM Compound: Cpd S	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32827851]
MGC-803	IC₅₀	50.78 μM Compound: Sorafenib	Antiproliferative activity against human MGC-803 cells measured after 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
MHCC97H	IC₅₀	9.32 μM Compound: Sorafenib	Growth inhibition of human MHCC97H cells after 48 hrs by MTT assay Growth inhibition of human MHCC97H cells after 48 hrs by MTT assay	[PMID: 29102175]
MHCC97H	IC₅₀	1.3 mg/kg Compound: Sorafenib	In vivo antitumor activity against human MHCC97H cells xenografted in po dosed nude mouse assessed as reduction tumor volume In vivo antitumor activity against human MHCC97H cells xenografted in po dosed nude mouse assessed as reduction tumor volume	[PMID: 36503229]
MHCC97H	IC₅₀	15 μM Compound: Sorafenib	Cytotoxicity against human MHCC97H cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Cytotoxicity against human MHCC97H cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 38536967]
MIA PaCa-2	IC₅₀	9.32 μM Compound: Sorafenib	Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay	[PMID: 29032031]
MKN-28	IC₅₀	17 μM Compound: Sorafenib	Antiproliferative activity against human MKN28 cells after 48 hrs by MTT assay Antiproliferative activity against human MKN28 cells after 48 hrs by MTT assay	[PMID: 29032031]
MKN-45	IC₅₀	2.32 μM Compound: Sorafenib	Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay	[PMID: 24826815]
MKN-45	IC₅₀	2.32 μM Compound: 5	Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay	[PMID: 25086238]
MKN-45	IC₅₀	2.32 μM Compound: 5	Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 25440879]
MKN-45	IC₅₀	2.32 μM Compound: 1	Antiproliferative activity against human MKN45 cells Antiproliferative activity against human MKN45 cells	[PMID: 30216849]
MOLM-13	GI₅₀	0.056 μM Compound: BAY-439006, 3	Antiproliferation activity against human MOLM13 cells expressing FLT3 mutation assessed as cell viability after 72 hrs by MTS method Antiproliferation activity against human MOLM13 cells expressing FLT3 mutation assessed as cell viability after 72 hrs by MTS method	[PMID: 21708468]
MOLM-13	GI₅₀	56 nM Compound: 2, BAY-439006	Antiproliferative activity against human MOLM13 cells expressing FLT3-ITD mutant Antiproliferative activity against human MOLM13 cells expressing FLT3-ITD mutant	[PMID: 22726931]
MOLM-13	GI₅₀	0.056 μM Compound: 2, BAY-43-9006	Cytotoxicity against human MOLM13 cells harboring mutant FLT3 after 72 hrs by MTS assay Cytotoxicity against human MOLM13 cells harboring mutant FLT3 after 72 hrs by MTS assay	[PMID: 23618709]
MOLM-13	IC₅₀	>3 μM Compound: Sorafenib	Antiproliferative activity against sorafenib-resistant human MOLM13 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis Antiproliferative activity against sorafenib-resistant human MOLM13 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis	[PMID: 24641103]
MOLM-13	IC₅₀	>3 μM Compound: Sorafenib	Inhibition of CDK4 in human MOLM13 cells assessed as inhibition of Rb phosphorylation at Ser780 after 24 hrs Inhibition of CDK4 in human MOLM13 cells assessed as inhibition of Rb phosphorylation at Ser780 after 24 hrs	[PMID: 24641103]
MOLM-13	IC₅₀	0.002 μM Compound: Sorafenib	Inhibition of FLT3 ITD mutant in human MOLM13 cells assessed as inhibition of STAT5 phosphorylation at Tyr694 after 24 hrs Inhibition of FLT3 ITD mutant in human MOLM13 cells assessed as inhibition of STAT5 phosphorylation at Tyr694 after 24 hrs	[PMID: 24641103]
MOLM-13	IC₅₀	0.005 μM Compound: Sorafenib	Antiproliferative activity against human MOLM13 cells harboring FLT3 ITD mutant assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis Antiproliferative activity against human MOLM13 cells harboring FLT3 ITD mutant assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis	[PMID: 24641103]
MOLM-13	GI₅₀	0.056 μM Compound: 2	Inhibition of FLT3 ITD heterozygous mutant in human MOLM-13 cells assessed as cell growth inhibition after 72 hrs by MTS assay Inhibition of FLT3 ITD heterozygous mutant in human MOLM-13 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 26081023]
MOLM-13	IC₅₀	8.7 nM Compound: Sorafenib	Anticancer activity against human MOLM-13 cells expressing heterogenous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay Anticancer activity against human MOLM-13 cells expressing heterogenous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay	[PMID: 35033885]
MOLM-13	GI₅₀	0.008 μM Compound: Sorafenib	Antiproliferative activity against FLT3-dependent human MOLM-13 cells assessed as cell growth inhibition incubated for 72 hrs by resorufin dye based fluorescence analysis Antiproliferative activity against FLT3-dependent human MOLM-13 cells assessed as cell growth inhibition incubated for 72 hrs by resorufin dye based fluorescence analysis	[PMID: 37535845]
MOLM-13	GI₅₀	0.934 μM Compound: Sorafenib	Antiproliferative activity against drug-resistant human MOLM-13 cells expressing FLT3-ITD-D835Y mutant assessed as cell growth inhibition incubated for 72 hrs by resorufin dye based fluorescence analysis Antiproliferative activity against drug-resistant human MOLM-13 cells expressing FLT3-ITD-D835Y mutant assessed as cell growth inhibition incubated for 72 hrs by resorufin dye based fluorescence analysis	[PMID: 37535845]
MOLT-4	GI₅₀	9 μM Compound: BAY-439006, 3	Antiproliferation activity against human MOLT4 after 72 hrs by MTS method Antiproliferation activity against human MOLT4 after 72 hrs by MTS method	[PMID: 21708468]
MOLT-4	GI₅₀	3.16 μM Compound: 1	Cytotoxicity against human MOLT4 cells after 48 hrs by SRB method Cytotoxicity against human MOLT4 cells after 48 hrs by SRB method	[PMID: 26590508]
MOLT-4	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human MOLT4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MOLT4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
MOLT-4	GI₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
MOLT-4	IC₅₀	5.94 μM Compound: Sor	Antiproliferative activity against human MOLT-4 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human MOLT-4 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
MOLT-4	IC₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
MOLT-4	IC₅₀	0.001 μM Compound: Sorafenib	Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
MOLT-4	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34237622]
MOLT-4	GI₅₀	3.16 μM Compound: Sorafenib	Anticancer activity against human MOLT-4 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human MOLT-4 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
MOLT-4	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human MOLT-4 cells measured after 48 hrs by SRB assay Antiproliferative activity against human MOLT-4 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
MOLT-4	IC₅₀	2502 nM Compound: 12; Sor	Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 36399923]
MOLT-4	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition	[PMID: 38850857]
MRC5	IC₅₀	24.11 μM Compound: Sorafenib	Antiproliferative activity against human MRC5 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human MRC5 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32739648]
MRC5	IC₅₀	11.1 μM Compound: 1	Cytotoxicity against human MRC5 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 36270111]
MV4-11	IC₅₀	0.87 nM Compound: Sorafenib	Cytotoxicity against human MV4-11 cells after 72 hrs by cell titer-blue assay Cytotoxicity against human MV4-11 cells after 72 hrs by cell titer-blue assay	[PMID: 19654408]
MV4-11	IC₅₀	0.87 nM Compound: BAY-439006, Sorafenib	Antiproliferative activity against human MV4-11 cells after 72 hrs by cell titer-blue cell viability assay Antiproliferative activity against human MV4-11 cells after 72 hrs by cell titer-blue cell viability assay	[PMID: 19754199]
MV4-11	IC₅₀	0.015 μM Compound: 2	Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay	[PMID: 20570526]
MV4-11	GI₅₀	0.03 μM Compound: BAY-439006, 3	Antiproliferation activity against FLT3/ITD harboring human MV4-11 cells after 72 hrs by MTS method Antiproliferation activity against FLT3/ITD harboring human MV4-11 cells after 72 hrs by MTS method	[PMID: 21708468]
MV4-11	IC₅₀	0.007 μM Compound: Sorafenib	Inhibition of FLT3-ITD mutant in human MV4-11 cells assessed as decrease in cell viability after 72 hrs by MTT assay Inhibition of FLT3-ITD mutant in human MV4-11 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 23362959]
MV4-11	GI₅₀	0.043 μM Compound: 2, BAY-43-9006	Cytotoxicity against human MV4-11 cells harboring FLT3/ITD mutant after 72 hrs by MTS assay Cytotoxicity against human MV4-11 cells harboring FLT3/ITD mutant after 72 hrs by MTS assay	[PMID: 23618709]
MV4-11	GI₅₀	0.043 μM Compound: 2	Inhibition of FLT3 ITD homozygous mutant in human MV4-11 cells assessed as cell growth inhibition after 72 hrs by MTS assay Inhibition of FLT3 ITD homozygous mutant in human MV4-11 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 26081023]
MV4-11	IC₅₀	0.007 μM Compound: Sorafenib	Cytotoxicity against human MV4-11 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human MV4-11 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26342867]
MV4-11	IC₅₀	0.3 μM Compound: Sorafenib	Antiproliferative activity human MV4-11 cells after 72 hrs by cell titer-glo luminescence assay Antiproliferative activity human MV4-11 cells after 72 hrs by cell titer-glo luminescence assay	[PMID: 28242553]
MV4-11	IC₅₀	0.004 μM Compound: Sorafenib	Growth inhibition of human MV4-11 cells after 72 hrs by CellTiter-Glo assay Growth inhibition of human MV4-11 cells after 72 hrs by CellTiter-Glo assay	[PMID: 29357250]
MV4-11	IC₅₀	<0.006 μM Compound: Sor	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay	[PMID: 29360358]
MV4-11	IC₅₀	0.3 μM Compound: Sorafenib	Antiproliferative activity against human MV4-11 cells after 72 hrs by Cell-Titer Glo assay Antiproliferative activity against human MV4-11 cells after 72 hrs by Cell-Titer Glo assay	[PMID: 30529543]
MV4-11	IC₅₀	0.51 μM Compound: 1	Antiproliferative activity against human MV4-11 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MV4-11 cells measured after 48 hrs by MTT assay	[PMID: 31053508]
MV4-11	IC₅₀	1.59 nM Compound: Sorafenib	Growth inhibition of human MV4-11 cells measured after 72 hrs by Celltiter-Glo assay Growth inhibition of human MV4-11 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31103903]
MV4-11	GI₅₀	0.0009 μM Compound: 3	Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition after 72 hrs by WST assay Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition after 72 hrs by WST assay	[PMID: 32272419]
MV4-11	IC₅₀	7.7 nM Compound: Sorafenib	Anticancer activity against human MV4-11 cells expressing homozygous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay Anticancer activity against human MV4-11 cells expressing homozygous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay	[PMID: 35033885]
MV4-11	IC₅₀	4 nM Compound: 12; Sor	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 36399923]
MV4-11	IC₅₀	0.87 nM Compound: 4	Antiproliferative activity against human MV4-11 cells by CellTiterGlo assay Antiproliferative activity against human MV4-11 cells by CellTiterGlo assay	10.1039/C1MD00175B
MX1	IC₅₀	8.27 μM Compound: Sorafenib	Cytotoxicity against human MX1 cells assessed as growth inhibition after 120 hrs by MTT assay Cytotoxicity against human MX1 cells assessed as growth inhibition after 120 hrs by MTT assay	[PMID: 24675135]
MX1	IC₅₀	8.27 μM Compound: 1	Antiproliferative activity against human MX1 cells Antiproliferative activity against human MX1 cells	[PMID: 30216849]
NCI/ADR-RES	GI₅₀	2.51 μM Compound: 1	Cytotoxicity against human NCI/ADR-RES cells after 48 hrs by SRB method Cytotoxicity against human NCI/ADR-RES cells after 48 hrs by SRB method	[PMID: 26590508]
NCI/ADR-RES	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
NCI/ADR-RES	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human NCI/ADR-RES cells assessed as reduction in cell growth Antiproliferative activity against human NCI/ADR-RES cells assessed as reduction in cell growth	[PMID: 27155467]
NCI/ADR-RES	GI₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
NCI/ADR-RES	IC₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
NCI/ADR-RES	GI₅₀	2.51 μM Compound: Sorafenib	Anticancer activity against human NCI/ADR-RES cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human NCI/ADR-RES cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
NCI/ADR-RES	IC₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human NCI-ADR-RES cells measured after 48 hrs by SRB assay Antiproliferative activity against human NCI-ADR-RES cells measured after 48 hrs by SRB assay	[PMID: 35764033]
NCI-H1299	IC₅₀	3.4 μM Compound: Sorafenib	Cytotoxicity against human NCI-H1299 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human NCI-H1299 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38354306]
NCI-H1417	IC₅₀	5.84 μM Compound: Sorafenib	Cytotoxicity against human NCI-H1417 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H1417 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
NCI-H146	IC₅₀	8.01 μM Compound: Sorafenib	Cytotoxicity against human NCI-H146 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H146 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
NCI-H1650	IC₅₀	18.09 μM Compound: Sorafenib	Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
NCI-H1975	EC₅₀	>1000 nM Compound: Sorafenib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay	[PMID: 27010810]
NCI-H1975	IC₅₀	9.27 μM Compound: Sorafenib	Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
NCI-H211	IC₅₀	16.47 μM Compound: Sorafenib	Cytotoxicity against human NCI-H211 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H211 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
NCI-H2170	IC₅₀	22.59 μM Compound: Sorafenib	Cytotoxicity against human NCI-H2170 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H2170 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
NCI-H226	GI₅₀	2 μM Compound: 1	Cytotoxicity against human NCI-H226 cells after 48 hrs by SRB method Cytotoxicity against human NCI-H226 cells after 48 hrs by SRB method	[PMID: 26590508]
NCI-H226	GI₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human NCI-H226 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H226 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
NCI-H226	GI₅₀	2 μM Compound: Sorafenib	Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
NCI-H226	IC₅₀	2 μM Compound: Sorafenib	Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
NCI-H226	IC₅₀	7.92 μM Compound: Sorafenib	Cytotoxicity against human NCI-H226 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H226 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
NCI-H226	GI₅₀	2 μM Compound: Sorafenib	Anticancer activity against human NCI-H226 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human NCI-H226 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
NCI-H226	IC₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human NCI-H226 cells measured after 48 hrs by SRB assay Antiproliferative activity against human NCI-H226 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
NCI-H23	GI₅₀	2 μM Compound: 1	Cytotoxicity against human NCI-H23 cells after 48 hrs by SRB method Cytotoxicity against human NCI-H23 cells after 48 hrs by SRB method	[PMID: 26590508]
NCI-H23	GI₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human NCI-H23 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H23 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
NCI-H23	GI₅₀	2 μM Compound: Sorafenib	Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
NCI-H23	IC₅₀	2 μM Compound: Sorafenib	Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
NCI-H23	GI₅₀	2 μM Compound: Sorafenib	Anticancer activity against human NCI-H23 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human NCI-H23 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
NCI-H23	IC₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human NCI-H23 cells measured after 48 hrs by SRB assay Antiproliferative activity against human NCI-H23 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
NCI-H23	IC₅₀	2.4 μM Compound: Sorafenib	Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38354306]
NCI-H322M	GI₅₀	2.51 μM Compound: 1	Cytotoxicity against human NCI-H322M cells after 48 hrs by SRB method Cytotoxicity against human NCI-H322M cells after 48 hrs by SRB method	[PMID: 26590508]
NCI-H322M	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human NCI-H322M cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H322M cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
NCI-H322M	GI₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
NCI-H322M	IC₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
NCI-H322M	IC₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human NCI-H322M cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human NCI-H322M cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34237622]
NCI-H322M	GI₅₀	2.51 μM Compound: Sorafenib	Anticancer activity against human NCI-H322M cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human NCI-H322M cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
NCI-H322M	IC₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human NCI-H322M cells measured after 48 hrs by SRB assay Antiproliferative activity against human NCI-H322M cells measured after 48 hrs by SRB assay	[PMID: 35764033]
NCI-H460	IC₅₀	3.9 μM Compound: Sorafenib	Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay	[PMID: 23454017]
NCI-H460	IC₅₀	10.8 μM Compound: Sorafenib	Cytotoxicity against human H460 cells after 48 hrs by MTT assay Cytotoxicity against human H460 cells after 48 hrs by MTT assay	[PMID: 24300920]
NCI-H460	IC₅₀	2.19 μM Compound: Sorafenib	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 24826815]
NCI-H460	IC₅₀	2.19 μM Compound: 5	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 25086238]
NCI-H460	IC₅₀	2.19 μM Compound: 5	Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 25440879]
NCI-H460	GI₅₀	2.51 μM Compound: 1	Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB method Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB method	[PMID: 26590508]
NCI-H460	IC₅₀	2.25 μM Compound: Sorafenib	Antiproliferative activity against human H460 cells after 72 hrs by MTT assay Antiproliferative activity against human H460 cells after 72 hrs by MTT assay	[PMID: 26991938]
NCI-H460	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
NCI-H460	GI₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
NCI-H460	IC₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
NCI-H460	IC₅₀	2.19 μM Compound: 1	Antiproliferative activity against human NCI-H460 cells Antiproliferative activity against human NCI-H460 cells	[PMID: 30216849]
NCI-H460	IC₅₀	2.15 μM Compound: Sorafenib	Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32739648]
NCI-H460	IC₅₀	3.68 μM Compound: Sorafenib	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
NCI-H460	GI₅₀	2.51 μM Compound: Sorafenib	Anticancer activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
NCI-H460	IC₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by SRB assay Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
NCI-H460	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition	[PMID: 38850857]
NCI-H520	IC₅₀	11.5 μM Compound: Sorafenib	Cytotoxicity against human NCI-H520 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H520 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
NCI-H522	IC₅₀	19.26 μM Compound: Sorafenib	Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 25461318]
NCI-H522	GI₅₀	2 μM Compound: 1	Cytotoxicity against human NCI-H522 cells after 48 hrs by SRB method Cytotoxicity against human NCI-H522 cells after 48 hrs by SRB method	[PMID: 26590508]
NCI-H522	GI₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human NCI-H522 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H522 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
NCI-H522	GI₅₀	2 μM Compound: Sorafenib	Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
NCI-H522	IC₅₀	2 μM Compound: Sorafenib	Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
NCI-H522	IC₅₀	5.01 μM Compound: Sorafenib	Antiproliferative activity against human NCI-H522 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human NCI-H522 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34237622]
NCI-H522	GI₅₀	2 μM Compound: Sorafenib	Anticancer activity against human NCI-H522 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human NCI-H522 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
NCI-H522	IC₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human NCI-H522 cells measured after 48 hrs by SRB assay Antiproliferative activity against human NCI-H522 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
NCI-H526	IC₅₀	14.68 μM Compound: Sorafenib	Cytotoxicity against human NCI-H526 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H526 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
NCI-H82	IC₅₀	1.77 μM Compound: Sorafenib	Cytotoxicity against human NCI-H82 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H82 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
Neutrophil	IC₅₀	1.27 μM Compound: Sorafenib	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide generation after 5 mins by spectrophotometric analysis Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide generation after 5 mins by spectrophotometric analysis	[PMID: 23647825]
Neutrophil	IC₅₀	5.62 μM Compound: Sorafenib	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins by spectrophotometric analysis Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins by spectrophotometric analysis	[PMID: 23647825]
Neutrophil	IC₅₀	2 μM Compound: Sorafenib	Antiinflammatory activity in human neutrophils assessed as FMLP/cytochalasin B-induced elastase release after 5 mins by spectrophotometry Antiinflammatory activity in human neutrophils assessed as FMLP/cytochalasin B-induced elastase release after 5 mins by spectrophotometry	[PMID: 24388689]
Neutrophil	IC₅₀	3.2 μM Compound: Sorafenib	Antiinflammatory activity in human neutrophils assessed as FMLP/cytochalasin B-induced superoxide anion generation after 5 mins by spectrophotometry Antiinflammatory activity in human neutrophils assessed as FMLP/cytochalasin B-induced superoxide anion generation after 5 mins by spectrophotometry	[PMID: 24388689]
Neutrophil	IC₅₀	1.9 μM Compound: Sorafenib	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins by spectrophotometry Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins by spectrophotometry	[PMID: 25419616]
Neutrophil	IC₅₀	6.3 μM Compound: Sorafenib	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins by spectrophotometry Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins by spectrophotometry	[PMID: 25419616]
Neutrophil	IC₅₀	2 μM Compound: Sorafenib	Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as substrate incubated for 5 mins by spectrophotometric analysis Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as substrate incubated for 5 mins by spectrophotometric analysis	[PMID: 26928286]
Neutrophil	IC₅₀	3.2 μM Compound: Sorafenib	Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion generation by measuring superoxide dismutase-inhibitable reduction of ferricytochrome c by spectrophotometric analysis Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion generation by measuring superoxide dismutase-inhibitable reduction of ferricytochrome c by spectrophotometric analysis	[PMID: 26928286]
Neutrophil	IC₅₀	0.9 μg/mL Compound: Sorafenib	Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release pre-incubated for 5 mins before fMLP/CB stimulation using MeO-Suc-Ala-Ala-Pro-Val-pnitroanilide as substrate Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release pre-incubated for 5 mins before fMLP/CB stimulation using MeO-Suc-Ala-Ala-Pro-Val-pnitroanilide as substrate	[PMID: 28218000]
Neutrophil	IC₅₀	1.5 μg/mL Compound: Sorafenib	Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase SOD-inhibitable ferricytochrome c reduction incubated for 5 mins before fMLP/CB stimulation for 3 mins Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase SOD-inhibitable ferricytochrome c reduction incubated for 5 mins before fMLP/CB stimulation for 3 mins	[PMID: 28218000]
NIH3T3	IC₅₀	24.75 μM Compound: Sorafenib, Nexavar	Antiproliferation activity against mouse NIH/3T3 cells after 48 hrs by MTT assay in presence of bovine calf serum Antiproliferation activity against mouse NIH/3T3 cells after 48 hrs by MTT assay in presence of bovine calf serum	[PMID: 21592628]
NIH3T3	IC₅₀	24.75 μM Compound: Sorafenib, Nexavar	Antiproliferative activity against mouse NIH/3T3 cells Antiproliferative activity against mouse NIH/3T3 cells	[PMID: 22647720]
NIH3T3	GI₅₀	>10 μM Compound: Sorafenib	Growth inhibition of human NIH3T3 cells incubated for 3 days by MTT assay Growth inhibition of human NIH3T3 cells incubated for 3 days by MTT assay	[PMID: 29133048]
NIH3T3	GI₅₀	0.32 μM Compound: Sorafenib	Growth inhibition of human NIH3T3 cells harboring RET C634Y mutant incubated for 3 days by MTT assay Growth inhibition of human NIH3T3 cells harboring RET C634Y mutant incubated for 3 days by MTT assay	[PMID: 29133048]
Non-small cell lung cancer cell line	GI₅₀	2.25 μM Compound: Sorafenib	Antiproliferative activity against human Panel non-small cell lung cancer (8 Carcinoma cell lines) assessed as reduction in mean cell growth Antiproliferative activity against human Panel non-small cell lung cancer (8 Carcinoma cell lines) assessed as reduction in mean cell growth	[PMID: 27155467]
OS-RC-2	IC₅₀	16 μM Compound: Sorafenib	Cytotoxicity against human OS-RC2 cells after 72 hrs by MTT assay Cytotoxicity against human OS-RC2 cells after 72 hrs by MTT assay	[PMID: 23454017]
OS-RC-2	IC₅₀	7 μM Compound: Sorafenib	Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK8 assay Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK8 assay	[PMID: 29297688]
OS-RC-2	IC₅₀	7 μM Compound: Sorafenib	Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK-8 assay Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK-8 assay	[PMID: 29517908]
OS-RC-2	IC₅₀	15 μM Compound: Sorafenib	Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK8 assay Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK8 assay	[PMID: 29786436]
OS-RC-2	IC₅₀	14 μM Compound: Sora	Cytotoxicity against human OS-RC2 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay Cytotoxicity against human OS-RC2 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay	[PMID: 31298537]
OS-RC-2	IC₅₀	~ 9 μM Compound: Sorafenib	Antiproliferative activity against human OS-RC-2 cells assessed as inhibition of cell growth incubated for 48 hrs Antiproliferative activity against human OS-RC-2 cells assessed as inhibition of cell growth incubated for 48 hrs	[PMID: 38354523]
OVCAR-3	GI₅₀	3.16 μM Compound: 1	Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB method Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB method	[PMID: 26590508]
OVCAR-3	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
OVCAR-3	GI₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
OVCAR-3	IC₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
OVCAR-3	IC₅₀	12 μM Compound: Sorafenib	Anticancer activity against human OVCAR3 assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human OVCAR3 assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30826508]
OVCAR-3	GI₅₀	3.16 μM Compound: Sorafenib	Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
OVCAR-3	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human OVCAR-3 cells measured after 48 hrs by SRB assay Antiproliferative activity against human OVCAR-3 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
OVCAR-3	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human OVCAR-3 cells assessed as cell growth inhibition Antiproliferative activity against human OVCAR-3 cells assessed as cell growth inhibition	[PMID: 38850857]
OVCAR-4	GI₅₀	3.16 μM Compound: 1	Cytotoxicity against human OVCAR4 cells after 48 hrs by SRB method Cytotoxicity against human OVCAR4 cells after 48 hrs by SRB method	[PMID: 26590508]
OVCAR-4	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human OVCAR4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human OVCAR4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
OVCAR-4	GI₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
OVCAR-4	IC₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
OVCAR-4	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human OVCAR-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human OVCAR-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34237622]
OVCAR-4	GI₅₀	3.16 μM Compound: Sorafenib	Anticancer activity against human OVCAR-4 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human OVCAR-4 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
OVCAR-4	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human OVCAR-4 cells measured after 48 hrs by SRB assay Antiproliferative activity against human OVCAR-4 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
OVCAR-4	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human OVCAR-4 cells assessed as cell growth inhibition Antiproliferative activity against human OVCAR-4 cells assessed as cell growth inhibition	[PMID: 38850857]
OVCAR-5	GI₅₀	3.16 μM Compound: 1	Cytotoxicity against human OVCAR5 cells after 48 hrs by SRB method Cytotoxicity against human OVCAR5 cells after 48 hrs by SRB method	[PMID: 26590508]
OVCAR-5	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human OVCAR5 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human OVCAR5 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
OVCAR-5	GI₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
OVCAR-5	IC₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
OVCAR-5	GI₅₀	3.16 μM Compound: Sorafenib	Anticancer activity against human OVCAR-5 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human OVCAR-5 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
OVCAR-5	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human OVCAR-5 cells measured after 48 hrs by SRB assay Antiproliferative activity against human OVCAR-5 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
OVCAR-8	GI₅₀	2.51 μM Compound: 1	Cytotoxicity against human OVCAR8 cells after 48 hrs by SRB method Cytotoxicity against human OVCAR8 cells after 48 hrs by SRB method	[PMID: 26590508]
OVCAR-8	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human OVCAR8 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human OVCAR8 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
OVCAR-8	GI₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
OVCAR-8	IC₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
OVCAR-8	GI₅₀	3.16 μM Compound: Sorafenib	Anticancer activity against human OVCAR-8 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human OVCAR-8 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
OVCAR-8	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human OVCAR-8 cells measured after 48 hrs by SRB assay Antiproliferative activity against human OVCAR-8 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
PANC-1	IC₅₀	12.3 μM Compound: Sorafenib	Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay	[PMID: 24300920]
PANC-1	IC₅₀	11.5 μM Compound: Sorafenib	Cytotoxicity against human PANC1 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 27503679]
PANC-1	IC₅₀	9.32 μM Compound: Sorafenib	Growth inhibition of human PANC1 cells after 48 hrs by MTT assay Growth inhibition of human PANC1 cells after 48 hrs by MTT assay	[PMID: 29102175]
PANC-1	IC₅₀	0.15 μM Compound: Sorafenib	Antiproliferative activity against human PANC1 cells Antiproliferative activity against human PANC1 cells	[PMID: 30503935]
PANC-1	IC₅₀	20 μM Compound: Sorafenib	Anticancer activity against human PANC1 assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human PANC1 assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30826508]
Panel breast (Carcinoma cell lines)	GI₅₀	2.17 μM Compound: Sorafenib	Antiproliferative activity against human Panel breast (6 Carcinoma cell lines) assessed as reduction in mean cell growth Antiproliferative activity against human Panel breast (6 Carcinoma cell lines) assessed as reduction in mean cell growth	[PMID: 27155467]
Panel CNS (Carcinoma cell lines)	GI₅₀	2.33 μM Compound: Sorafenib	Antiproliferative activity against human Panel CNS (6 Carcinoma cell lines) assessed as reduction in mean cell growth Antiproliferative activity against human Panel CNS (6 Carcinoma cell lines) assessed as reduction in mean cell growth	[PMID: 27155467]
Panel colon (Carcinoma cell lines)	GI₅₀	2.19 μM Compound: Sorafenib	Antiproliferative activity against human Panel colon (7 Carcinoma cell lines) assessed as reduction in mean cell growth Antiproliferative activity against human Panel colon (7 Carcinoma cell lines) assessed as reduction in mean cell growth	[PMID: 27155467]
Panel leukemia (Carcinoma cell lines)	GI₅₀	2.43 μM Compound: Sorafenib	Antiproliferative activity against human Panel leukemia (5 Carcinoma cell lines) assessed as reduction in mean cell growth Antiproliferative activity against human Panel leukemia (5 Carcinoma cell lines) assessed as reduction in mean cell growth	[PMID: 27155467]
Panel melanoma (Carcinoma cell lines)	GI₅₀	1.87 μM Compound: Sorafenib	Antiproliferative activity against human Panel melanoma (9 Carcinoma cell lines) assessed as reduction in mean cell growth Antiproliferative activity against human Panel melanoma (9 Carcinoma cell lines) assessed as reduction in mean cell growth	[PMID: 27155467]
Panel ovarian (Carcinoma cell lines)	GI₅₀	2.88 μM Compound: Sorafenib	Antiproliferative activity against human Panel ovarian (7 Carcinoma cell lines) assessed as reduction in mean cell growth Antiproliferative activity against human Panel ovarian (7 Carcinoma cell lines) assessed as reduction in mean cell growth	[PMID: 27155467]
Panel prostate (Carcinoma cell lines)	GI₅₀	2.58 μM Compound: Sorafenib	Antiproliferative activity against human Panel prostate (2 Carcinoma cell lines) assessed as reduction in mean cell growth Antiproliferative activity against human Panel prostate (2 Carcinoma cell lines) assessed as reduction in mean cell growth	[PMID: 27155467]
Panel renal (Carcinoma cell lines)	GI₅₀	2.94 μM Compound: Sorafenib	Antiproliferative activity against human Panel renal (8 Carcinoma cell lines) assessed as reduction in mean cell growth Antiproliferative activity against human Panel renal (8 Carcinoma cell lines) assessed as reduction in mean cell growth	[PMID: 27155467]
PC-3	IC₅₀	6.8 μM Compound: Sorafenib, Nexavar, BAY-439006	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 23021967]
PC-3	IC₅₀	24.2 μM Compound: Sorafenib, BAY 43-9006	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 23644219]
PC-3	IC₅₀	24.2 μM Compound: Sorafenib	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 24440479]
PC-3	IC₅₀	4.13 μM Compound: Sorafenib	Antiproliferative activity against human PC3 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay	[PMID: 25778995]
PC-3	GI₅₀	2 μM Compound: 1	Cytotoxicity against human PC3 cells after 48 hrs by SRB method Cytotoxicity against human PC3 cells after 48 hrs by SRB method	[PMID: 26590508]
PC-3	GI₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
PC-3	IC₅₀	8.08 μM Compound: Sorafenib	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27043268]
PC-3	GI₅₀	1.99 μM Compound: Sorafenib	Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth	[PMID: 27155467]
PC-3	IC₅₀	3.24 μM Compound: Sorafenib	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 27777009]
PC-3	GI₅₀	2 μM Compound: Sorafenib	Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
PC-3	IC₅₀	3.03 μM Compound: Sorafenib	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 28340913]
PC-3	IC₅₀	3.18 μM Compound: Sorafenib	Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28927801]
PC-3	IC₅₀	2 μM Compound: Sorafenib	Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
PC-3	IC₅₀	9.77 μM Compound: Sorafenib	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay	[PMID: 32422489]
PC-3	IC₅₀	0.001 μM Compound: Sorafenib	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
PC-3	IC₅₀	15.5 μM Compound: Sorafenib	Antiproliferative activity against human PC-3 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human PC-3 cells incubated for 48 hrs by MTT assay	[PMID: 33328104]
PC-3	IC₅₀	6.3 μM Compound: 1	Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34634618]
PC-3	GI₅₀	2 μM Compound: Sorafenib	Anticancer activity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
PC-3	IC₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human PC-3 cells measured after 48 hrs by SRB assay Antiproliferative activity against human PC-3 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
PC-3	IC₅₀	11.53 μM Compound: SOR	Antiproliferative activity against human PC-3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC-3 cells after 72 hrs by MTT assay	[PMID: 35964425]
PC-3	GI₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition	[PMID: 38850857]
PC-3	IC₅₀	10.98 μM Compound: Sorafenib	Antiproliferative activity against human PC3 cells by MTT assay Antiproliferative activity against human PC3 cells by MTT assay	10.1039/C4MD00536H
PLC-PRF-5	IC₅₀	8.3 μM Compound: BAY-439006, Nexavar	Cytotoxicity against human PLC/PRF/5 cells assessed as growth inhibition Cytotoxicity against human PLC/PRF/5 cells assessed as growth inhibition	[PMID: 21531053]
PLC-PRF-5	IC₅₀	29.9 μM Compound: Sorafenib	Cytotoxicity against human PLC/PRF/5 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human PLC/PRF/5 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 28109948]
PLC-PRF-5	IC₅₀	7.51 μM Compound: Sor	Antiproliferative activity against human PLC-PRF-5 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human PLC-PRF-5 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
PLC-PRF-5	IC₅₀	0.001 μM Compound: Sorafenib	Cytotoxicity against human PLC-PRF-5 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human PLC-PRF-5 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
Raji	IC₅₀	3.94 μM Compound: Sor	Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
Raji	IC₅₀	0.001 μM Compound: Sorafenib	Cytotoxicity against human Raji cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human Raji cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
Ramos	IC₅₀	0.001 μM Compound: Sorafenib	Cytotoxicity against human Ramos cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human Ramos cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
Rhabdomyosarcoma cell	CC₅₀	7.05 μM Compound: Sorafenib	Cytotoxicity activity against human rhabdomyosarcoma cells after 24 hrs by MTT assay Cytotoxicity activity against human rhabdomyosarcoma cells after 24 hrs by MTT assay	[PMID: 27288186]
RKO	IC₅₀	24.18 μM Compound: Sorafenib	Antiproliferative activity against human RKO cells measured after 72 hrs by MTT assay Antiproliferative activity against human RKO cells measured after 72 hrs by MTT assay	[PMID: 35462164]
RPMI-8226	GI₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human RPMI8226 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human RPMI8226 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
RPMI-8226	GI₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
RPMI-8226	IC₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
RPMI-8226	GI₅₀	1.58 μM Compound: Sorafenib	Anticancer activity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
RPMI-8226	IC₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human RPMI-8226 cells measured after 48 hrs by SRB assay Antiproliferative activity against human RPMI-8226 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
RS4-11	IC₅₀	2 nM Compound: Sorafenib	Inhibition of FLT3 ITD mutant autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay Inhibition of FLT3 ITD mutant autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay	[PMID: 19654408]
RS4-11	IC₅₀	3.2 nM Compound: Sorafenib	Inhibition of FLT3 autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay Inhibition of FLT3 autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay	[PMID: 19654408]
RS4-11	IC₅₀	>5 μM Compound: 2	Antiproliferative activity against human RS4:11 cells after 72 hrs by MTT assay Antiproliferative activity against human RS4:11 cells after 72 hrs by MTT assay	[PMID: 20570526]
RS4-11	GI₅₀	9.4 μM Compound: BAY-439006, 3	Antiproliferation activity against human RS4:11 cells expressing wild type FLT3 after 72 hrs by MTS method Antiproliferation activity against human RS4:11 cells expressing wild type FLT3 after 72 hrs by MTS method	[PMID: 21708468]
RS4-11	GI₅₀	9.3 μM Compound: 2, BAY-43-9006	Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by MTS assay Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by MTS assay	[PMID: 23618709]
RXF 393	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human RXF393 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human RXF393 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
RXF 393	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human RXF 393 cells assessed as reduction in cell growth Antiproliferative activity against human RXF 393 cells assessed as reduction in cell growth	[PMID: 27155467]
RXF 393	GI₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
RXF 393	IC₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
RXF 393	GI₅₀	3.16 μM Compound: Sorafenib	Anticancer activity against human RXF 393 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human RXF 393 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
RXF 393	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human RXF 393 cells measured after 48 hrs by SRB assay Antiproliferative activity against human RXF 393 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
RXF 393	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human RXF 393 cells assessed as cell growth inhibition Antiproliferative activity against human RXF 393 cells assessed as cell growth inhibition	[PMID: 38850857]
SF-268	GI₅₀	2.51 μM Compound: 1	Cytotoxicity against human SF268 cells after 48 hrs by SRB method Cytotoxicity against human SF268 cells after 48 hrs by SRB method	[PMID: 26590508]
SF-268	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human SF268 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human SF268 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
SF-268	GI₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
SF-268	IC₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
SF-268	GI₅₀	2.51 μM Compound: Sorafenib	Anticancer activity against human SF-268 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human SF-268 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
SF-268	IC₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human SF-268 cells measured after 48 hrs by SRB assay Antiproliferative activity against human SF-268 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
SF-295	GI₅₀	1.58 μM Compound: 1	Cytotoxicity against human SF295 cells after 48 hrs by SRB method Cytotoxicity against human SF295 cells after 48 hrs by SRB method	[PMID: 26590508]
SF-295	GI₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human SF295 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human SF295 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
SF-295	GI₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
SF-295	IC₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
SF-295	GI₅₀	1.58 μM Compound: Sorafenib	Anticancer activity against human SF-295 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human SF-295 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
SF-295	IC₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human SF-295 cells measured after 48 hrs by SRB assay Antiproliferative activity against human SF-295 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
SF-295	GI₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human SF-295 cells assessed as cell growth inhibition Antiproliferative activity against human SF-295 cells assessed as cell growth inhibition	[PMID: 38850857]
SF-539	GI₅₀	1.58 μM Compound: 1	Cytotoxicity against human SF539 cells after 48 hrs by SRB method Cytotoxicity against human SF539 cells after 48 hrs by SRB method	[PMID: 26590508]
SF-539	GI₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human SF539 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human SF539 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
SF-539	GI₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
SF-539	IC₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
SF-539	GI₅₀	1.58 μM Compound: Sorafenib	Anticancer activity against human SF-539 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human SF-539 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
SF-539	IC₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human SF-539 cells measured after 48 hrs by SRB assay Antiproliferative activity against human SF-539 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
SF-539	GI₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human SF-539 cells assessed as cell growth inhibition Antiproliferative activity against human SF-539 cells assessed as cell growth inhibition	[PMID: 38850857]
Sf9	IC₅₀	0.043 μM Compound: 2, sorafenib	Inhibition of human BRAF V600E mutant expressed in SF9 cells Inhibition of human BRAF V600E mutant expressed in SF9 cells	[PMID: 18473434]
Sf9	IC₅₀	0.003 μM Compound: BAY-439006, 3	Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay	[PMID: 21708468]
Sf9	IC₅₀	0.018 μM Compound: BAY-439006, 3	Inhibition of recombinant GST-tagged VEGFR1 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay Inhibition of recombinant GST-tagged VEGFR1 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay	[PMID: 21708468]
Sf9	IC₅₀	0.054 μM Compound: BAY-439006, 3	Inhibition of GST-tagged FLT3 expressing wild type kinase domain expressed in Sf9 insect cells after 4 hrs by Kinase-Glo assay Inhibition of GST-tagged FLT3 expressing wild type kinase domain expressed in Sf9 insect cells after 4 hrs by Kinase-Glo assay	[PMID: 21708468]
Sf9	IC₅₀	3.8 μM Compound: BAY-439006, 3	Inhibition of recombinant GST-tagged Aurora A expressed in Sf9 insect cells after 90 mins by Kinase-Glo assay Inhibition of recombinant GST-tagged Aurora A expressed in Sf9 insect cells after 90 mins by Kinase-Glo assay	[PMID: 21708468]
Sf9	IC₅₀	<100 nM Compound: Sorafenib	Inhibition of mouse PDGFRbeta expressed in SF9 insect cells by TR-FRET assay Inhibition of mouse PDGFRbeta expressed in SF9 insect cells by TR-FRET assay	[PMID: 23442188]
Sf9	IC₅₀	<100 nM Compound: Sorafenib	Inhibition of VEGFR2 (unknown origin) expressed in SF9 insect cells by TR-FRET assay Inhibition of VEGFR2 (unknown origin) expressed in SF9 insect cells by TR-FRET assay	[PMID: 23442188]
Sf9	IC₅₀	90 nM Compound: sorafenib	Inhibition of human VEGFR2 kinase domain expressed in SF9 cells by TR-FRET assay Inhibition of human VEGFR2 kinase domain expressed in SF9 cells by TR-FRET assay	[PMID: 23562241]
Sf9	IC₅₀	0.02 μM Compound: 2, BAY-43-9006	Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis	[PMID: 23618709]
Sf9	IC₅₀	0.054 μM Compound: 2, BAY-43-9006	Inhibition of wild type GST tagged FLT3 kinase (567 to 993) (unknown origin) transfected in insect sf9 cells after 4 hrs by wallac counting analysis Inhibition of wild type GST tagged FLT3 kinase (567 to 993) (unknown origin) transfected in insect sf9 cells after 4 hrs by wallac counting analysis	[PMID: 23618709]
Sf9	IC₅₀	3.8 μM Compound: 2, BAY-43-9006	Inhibition of recombinant GST tagged Aurora A kinase (123 to 401) (unknown origin) transfected in insect sf9 cells after 90 mins by wallac counting analysis Inhibition of recombinant GST tagged Aurora A kinase (123 to 401) (unknown origin) transfected in insect sf9 cells after 90 mins by wallac counting analysis	[PMID: 23618709]
Sf9	IC₅₀	0.042 μM Compound: 2	Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay	[PMID: 26081023]
Sf9	IC₅₀	0.044 μM Compound: 2	Inhibition of wild type GST-tagged FLT3 kinase domain (Y567 to S993) (unknown origin) expressed in baculovirus infected insect Sf9 cells using Her2 peptide as substrate after 4 hrs by Kinase-Glo assay Inhibition of wild type GST-tagged FLT3 kinase domain (Y567 to S993) (unknown origin) expressed in baculovirus infected insect Sf9 cells using Her2 peptide as substrate after 4 hrs by Kinase-Glo assay	[PMID: 26081023]
Sf9	IC₅₀	3.8 μM Compound: 2	Inhibition of recombinant GST-tagged Aurora-A kinase domain (S123 to S401) (unknown origin) expressed in insect Sf9 cells using tetra(LRRASLG) peptide as substrate after 90 mins by Kinase-Glo assay Inhibition of recombinant GST-tagged Aurora-A kinase domain (S123 to S401) (unknown origin) expressed in insect Sf9 cells using tetra(LRRASLG) peptide as substrate after 90 mins by Kinase-Glo assay	[PMID: 26081023]
Sf9	IC₅₀	0.057 μM Compound: Sorafenib	Inhibition of recombinant human N-terminal GST-tagged EGFR (695 to end) expressed in baculovirus infected Sf9 cells using ATP as substrate after 40 mins by Kinase-Glo MAX luminescence assay Inhibition of recombinant human N-terminal GST-tagged EGFR (695 to end) expressed in baculovirus infected Sf9 cells using ATP as substrate after 40 mins by Kinase-Glo MAX luminescence assay	[PMID: 30826508]
Sf9	IC₅₀	0.1 μM Compound: I; BAY 43-9006	Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay	[PMID: 31284081]
Sf9	IC₅₀	14520 nM Compound: 59	Inhibition of human full length N-terminal GST-tagged RIPK3 expressed in baculovirus infected sf9 insect cells assessed as reduction in MBP phosphorylation using MBP as substrate by kinase-Glo luminescence assay Inhibition of human full length N-terminal GST-tagged RIPK3 expressed in baculovirus infected sf9 insect cells assessed as reduction in MBP phosphorylation using MBP as substrate by kinase-Glo luminescence assay	[PMID: 31622096]
SGC-7901	IC₅₀	10.37 μM Compound: Sorafenib	Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay	[PMID: 20435479]
SGC-7901	IC₅₀	6.9 μM Compound: Sorafenib	Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay	[PMID: 23454017]
SGC-7901	IC₅₀	11.5 μM Compound: Sorafenib	Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay	[PMID: 24300920]
SGC-7901	IC₅₀	101 μM Compound: Sorafenib	Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay	[PMID: 24315192]
SGC-7901	IC₅₀	8.84 μM Compound: Sorafenib	Antiproliferative activity against human SGC-7901 cells measured after 72 hrs by MTT assay Antiproliferative activity against human SGC-7901 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
SGC-7901	IC₅₀	102 μM Compound: BAY-93-4006	Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay	10.1039/C3MD00192J
SH-SY5Y	IC₅₀	19.54 μM Compound: Sorafenib	Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay	[PMID: 23871909]
SH-SY5Y	IC₅₀	5.73 μM Compound: Sorafenib	Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTT assay Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTT assay	[PMID: 24315192]
SH-SY5Y	IC₅₀	27.71 μM Compound: Sorafenib	Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay	[PMID: 27162123]
SH-SY5Y	IC₅₀	>100 μM Compound: Sorafenib	Antiproliferative activity against human SH-SY5Y cells incubated for 72 hrs by MTT assay Antiproliferative activity against human SH-SY5Y cells incubated for 72 hrs by MTT assay	[PMID: 31488358]
SH-SY5Y	IC₅₀	5.73 μM Compound: BAY-93-4006	Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTT assay Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTT assay	10.1039/C3MD00192J
SK-BR-3	IC₅₀	5.21 μM Compound: BAY-93-4006	Antiproliferative activity against human SK-BR-3 cells after 48 hrs by MTT assay Antiproliferative activity against human SK-BR-3 cells after 48 hrs by MTT assay	10.1039/C3MD00192J
SK-HEP1	IC₅₀	8.37 μM Compound: Sor	Antiproliferative activity against human SK-HEP1 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human SK-HEP1 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
SK-HEP1	IC₅₀	9.64 μM Compound: Sorafenib	Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 32791397]
SK-HEP1	IC₅₀	0.001 μM Compound: Sorafenib	Cytotoxicity against human SK-HEP1 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human SK-HEP1 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
SK-HEP1	IC₅₀	7.3 μM Compound: 1	Anticancer activity against human SK-HEP1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Anticancer activity against human SK-HEP1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34634618]
SK-HEP1	IC₅₀	1.98 μM Compound: sorafenib	Antiproliferative activity against human SK-HEP1 cells treated for 72 hrs by MTT assay Antiproliferative activity against human SK-HEP1 cells treated for 72 hrs by MTT assay	[PMID: 35639640]
SK-HEP1	IC₅₀	8.63 μM Compound: Sorafenib	Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 37182331]
SK-HEP1	IC₅₀	11.7 μM Compound: Sorafenib	Anti-hepatoma activity against human SK-HEP1 cells assessed as inhibition of cell growth incubated for 48 hrs Anti-hepatoma activity against human SK-HEP1 cells assessed as inhibition of cell growth incubated for 48 hrs	[PMID: 38521176]
SK-MEL	IC₅₀	10 μM Compound: Sorafenib	Cytotoxicity against human SK-MEL cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human SK-MEL cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33882233]
SK-MEL-2	GI₅₀	1.58 μM Compound: 1	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB method Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB method	[PMID: 26590508]
SK-MEL-2	GI₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human SK-MEL-2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human SK-MEL-2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
SK-MEL-2	GI₅₀	2 μM Compound: Sorafenib	Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
SK-MEL-2	IC₅₀	11.35 μM Compound: Sorafenib	Antiproliferative activity human SK-MEL-2 cells after 72 hrs by cell titer-glo luminescence assay Antiproliferative activity human SK-MEL-2 cells after 72 hrs by cell titer-glo luminescence assay	[PMID: 28242553]
SK-MEL-2	IC₅₀	2 μM Compound: Sorafenib	Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
SK-MEL-2	IC₅₀	11.4 μM Compound: Sorafenib	Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by Cell-Titer Glo assay Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by Cell-Titer Glo assay	[PMID: 30529543]
SK-MEL-2	GI₅₀	2 μM Compound: Sorafenib	Anticancer activity against human SK-MEL-2 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human SK-MEL-2 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
SK-MEL-2	IC₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human SK-MEL-2 cells measured after 48 hrs by SRB assay Antiproliferative activity against human SK-MEL-2 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
SK-MEL-28	EC₅₀	1.3 μM Compound: 1, sorafenib, BAY-439006	Antiproliferative activity against human SK-MEL-28 cells after 3 days by WST-1 assay Antiproliferative activity against human SK-MEL-28 cells after 3 days by WST-1 assay	[PMID: 18942827]
SK-MEL-28	GI₅₀	2 μM Compound: 1	Cytotoxicity against human SK-MEL-28 cells after 48 hrs by SRB method Cytotoxicity against human SK-MEL-28 cells after 48 hrs by SRB method	[PMID: 26590508]
SK-MEL-28	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human SK-MEL-28 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human SK-MEL-28 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
SK-MEL-28	GI₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
SK-MEL-28	IC₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
SK-MEL-28	IC₅₀	9.45 μM Compound: Sorafenib	Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability by MTT assay	[PMID: 30955995]
SK-MEL-28	IC₅₀	1.95 μM Compound: Sorafenib	Antiproliferative activity against human SK-MEL-28 cells measured after 48 hrs by MTT assay Antiproliferative activity against human SK-MEL-28 cells measured after 48 hrs by MTT assay	[PMID: 33316752]
SK-MEL-28	GI₅₀	2.51 μM Compound: Sorafenib	Anticancer activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
SK-MEL-28	IC₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human SK-MEL-28 cells measured after 48 hrs by SRB assay Antiproliferative activity against human SK-MEL-28 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
SK-MEL-28	IC₅₀	9.49 μM Compound: Sorafenib	Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability by MTT assay	[PMID: 38744089]
SK-MEL-28	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition	[PMID: 38850857]
SK-MEL-30	IC₅₀	3900 nM Compound: 1	Cytotoxicity against human SK-MEL-30 cells after 48 hrs by CellTiter-Glo assay Cytotoxicity against human SK-MEL-30 cells after 48 hrs by CellTiter-Glo assay	[PMID: 29461827]
SK-MEL-5	GI₅₀	1.58 μM Compound: 1	Cytotoxicity against human SK-MEL-5 cells after 48 hrs by SRB method Cytotoxicity against human SK-MEL-5 cells after 48 hrs by SRB method	[PMID: 26590508]
SK-MEL-5	GI₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human SK-MEL-5 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human SK-MEL-5 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
SK-MEL-5	GI₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human SK-MEL-5 cells assessed as reduction in cell growth Antiproliferative activity against human SK-MEL-5 cells assessed as reduction in cell growth	[PMID: 27155467]
SK-MEL-5	GI₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
SK-MEL-5	IC₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
SK-MEL-5	IC₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34237622]
SK-MEL-5	GI₅₀	1.58 μM Compound: Sorafenib	Anticancer activity against human SK-MEL-5 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human SK-MEL-5 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
SK-MEL-5	IC₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human SK-MEL-5 cells measured after 48 hrs by SRB assay Antiproliferative activity against human SK-MEL-5 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
SK-OV-3	IC₅₀	9.25 μM Compound: Sorafenib	Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 24300920]
SK-OV-3	GI₅₀	2.51 μM Compound: 1	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB method Cytotoxicity against human SKOV3 cells after 48 hrs by SRB method	[PMID: 26590508]
SK-OV-3	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human SKOV3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human SKOV3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
SK-OV-3	GI₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
SK-OV-3	IC₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
SK-OV-3	GI₅₀	2.51 μM Compound: Sorafenib	Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
SK-OV-3	IC₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human SK-OV-3 cells measured after 48 hrs by SRB assay Antiproliferative activity against human SK-OV-3 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
SMMC-7721	IC₅₀	17.3 μM Compound: sorafenib	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT based ELISA Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT based ELISA	[PMID: 21504204]
SMMC-7721	IC₅₀	6.23 μM Compound: Sorafenib	Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 22721924]
SMMC-7721	IC₅₀	18.7 μM Compound: Sorafenib	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 24300920]
SMMC-7721	IC₅₀	9.96 μM Compound: Sorafenib	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 25637123]
SMMC-7721	IC₅₀	0.37 μM Compound: Sorafenib	Cytotoxicity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25982075]
SMMC-7721	IC₅₀	0.65 μM Compound: BAY-43-9006	Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition after after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition after after 48 hrs by MTT assay	[PMID: 26342134]
SMMC-7721	IC₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26753815]
SMMC-7721	IC₅₀	10.61 μM Compound: Sorafenib	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 29032031]
SMMC-7721	IC₅₀	0.3 μM Compound: Sorafenib	Antiproliferative activity against human SMMC7721 cells Antiproliferative activity against human SMMC7721 cells	[PMID: 30503935]
SMMC-7721	IC₅₀	>10 μM Compound: Sorafenib	Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32842729]
SMMC-7721	IC₅₀	4.88 μM Compound: Sorafenib	Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35525080]
SMMC-7721	IC₅₀	2.37 μM Compound: sorafenib	Antiproliferative activity against human SMMC-7721 cells treated for 72 hrs by MTT assay Antiproliferative activity against human SMMC-7721 cells treated for 72 hrs by MTT assay	[PMID: 35639640]
SMMC-7721	IC₅₀	8.8 μM Compound: Sorafenib	Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36745506]
SMMC-7721	IC₅₀	9.86 μM Compound: BAY-93-4006	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	10.1039/C3MD00192J
SN12C	GI₅₀	2.51 μM Compound: 1	Cytotoxicity against human SN12C cells after 48 hrs by SRB method Cytotoxicity against human SN12C cells after 48 hrs by SRB method	[PMID: 26590508]
SN12C	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human SN12C cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human SN12C cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
SN12C	GI₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
SN12C	IC₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
SN12C	GI₅₀	2.51 μM Compound: Sorafenib	Anticancer activity against human SN12C cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human SN12C cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
SN12C	IC₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human SN12C cells measured after 48 hrs by SRB assay Antiproliferative activity against human SN12C cells measured after 48 hrs by SRB assay	[PMID: 35764033]
SN12C	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human SN12C cells assessed as cell growth inhibition Antiproliferative activity against human SN12C cells assessed as cell growth inhibition	[PMID: 38850857]
SNB-19	GI₅₀	3.16 μM Compound: 1	Cytotoxicity against human SNB19 cells after 48 hrs by SRB method Cytotoxicity against human SNB19 cells after 48 hrs by SRB method	[PMID: 26590508]
SNB-19	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human SNB19 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human SNB19 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
SNB-19	GI₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
SNB-19	IC₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
SNB-19	GI₅₀	3.16 μM Compound: Sorafenib	Anticancer activity against human SNB-19 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human SNB-19 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
SNB-19	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human SNB-19 cells measured after 48 hrs by SRB assay Antiproliferative activity against human SNB-19 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
SNB-75	GI₅₀	3.16 μM Compound: 1	Cytotoxicity against human SNB75 cells after 48 hrs by SRB method Cytotoxicity against human SNB75 cells after 48 hrs by SRB method	[PMID: 26590508]
SNB-75	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human SNB75 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human SNB75 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
SNB-75	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human SNB-75 cells assessed as reduction in cell growth Antiproliferative activity against human SNB-75 cells assessed as reduction in cell growth	[PMID: 27155467]
SNB-75	GI₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
SNB-75	IC₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
SNB-75	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human SNB-75 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human SNB-75 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34237622]
SNB-75	GI₅₀	3.16 μM Compound: Sorafenib	Anticancer activity against human SNB-75 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human SNB-75 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
SNB-75	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human SNB-75 cells measured after 48 hrs by SRB assay Antiproliferative activity against human SNB-75 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
SNB-75	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human SNB-75 cells assessed as cell growth inhibition Antiproliferative activity against human SNB-75 cells assessed as cell growth inhibition	[PMID: 38850857]
SNU-387	IC₅₀	8.29 μM Compound: Sor	Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
SNU-387	IC₅₀	0.001 μM Compound: Sorafenib	Cytotoxicity against human SNU-387 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human SNU-387 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
SNU-387	IC₅₀	258.91 μM Compound: Sorafenib	Antiproliferative activity against human SNU-387 cells by MTT assay Antiproliferative activity against human SNU-387 cells by MTT assay	[PMID: 34128674]
SNU-387	IC₅₀	12.33 μM Compound: Sorafenib	Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35525080]
SNU-398	IC₅₀	3.38 μM Compound: Sor	Antiproliferative activity against human SNU-398 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human SNU-398 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
SNU-398	IC₅₀	0.001 μM Compound: Sorafenib	Cytotoxicity against human SNU-398 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human SNU-398 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
SR	GI₅₀	3.16 μM Compound: 1	Cytotoxicity against human SR cells after 48 hrs by SRB method Cytotoxicity against human SR cells after 48 hrs by SRB method	[PMID: 26590508]
SR	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human SR cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human SR cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
SR	GI₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
SR	IC₅₀	3.16 μM Compound: Sorafenib	Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
SR	IC₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human SR cells measured after 48 hrs by SRB assay Antiproliferative activity against human SR cells measured after 48 hrs by SRB assay	[PMID: 35764033]
SR	GI₅₀	3.16 μM Compound: Sorafenib	Antiproliferative activity against human SR cells assessed as cell growth inhibition Antiproliferative activity against human SR cells assessed as cell growth inhibition	[PMID: 38850857]
SU-DHL-6	IC₅₀	3.82 μM Compound: Sor	Antiproliferative activity against human SU-DHL-6 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human SU-DHL-6 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
SU-DHL-6	IC₅₀	0.001 μM Compound: Sorafenib	Cytotoxicity against human SU-DHL-6 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human SU-DHL-6 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
SW480	GI₅₀	15.6 μM Compound: Sorafenib	Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 36068975]
SW480	GI₅₀	14.7 μM Compound: Sorafenib	Antiproliferative activity against human SW480 cells assessed as cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 36126227]
SW-620	GI₅₀	2.51 μM Compound: 1	Cytotoxicity against human SW620 cells after 48 hrs by SRB method Cytotoxicity against human SW620 cells after 48 hrs by SRB method	[PMID: 26590508]
SW-620	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human SW620 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human SW620 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
SW-620	GI₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
SW-620	IC₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
SW-620	GI₅₀	2.51 μM Compound: Sorafenib	Anticancer activity against human SW-620 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human SW-620 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
SW-620	IC₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human SW-620 cells measured after 48 hrs by SRB assay Antiproliferative activity against human SW-620 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
SW-620	IC₅₀	2.3 μM Compound: Sorafenib	Cytotoxicity against human SW620 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human SW620 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38354306]
SW-620	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human SW-620 cells assessed as cell growth inhibition Antiproliferative activity against human SW-620 cells assessed as cell growth inhibition	[PMID: 38850857]
T-24	IC₅₀	5.31 μM Compound: Cpd S	Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 32827851]
T47D	IC₅₀	0.61 μM Compound: Sorafenib	Antiproliferative activity against human T47D cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay Antiproliferative activity against human T47D cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay	[PMID: 25778995]
T47D	GI₅₀	1.58 μM Compound: 1	Cytotoxicity against human T47D cells after 48 hrs by SRB method Cytotoxicity against human T47D cells after 48 hrs by SRB method	[PMID: 26590508]
T47D	GI₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human T47D cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human T47D cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
T47D	GI₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
T47D	IC₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
T47D	IC₅₀	1.6 μM Compound: I; BAY 43-9006	Cytotoxicity against human T47D cells expressing wild type BRAF measured after 48 hrs by sulforhodamine B assay Cytotoxicity against human T47D cells expressing wild type BRAF measured after 48 hrs by sulforhodamine B assay	[PMID: 31284081]
T47D	IC₅₀	6.4 μM Compound: Sorafenib	Antiproliferative activity against human T47D cells incubated for 48 hrs by MTT assay Antiproliferative activity against human T47D cells incubated for 48 hrs by MTT assay	[PMID: 33328104]
T47D	GI₅₀	1.58 μM Compound: Sorafenib	Anticancer activity against human T47D cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human T47D cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
T47D	IC₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human T47D cells measured after 48 hrs by SRB assay Antiproliferative activity against human T47D cells measured after 48 hrs by SRB assay	[PMID: 35764033]
THLE-2	CC₅₀	19.6 μM Compound: Sorafenib	Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability by CCK-8 assay Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability by CCK-8 assay	[PMID: 38521176]
THP-1	IC₅₀	0.31 μM Compound: 2	Antiproliferative activity against human THP1 cells after 72 hrs by MTT assay Antiproliferative activity against human THP1 cells after 72 hrs by MTT assay	[PMID: 20570526]
TK-10	GI₅₀	3.98 μM Compound: Sorafenib	Antiproliferative activity against human TK10 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human TK10 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
TK-10	GI₅₀	3.98 μM Compound: Sorafenib	Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
TK-10	IC₅₀	3.98 μM Compound: Sorafenib	Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
TK-10	GI₅₀	3.98 μM Compound: Sorafenib	Anticancer activity against human TK-10 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human TK-10 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
TK-10	IC₅₀	3.98 μM Compound: Sorafenib	Antiproliferative activity against human TK-10 cells measured after 48 hrs by SRB assay Antiproliferative activity against human TK-10 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
TPC1	EC₅₀	2.6 μM Compound: Sorafenib	Antiproliferative activity against human TPC1 cells Antiproliferative activity against human TPC1 cells	[PMID: 22559926]
TT	IC₅₀	1.4 nM Compound: sorafenib	Antiproliferative activity against human TT cells after 13 days by fluorescence assay Antiproliferative activity against human TT cells after 13 days by fluorescence assay	[PMID: 18849971]
U-251	IC₅₀	24.71 μM Compound: Sorafenib	Cytotoxicity against human U251 cells after 48 hrs by MTT assay Cytotoxicity against human U251 cells after 48 hrs by MTT assay	[PMID: 20435479]
U-251	GI₅₀	2 μM Compound: 1	Cytotoxicity against human U251 cells after 48 hrs by SRB method Cytotoxicity against human U251 cells after 48 hrs by SRB method	[PMID: 26590508]
U-251	GI₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
U-251	GI₅₀	2 μM Compound: Sorafenib	Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
U-251	IC₅₀	2 μM Compound: Sorafenib	Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
U-251	IC₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human U-251 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human U-251 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34237622]
U-251	GI₅₀	2 μM Compound: Sorafenib	Anticancer activity against human U-251 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human U-251 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
U-251	IC₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human U-251 cells measured after 48 hrs by SRB assay Antiproliferative activity against human U-251 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
U-87MG ATCC	IC₅₀	21.07 μM Compound: Sorafenib	Cytotoxicity against human U87 cells after 48 hrs by MTT assay Cytotoxicity against human U87 cells after 48 hrs by MTT assay	[PMID: 20435479]
U-87MG ATCC	IC₅₀	15.57 μM Compound: Sorafenib	Cytotoxicity against human U87MG cells after 72 hrs by MTT assay Cytotoxicity against human U87MG cells after 72 hrs by MTT assay	[PMID: 24826815]
U-87MG ATCC	IC₅₀	8.46 μM Compound: Sorafenib	Antiproliferative activity against human U87 cells measured after 72 hrs by MTT assay Antiproliferative activity against human U87 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
U-87MG ATCC	IC₅₀	12.67 μM Compound: Sorafenib	Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36508995]
U-87MG ATCC	IC₅₀	1.282 μM Compound: Sorafenib	Antiproliferative activity against human U87 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human U87 cells incubated for 48 hrs by MTT assay	[PMID: 37216813]
U-937	IC₅₀	>5 μM Compound: 2	Antiproliferative activity against human U937 cells after 72 hrs by MTT assay Antiproliferative activity against human U937 cells after 72 hrs by MTT assay	[PMID: 20570526]
U-937	GI₅₀	3.4 μM Compound: BAY-439006, 3	Antiproliferation activity against human FLT3 gene-deficient U937 cells after 72 hrs by MTS method Antiproliferation activity against human FLT3 gene-deficient U937 cells after 72 hrs by MTS method	[PMID: 21708468]
U-937	GI₅₀	2.85 μM Compound: Sorafenib	Growth inhibition of human U937 cells after 24 hrs by thiazolyl blue tetrazolium bromide staining-based MTT assay Growth inhibition of human U937 cells after 24 hrs by thiazolyl blue tetrazolium bromide staining-based MTT assay	[PMID: 22014755]
U-937	GI₅₀	3.4 μM Compound: 2, BAY-43-9006	Cytotoxicity against human FLT3 negative U937 cells after 72 hrs by MTS assay Cytotoxicity against human FLT3 negative U937 cells after 72 hrs by MTS assay	[PMID: 23618709]
U-937	IC₅₀	>3 μM Compound: Sorafenib	Antiproliferative activity against human U937 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis Antiproliferative activity against human U937 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis	[PMID: 24641103]
U-937	GI₅₀	2.74 μM Compound: Sorafenib	Cytotoxicity against human U937 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human U937 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24878193]
U-937	GI₅₀	3.4 μM Compound: 2	Cytotoxicity against FLT3-deficient human U937 cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against FLT3-deficient human U937 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 26081023]
U-937	GI₅₀	2.74 μM Compound: Sorafenib	Antiproliferative activity against human U937 cells after 24 hrs by MTT assay Antiproliferative activity against human U937 cells after 24 hrs by MTT assay	[PMID: 26318067]
U-937	GI₅₀	2.34 μM Compound: Sorafenib	Antiproliferative activity against human U937 cells after 24 hrs by MTT assay Antiproliferative activity against human U937 cells after 24 hrs by MTT assay	[PMID: 29459144]
UACC-257	GI₅₀	2 μM Compound: 1	Cytotoxicity against human UACC257 cells after 48 hrs by SRB method Cytotoxicity against human UACC257 cells after 48 hrs by SRB method	[PMID: 26590508]
UACC-257	GI₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human UACC257 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human UACC257 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
UACC-257	GI₅₀	2 μM Compound: Sorafenib	Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
UACC-257	IC₅₀	2 μM Compound: Sorafenib	Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
UACC-257	GI₅₀	2 μM Compound: Sorafenib	Anticancer activity against human UACC-257 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human UACC-257 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
UACC-257	IC₅₀	2 μM Compound: Sorafenib	Antiproliferative activity against human UACC-257 cells measured after 48 hrs by SRB assay Antiproliferative activity against human UACC-257 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
UACC-62	GI₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human UACC62 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human UACC62 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
UACC-62	GI₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
UACC-62	IC₅₀	1.58 μM Compound: Sorafenib	Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
UACC-62	IC₅₀	1.95 μM Compound: Sorafenib	Antiproliferative activity against human UACC-62 cells measured after 48 hrs by MTT assay Antiproliferative activity against human UACC-62 cells measured after 48 hrs by MTT assay	[PMID: 33316752]
UACC-62	GI₅₀	1.58 μM Compound: Sorafenib	Anticancer activity against human UACC-62 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human UACC-62 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
UACC-62	IC₅₀	1.58 μM Compound: Sorafenib	Antiproliferative activity against human UACC-62 cells measured after 48 hrs by SRB assay Antiproliferative activity against human UACC-62 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
UO-31	GI₅₀	2.51 μM Compound: 1	Cytotoxicity against human UO31 cells after 48 hrs by SRB method Cytotoxicity against human UO31 cells after 48 hrs by SRB method	[PMID: 26590508]
UO-31	GI₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human UO31 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human UO31 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 27017549]
UO-31	GI₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28088086]
UO-31	IC₅₀	2.51 μM Compound: Sorafenib	Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 30006168]
UO-31	IC₅₀	2.51 μM Compound: 1	Antiproliferative activity against human UO31 cells Antiproliferative activity against human UO31 cells	[PMID: 30216849]
UO-31	IC₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human UO-31 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human UO-31 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34237622]
UO-31	GI₅₀	2.51 μM Compound: Sorafenib	Anticancer activity against human UO-31 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human UO-31 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
UO-31	IC₅₀	2.51 μM Compound: Sorafenib	Antiproliferative activity against human UO-31 cells measured after 48 hrs by SRB assay Antiproliferative activity against human UO-31 cells measured after 48 hrs by SRB assay	[PMID: 35764033]
WI-38	IC₅₀	7.54 μM Compound: Sorafenib	Cytotoxicity against human WI38 cells after 72 hrs by MTT assay Cytotoxicity against human WI38 cells after 72 hrs by MTT assay	[PMID: 24826815]
WI-38	IC₅₀	8.42 μM Compound: Sorafenib	Cytotoxicity against human WI38 cells after 72 hrs by MTT assay Cytotoxicity against human WI38 cells after 72 hrs by MTT assay	[PMID: 26991938]
WI-38	IC₅₀	>30 μM Compound: Sorafenib	Cytotoxicity against human WI-38 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human WI-38 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 33310290]
WI-38	GI₅₀	>20 μM Compound: Sorafenib	Cytotoxicity against human WI-38 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Cytotoxicity against human WI-38 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35551038]
WI-38	IC₅₀	14.7 μM Compound: Sorafenib	Antiproliferative activity against human WI-38 cells measured by MTT assay Antiproliferative activity against human WI-38 cells measured by MTT assay	[PMID: 35764033]
WI-38	IC₅₀	10.65 μM Compound: SOR	Antiproliferative activity against human WI-38 cells after 72 hrs by MTT assay Antiproliferative activity against human WI-38 cells after 72 hrs by MTT assay	[PMID: 35964425]
WI-38	IC₅₀	17.7 μM Compound: Sorafenib	Cytotoxicity against human WI-38 cells assessed as reduction in cell growth measured after 48 hrs by MTT assay Cytotoxicity against human WI-38 cells assessed as reduction in cell growth measured after 48 hrs by MTT assay	[PMID: 38850857]
WISH	IC₅₀	17.54 μM Compound: Sorafenib	Cytotoxicity against human WISH cells assessed as cell growth inhibition Cytotoxicity against human WISH cells assessed as cell growth inhibition	[PMID: 37453330]
WM 266-4	IC₅₀	5 μM Compound: Sorafenib	Growth inhibition of human WM266.4 cells expressing BRAF mutant by SRB assay Growth inhibition of human WM266.4 cells expressing BRAF mutant by SRB assay	[PMID: 19323560]
WM 266-4	GI₅₀	4.933 μM Compound: 2	Antiproliferative activity against human WM266.4 cells after 6 days by SRB assay Antiproliferative activity against human WM266.4 cells after 6 days by SRB assay	[PMID: 20148563]
WM 266-4	GI₅₀	4.5 μM Compound: Sorafenib	Growth inhibition of wild type human WM266.4 cells after 5 days by SRB assay Growth inhibition of wild type human WM266.4 cells after 5 days by SRB assay	[PMID: 20199087]
WM 266-4	GI₅₀	8.3 μM Compound: Sorafenib	Growth inhibition of human WM266.4 cells expressing B-Raf V600E mutant after 24 hrs by MTT assay Growth inhibition of human WM266.4 cells expressing B-Raf V600E mutant after 24 hrs by MTT assay	[PMID: 22361686]
WM 266-4	GI₅₀	8.12 μM Compound: Sorafenib	Antiproliferative activity against human WM266.4 cells after 24 hrs by MTT assay Antiproliferative activity against human WM266.4 cells after 24 hrs by MTT assay	[PMID: 22583669]
WM 266-4	GI₅₀	8.1 μM Compound: Sorafenib	Antiproliferative activity against human WM266.4 cells expressing BRAF V600E mutant after 24 hrs by MTT assay Antiproliferative activity against human WM266.4 cells expressing BRAF V600E mutant after 24 hrs by MTT assay	[PMID: 23025996]
WM 266-4	IC₅₀	0.06 μM Compound: Sorafenib	Antiproliferative activity against human WM266.4 cells after 48 hrs by MTT assay Antiproliferative activity against human WM266.4 cells after 48 hrs by MTT assay	[PMID: 25496804]
WM164	IC₅₀	4.9 μM Compound: sorafenib, velcade	Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay	[PMID: 17561392]
WM164	IC₅₀	5 μM Compound: Sorafenib	Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay	[PMID: 20056548]
ZR-75-30	IC₅₀	2.96 μM Compound: Sorafenib	Growth inhibition of human ZR75-30 cells after 48 hrs by MTT assay Growth inhibition of human ZR75-30 cells after 48 hrs by MTT assay	[PMID: 29102175]

In Vitro

Sorafenib (0.01-3 μM; 2 h) selectively inhibits the MAPK pathway, while has no effect on the PKB pathway in MDA-MB-231 cells^[1].
Sorafenib (0.01-15 μM; 2 h) inhibits MEK 1/2 and ERK 1/2 phosphorylation in MDA-MB-231 human breast carcinoma cells (IC₅₀s of 40 and 90 nmol/L, respectively), ERK 1/2 phosphorylation in BxPC-3, LOX, HCT 116, HT-29, Colo-205, and Mia PaCa-2 cells, but does not inhibit ERK 1/2 phosphorylation in A549 and NCI-H460 cells^[1].
Sorafenib (0.01-10 μM; 72 h) inhibits proliferation of MDA-MB-231 cells with an IC₅₀ of 2600 nmol/L)^[1].
Sorafenib (8.9 μM) exhibits an IC₅₀ of 8.9 μM in human colorectal carcinoma HCT8 and HT29 cell lines, and causes marked antagonism with oxaliplatin and cisplatin across all tested incubation schedules, reducing platinum-induced cytotoxicity^[2].
Sorafenib (4-24 μM; 24 h) reduces expression of p21^Cip1 protein and cyclin D1 expression in HCT8 and HT29 cells when incubated simultaneously with Oxaliplatin (HY-17371) or Cisplatin (HY-17394)^[2].
Sorafenib (24 μM; 4 h) significantly reduces Cisplatin- and Oxaliplatin-induced DNA adduct levels in HCT8 and HT29 cells when applied simultaneously, but does not affect adduct levels or repair when applied consecutively^[2].
Sorafenib (0-20 μmol/L; 24-72 h) inhibits the proliferation of HCCLM3, HepG2, and rat Morris hepatoma 3924A (MH) HCC cell lines in a time- and dose-dependent manner^[3].
Sorafenib (0-20 μmol/L; 2-24 h) durably inhibits phosphorylation of STAT3^Y705 and ^S727, ERK1/2, and Akt, and reduces cyclin D1 expression, without altering JAK2 or SHP2 phosphorylation, in HCCLM3, HepG2, and MH HCC cell lines^[3].
Sorafenib (5 μM; 48 h) significantly increases clonogenicity, enhances tumoursphere formation, and upregulates cancer stem cell-associated pluripotency markers Sox2 and Oct4 in A549, NCI-H460, and NCI-H1299 NSCLC cells^[5].
Sorafenib (5 μM; 48 h) increases ALDH-positive cancer stem cell populations in A549 NSCLC cells^[5].
Sorafenib (5 μM; 48 h) significantly enhances migration capacity in NCI-H460 NSCLC cells^[5].
Sorafenib (5 μM; 48 h) induces epithelial-to-mesenchymal transition in NCI-H460 NSCLC cells via downregulation of E-cadherin and upregulation of N-cadherin, vimentin, and MMP2, and activates the AKT pathway via increased AKT phosphorylation^[5].
Sorafenib (5 μM; 48 h) upregulates STMN1, FOXM1, and E2F1 expression at the mRNA and protein levels in NCI-H460 and NCI-H1299 NSCLC cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

MDA-MB-231
Concentration:

0.01, 0.03, 0.1, 0.3, 1, 3 μM
Incubation Time:

2 h
Result:

Dose-dependently inhibited basal MEK 1/2 phosphorylation in MDA-MB-231 cells with an IC₅₀ of 40 nmol/L.
Inhibited ERK 1/2 phosphorylation in MDA-MB-231 cells with an IC₅₀ of 90 nmol/L.
Showed no effect on PKB phosphorylation in MDA-MB-231 cells.
Completely blocked activation of the MAPK pathway.

Cell Proliferation Assay^[1]

Cell Line:

MDA-MB-231
Concentration:

0.01-10 μM
Incubation Time:

72 h
Result:

Inhibited MDA-MB-231 cell proliferation with an IC₅₀ of 2600 nmol/L.

Western Blot Analysis^[2]

Cell Line:

HCT8 and HT29 cells
Concentration:

4, 24 μM
Incubation Time:

24 h
Result:

Reduced p21Cip1 protein expression induced by Oxaliplatin or Cisplatin at 4 μM when applied simultaneously.
Completely inhibited platinum-induced p21Cip1 expression at 24 μM when applied simultaneously.
Reduced cyclin D1 expression enhanced by Oxaliplatin when applied simultaneously.
Reduced cdc2 expression enhanced by cisplatin when applied simultaneously.
Showed no effect on these protein levels when applied consecutively after platinum treatment.

Cell Proliferation Assay^[3]

Cell Line:

HCCLM3, HepG2, MH cells
Concentration:

0, 0.05, 0.1, 1, 5, 10, 20 μmol/L
Incubation Time:

24, 48, 72 h
Result:

Inhibited HCC cell growth in a time- and dose-dependent manner across all three cell lines.
Increased inhibition rates with both higher sorafenib concentrations and longer incubation periods.
Exhibited the strongest inhibition at 20 μmol/L after 72 h of treatment.

Western Blot Analysis^[3]

Cell Line:

HCCLM3, HepG2, MH cells
Concentration:

0, 2, 5, 10, 20 μmol/L
Incubation Time:

2 h (0-20 μmol/L); 2, 6, 12, 24 h (10 μmol/L)
Result:

Inhibited phosphorylation of STAT3 at Y705 and S727, as well as phosphorylation of ERK1/2, in a dose-dependent manner after 2 h of treatment across all three cell lines.
Durably inhibited phosphorylation of STAT3 (Y705 and S727) and ERK1/2 for up to 24 h at 10 μmol/L, while total STAT3 protein levels and JAK2 phosphorylation remained unchanged.
Inhibited Akt phosphorylation primarily at 2 μmol/L after 2 h and reduced cyclin D1 protein expression, while leaving SHP2 phosphorylation unchanged.

Western Blot Analysis^[5]

Cell Line:

A549, NCI-H460, NCI-H1299 cells
Concentration:

5 μM
Incubation Time:

48 h
Result:

Upregulated expression levels of Sox2 and Oct4 in all three NSCLC cell lines compared to untreated controls.
Markedly decreased the epithelial marker E-cadherin compared to untreated controls.
Correspondingly increased mesenchymal markers N-cadherin, vimentin, and MMP2 compared to untreated controls. Upregulated the expression of phosphorylated AKT in NCI-H460 cells compared to untreated controls.
Showed no obvious effect on phosphorylated JNK expression compared to untreated controls in NCI-H460 cells.
Showed an increase in phosphorylated ERK expression compared to untreated controls in NCI-H460 cells.

Cell Migration Assay ^[5]

Cell Line:

NCI-H460 cells
Concentration:

5 μM
Incubation Time:

48 h
Result:

Resulted in the strongest enhancement of cell migration.
Showed a higher CI (the capacity for cell migration) slope indicating faster migration velocity compared to DMSO-treated controls.

Western Blot Analysis^[5]

Cell Line:

NCI-H460, NCI-H1299 cells
Concentration:

5 μM
Incubation Time:

48 h
Result:

Upregulated STMN1, FOXM1, and E2F1 protein expression in both cell lines compared to untreated controls.

In Vivo

Sorafenib (7.5-60 mg/kg; p.o.; daily for 5 or 9 days) inhibits tumor growth, suppresses RAF/MEK/ERK signaling, and reduces angiogenesis in mouse breast, colon, and NSCLC xenograft models, with no observed toxicity^[1].
Sorafenib (30 mg/kg; i.g.; once daily; once daily from day 17 to day 38) inhibits hepatocellular carcinoma tumor growth and metastasis in an orthotopic rat Morris Hepatoma (MH) model, while inducing tumor apoptosis and suppressing STAT3, Akt, and ERK phosphorylation^[3].
Sorafenib (10 mg/kg; p.o.; daily; 2 weeks) exhibits antineoplastic activity in Diethyl Nitrosamin (DENA)-induced hepatocellular carcinoma in albino rats^[4].
Sorafenib (4 mg/kg; i.p.; twice a week for 4 weeks) in combined with intratumoral siTUC338 significantly reduces tumor volume in mouse HepG2/Sor xenografts via upregulation of RASAL1^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female NCr-nu/nu mice subcutaneously injected with MDA-MB-231 cells ^[1]
Dosage:

7.5; 15; 30; 60 mg/kg
Administration:

p.o.; daily for 5 or 9 days
Result:

Produced a 42% reduction in mean tumor weight after 9 days at 30 mg/kg .
Inhibited microvessel area (MVA) and microvessel density (MVD) in tumors, induced extensive tumor necrosis, reduced phosphorylated ERK 1/2 (pERK) levels, and decreased Ki-67 staining at 30 or 60 mg/kg daily for 5 days.
Caused no toxicity in treated group.

Animal Model:

Female NCr-nu/nu mice subcutaneously injected with Colo-205, HT-29, and DLD-1 cells^[1]
Dosage:

7.5; 15; 30; 60 mg/kg
Administration:

p.o.; daily for 5 or 9 days
Result:

Produced complete tumor stasis during treatment at 30 to 60 mg/kg daily for 9 days.
Reduced MVA to ~0.4% and MVD to ~80/mm² at 30 mg/kg daily for 5 days, and reduced MVA to ~0.2% and MVD to ~50/mm² at 60 mg/kg daily for 5 days relative to vehicle controls.
Detected no reduction in pERK levels at 30 or 60 mg/kg daily for 5 days.
Caused no toxicity in any treated group.\n
Produced complete tumor stasis during treatment at 30 to 60 mg/kg daily for 9 days.
Inhibited MVA and MVD in tumors by 50 to 80%, reduced pERK levels, and inhibited MEK 1/2 phosphorylation at 30 or 60 mg/kg daily for 5 days.
Caused no toxicity in any treated group.

Animal Model:

Female NCr-nu/nu mice subcutaneously injected with NCI-H460, and A549 cells^[1]
Dosage:

7.5; 15; 30; 60 mg/kg
Administration:

p.o.; daily; 9 days
Result:

Produced complete tumor stasis during treatment at 30 to 60 mg/kg daily.
Caused no toxicity in any treated group.

Animal Model:

Male ACI rats (200-220 g) orthotopic implantated with Morris Hepatoma (MH) fragments^[3]
Dosage:

30 mg/kg
Administration:

i.g.; once daily from day 17 to day 38
Result:

Reduced mean tumor volume to 351.26 mm³ in early treatment group and 2248.33 mm³ in late treatment group.
Prevented lung, lymph node metastasis, peritoneal seeding, and ascites in 10/10 rats in early treatment group, and lymph node metastasis, peritoneal seeding, and ascites in 10/10 rats in late treatment group.
Induced tumor cell apoptosis with an apoptosis index of 0.909.
Reduced phosphorylation of STAT3 (Y705 and S727), Akt, and ERK in tumor tissue.
Decreased cyclin D1 expression.
Did not affect STAT3 mRNA levels, JAK2 phosphorylation, or SHP2 phosphorylation in tumor tissue.

Animal Model:

Male albino rats (100-120 g) with Diethyl Nitrosamin (DENA)-induced hepatocellular carcinoma)^[4]
Dosage:

10 mg/kg
Administration:

p.o.; daily; 2 weeks
Result:

Improved survival rate to 83.3%.
Significantly decreased liver index below normal control group level.
Reduced hepatocellular foci size by 34.8% compared to the DENA-only group.
Lowered total hepatic foci count to 10 compared to 18 in the DENA-only group.
Decreased cyclin D1 and β-catenin gene expression.
Reduced liver Bcl-2 protein and liver glutathione (GSH) levels.

Animal Model:

Male nude mice (4-6 weeks, 18-20 g) subcutaneously injected with HepG2/Sor cells^[6]
Dosage:

4 mg/kg
Administration:

i.p.; twice a week; 4 weeks
Result:

Achieved statistically significantly lower mean tumor volume compared to sorafenib combined with saline or siNC.
Significantly downregulated TUC338 expression in tumor tissue relative to control groups.
Significantly upregulated RASAL1 mRNA and protein levels in tumor tissue relative to control groups.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 284461-73-0
Appearance Solid
Molecular Weight 464.83
Formel C₂₁H₁₆ClF₃N₄O₃
Color White to off-white
SMILES

O=C(NC(C=C1)=CC=C1OC2=CC(C(NC)=O)=NC=C2)NC3=CC=C(Cl)C(C(F)(F)F)=C3
Synonyms

Bay 43-9006
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (292)

All Cell Imaging/StainingRT-PCRWBHistological Imaging/StainingIn Vivo Efficacy StudyCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Targeting AKR1B1 inhibits metabolic reprogramming to reverse systemic therapy resistance in hepatocellular carcinoma. [Abstract]

2025 Aug 1;10(1):244. PMID: 40750772
Signal Transduct Target Ther

Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study. [Abstract]

2023 Sep 14;8(1):348. PMID: 37704613
Cancer Discov

Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening. [Abstract]

2021 Oct;11(10):2544-2563. PMID: 34127480
Cancer Discov

Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma. [Abstract]

2019 Dec;9(12):1686-1695. PMID: 31575540
Cell Metab

The thermogenic activity of adjacent adipocytes fuels the progression of ccRCC and compromises anti-tumor therapeutic efficacy. [Abstract]

2021 Oct 5;33(10):2021-2039.e8. PMID: 34508696
Nat Cancer

Targeting a lineage-specific PI3Kɣ-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule. [Abstract]

2024 Jul;5(7):1082-1101. PMID: 38816660

Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2024 Jul;5(7):1082-1101. [Abstract]

Growth inhibition, IC50 and AUC values, of OCI-AML2 cells transduced with either a non-targeting control, two PIK3CG-directed, or two PIK3R5-directed sgRNAs and treated with increasing concentrations of the FLT3 inhibitors, Gilteritinib (10-1000 nM) and Sorafenib (10-1000 nM), or KIT inhibitors, Amuvanib and Telatinib
Cancer Res

The Acetyltransferase ARD1 Induces Glutathione Synthesis to Facilitate Ferroptosis Evasion in Hepatocellular Carcinoma. [Abstract]

2025 Aug 21. PMID: 40838989
Mol Cell

EGFR promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma. [Abstract]

2023 Dec 7;83(23):4334-4351.e7. PMID: 37979586
ACS Nano

Long Noncoding RNA URB1-Antisense RNA 1 (AS1) Suppresses Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma by Driving Ferritin Phase Separation. [Abstract]

2023 Nov 28;17(22):22240-22258. PMID: 37966480

Sorafenib purchased from MedChemExpress. Usage Cited in: ACS Nano. 2023 Nov 28;17(22):22240-22258. [Abstract]

Western blot to detect the ferritin H protein level by the gain or loss of URB1-AS1 in sorafenib-sensitive or sorafenib-resistant HepG2 cells.

Sorafenib purchased from MedChemExpress. Usage Cited in: ACS Nano. 2023 Nov 28;17(22):22240-22258. [Abstract]

qPCR showing the nuclear and cytoplasmic fractions of URB1-AS1 in sorafenib-resistant HepG2 cells with β-actin and MALAT1 as cytoplasmic and nuclear controls, respectively.
Nat Commun

Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma. [Abstract]

2025 Nov 18;16(1):10096. PMID: 41253833
Nat Commun

Positive feedback between arginine methylation of YAP and methionine transporter SLC43A2 drives anticancer drug resistance. [Abstract]

2025 Jan 2;16(1):87. PMID: 39747898

Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 2;16(1):87. [Abstract]

The cell viability of YAP-, YAP-S127A-, or YAP-R124F-overexpressed Huh-7 cells cultured in methionine-deprived medium (MD) and treated with sorafenib (1.5-3 μM) for 24 h.
Nat Commun

Synthetic vectors for activating the driving axis of ferroptosis. [Abstract]

2024 Sep 10;15(1):7923. PMID: 39256387
Nat Commun

N7-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis. [Abstract]

2022 Mar 18;13(1):1478. PMID: 35304469
Cell Death Differ

Branched-chain amino acid aminotransferase 2 regulates ferroptotic cell death in cancer cells. [Abstract]

2021 Apr;28(4):1222-1236. PMID: 33097833
Bone Res

Sorafenib inhibits ossification of the posterior longitudinal ligament by blocking LOXL2-mediated vascularization. [Abstract]

2024 Apr 10;12(1):24. PMID: 38594260

Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]

Sorafenib tosylate (90-900 nM) markedly suppressed the upregulation of endothelial-like differentiation in ligament cells mediated by LOXL2.

Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]

Sorafenib tosylate (50 mg/kg; i.g.; one daily for 14 d) significantly decreased bone volume (BV) in BMP-induced ossification mice.

Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]

Sorafenib tosylate (50 mg/kg; i.g.; once daily for 14 d) caused sparse trabecular bone structures in BMP-induced ossification mice, accompanied by numerous cartilage structures and amorphous matrix deposition, indicating a delay in endochondral ossification.

Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]

Sorafenib tosylate (50 mg/kg; i.g.; once daily for 14 d) significantly lowered the level of SP7 in BMP-induced ossification mice.

Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]

Sorafenib tosylate (50 mg/kg; i.g.; once daily for 14 d)caused a shorter response time to thermal stimulation and less paw withdrawal threshold to mechanical stimulation of BMP-induced ossification mice.
Acta Pharm Sin B

Sorafenib promotes the E3 ubiquitin ligase FBXW7 to increase tau degradation and ameliorate tauopathies. [Abstract]

2025 Nov;15(11):5817-5831. PMID: 41311387
Acta Pharm Sin B

A high-throughput Gaussia luciferase reporter assay for screening potential gasdermin E activators against pancreatic cancer. [Abstract]

2023 Oct;13(10):4253-4272. PMID: 37799380

Sorafenib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Oct;13(10):4253-4272. [Abstract]

PANC-1 cells were transfected with the recombinant plasmid for 24 h and treated with sorafenib (0–70 μmol/L) for another 24 h, and then total cellular extracts were subjected to Western blotting using antibodies against caspase-3, GSDME and β-tubulin.

Sorafenib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Oct;13(10):4253-4272. [Abstract]

Sorafenib (12.5-125 μM; 24 h) inhibits the viability of PANC-1 cells in a dose-dependent manner.
Acta Pharm Sin B

The suppression of cervical cancer ferroptosis by macrophages: The attenuation of ALOX15 in cancer cells by macrophages-derived exosomes. [Abstract]

2023 Jun;13(6):2645-2662. PMID: 37425043

Sorafenib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Jun;13(6):2645-2662. [Abstract]

HeLa and SiHa cells were treated with condition medium (CM) from human PBMC-derived M0 macrophages (Ctrl) and TAM. And then cells were treated with indicated dose of Sorafenib (Sora) for 48 h. Inhibition ratio of cell viability was detected by CCK-8 assay.
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
J Extracell Vesicles

Oxidative stress induces extracellular vesicle release by upregulation of HEXB to facilitate tumour growth in experimental hepatocellular carcinoma. [Abstract]

2024 Jul;13(7):e12468. PMID: 38944674
Autophagy

Kitasamycin overcomes ferroptosis and immunotherapy resistance by targeting the HUWE1-NCOA4-FTH1 axis. [Abstract]

2026 Feb 15:1-19. PMID: 41612599
Autophagy

The human vault RNA enhances tumorigenesis and chemoresistance through the lysosome in hepatocellular carcinoma. [Abstract]

2022 Jan;18(1):191-203. PMID: 33960270
Adv Sci (Weinh)

Clathrin Light Chain B Drives Hepatocellular Carcinoma Progression Through Dual Mechanisms: Small Extracellular Vesicle-Mediated Angiogenesis and the NF-κB-PCLAF Signaling Axis. [Abstract]

2025 Aug 18:e08613. PMID: 40820941
Adv Sci (Weinh)

TRIM21-Mediated K11-Linked Ubiquitination of ID1 Suppresses Tumorigenesis and Promotes Cuproptosis in Esophageal Squamous Cell Carcinoma. [Abstract]

2025 Jul 13:e02501. PMID: 40652518
Adv Sci (Weinh)

PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma. [Abstract]

2025 May 8:e2501730. PMID: 40344394
Adv Sci (Weinh)

Stabilization of TGF-β Receptor 1 by a Receptor-Associated Adaptor Dictates Feedback Activation of the TGF-β Signaling Pathway to Maintain Liver Cancer Stemness and Drug Resistance. [Abstract]

2024 Jul 9:e2402327. PMID: 38981014
Adv Sci (Weinh)

Micro-Engineered Organoid-on-a-Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients. [Abstract]

2023 Sep;10(27):e2302640. PMID: 37485650
Adv Sci (Weinh)

Donafenib and GSK-J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression. [Abstract]

2023 Aug;10(22):e2206798. PMID: 37330650
Adv Sci (Weinh)

STING Suppresses Mitochondrial VDAC2 to Govern RCC Growth Independent of Innate Immunity. [Abstract]

2023 Jan;10(3):e2203718. PMID: 36445063
Adv Sci (Weinh)

Engineered EGCG-Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy. [Abstract]

2022 May;9(15):e2105894. PMID: 35486032
Adv Sci (Weinh)

PADI2-Catalyzed MEK1 Citrullination Activates ERK1/2 and Promotes IGF2BP1-Mediated SOX2 mRNA Stability in Endometrial Cancer. [Abstract]

2021 Jan 29;8(6):2002831. PMID: 33747724
Exp Hematol Oncol

Effects of molecularly targeted therapies on murine thymus: highly selective mTOR inhibitors induce reversible thymic involution. [Abstract]

2016 Jul 29:5:22. PMID: 27478685
Theranostics

Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy. [Abstract]

2020 Aug 21;10(23):10498-10512. PMID: 32929362
Biomaterials

Automated discovery of nanomaterials via drug aggregation induced emission. [Abstract]

2022 Oct:289:121800. PMID: 36166893
J Exp Clin Cancer Res

Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. [Abstract]

2023 Jan 6;42(1):6. PMID: 36604718
J Exp Clin Cancer Res

Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma. [Abstract]

2022 Mar 30;41(1):116. PMID: 35354475
J Exp Clin Cancer Res

GPR119 agonist enhances gefitinib responsiveness through lactate-mediated inhibition of autophagy. [Abstract]

2018 Nov 29;37(1):295. PMID: 30497501
Cell Discov

Dynamic O-GlcNAcylation coordinates ferritinophagy and mitophagy to activate ferroptosis. [Abstract]

2022 May 3;8(1):40. PMID: 35504898
Redox Biol

USP20 governs tyrosine kinase inhibitors resistance through ferroptosis evasion by targeting GPX4 in cancers. [Abstract]

2026 May:92:104086. PMID: 41844497
Redox Biol

ATF7IP inhibits Sorafenib-induced ferroptosis in hepatocellular carcinoma cells by inhibiting CYB5R2 transcription and stabilizing PARK7 protein. [Abstract]

2025 Sep:85:103786. PMID: 40716153
Redox Biol

Reactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRASG12C inhibitor resistant tumors. [Abstract]

2024 Nov 5:78:103419. PMID: 39527862
Redox Biol

MAPK15 controls cellular responses to oxidative stress by regulating NRF2 activity and expression of its downstream target genes. [Abstract]

2024 Jun:72:103131. PMID: 38555711
Redox Biol

Increased ATF2 expression predicts poor prognosis and inhibits sorafenib-induced ferroptosis in gastric cancer. [Abstract]

2023 Feb:59:102564. PMID: 36473315
J Hazard Mater

Nanoplastic-induced NAT10/ac4C axis drives both oxidative stress and chemoresistance. [Abstract]

2025 Oct 19:499:140193. PMID: 41124733
Gut Microbes

Synergistic activity of Enterococcus Faeciu m-induced ferroptosis via expansion of IFN-γ+CD8+ T cell population in advanced hepatocellular carcinoma treated with sorafenib. [Abstract]

2024 Jan-Dec;16(1):2410474. PMID: 39353096
MedComm (2020)

circRNA-SORE/UBQLN1/GPX4 Mediates the Acquisition of Sorafenib Resistance in Hepatocellular Carcinoma Through Inhibition of Ferroptosis. [Abstract]

2025 Nov 23;6(12):e70488. PMID: 41287824
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
J Immunother Cancer

Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC. [Abstract]

2022 Aug;10(8):e004006. PMID: 36002188
Pharmacol Res

Epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis synergises the anticancer effects of sorafenib in hepatocellular carcinoma. [Abstract]

2022 Jun;180:106244. PMID: 35550167
Pharmacol Res

Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib. [Abstract]

2022 Mar:177:106050. PMID: 34973468
Clin Cancer Res

CDK9 inhibition by dinaciclib is a therapeutic vulnerability in epithelioid hemangioendothelioma. [Abstract]

2024 Sep 13;30(18):4179-4189. PMID: 39052240
Cancer Lett

Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma. [Abstract]

2022 Jan 1:524:161-171. PMID: 34687791
Cancer Lett

Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance. [Abstract]

2021 Nov 1:520:243-254. PMID: 34339801
Cancer Lett

PTK2 promotes cancer stem cell traits in hepatocellular carcinoma by activating Wnt/β-catenin signaling. [Abstract]

2019 May 28:450:132-143. PMID: 30849480
Int J Biol Sci

Chemical and genetic inhibition of STAT3 sensitizes hepatocellular carcinoma cells to sorafenib induced cell death. [Abstract]

2018 Apr 25;14(5):577-585. PMID: 29805309

Sorafenib purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2018 Apr 25;14(5):577-585. [Abstract]

Hep3B, HepG2 and Huh7 cells are treated with 5 μM Sorafenib. The expressing levels of JAK1, JAK2, STAT3, SHP1, SHP2, actin and phosphorylation levels of STAT3 are determined by western blot using the antibodies, respectively.
Cell Death Dis

SOX4-STAT6-MTHFD2 axis drives hepatocellular carcinoma progression and treatment resistance. [Abstract]

2026 Jan 3. PMID: 41484064
Cell Death Dis

Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer models. [Abstract]

2025 Nov 17;16(1):839. PMID: 41249113
Cell Death Dis

DCAF7 recruits USP2 to facilitate hepatocellular carcinoma progression by suppressing clockophagy-induced ferroptosis. [Abstract]

2025 Aug 28;16(1):654. PMID: 40877242
Cell Death Dis

IFNγ augments TKI efficacy by alleviating protein unfolding stress to promote GSDME-mediated pyroptosis in hepatocellular carcinoma. [Abstract]

2025 Jul 11;16(1):512. PMID: 40645933
Cell Death Dis

Pharmacological targeting of the mitochondrial phosphatase PTPMT1 sensitizes hepatocellular carcinoma to ferroptosis. [Abstract]

2025 Apr 6;16(1):257. PMID: 40189563
Cell Death Dis

Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment. [Abstract]

2025 Jan 26;16(1):42. PMID: 39863613
Cell Death Dis

Phosphorylated FOXQ1, a novel substrate of JNK1, inhibits sorafenib-induced ferroptosis by activating ETHE1 in hepatocellular carcinoma. [Abstract]

2024 Jun 5;15(6):395. PMID: 38839744
Cell Death Dis

Transcription factor Sp1 transcriptionally enhances GSDME expression for pyroptosis. [Abstract]

2024 Jan 18;15(1):66. PMID: 38238307
Adv Healthc Mater

A Novel Patient-Personalized Nanovector Based on Homotypic Recognition and Magnetic Hyperthermia for an Efficient Treatment of Glioblastoma Multiforme. [Abstract]

2023 Jul;12(19):e2203120. PMID: 37058273
Cell Death Dis

SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase. [Abstract]

2023 Jan 12;14(1):22. PMID: 36635256
Cell Death Dis

PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis. [Abstract]

2022 Feb 4;13(2):118. PMID: 35121728
Cell Death Dis

MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma. [Abstract]

2021 Jul 9;12(7):691. PMID: 34244479
Cell Death Dis

Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells. [Abstract]

2019 Apr 15;10(5):331. PMID: 30988278
Genes Dis

PCK1 attenuates tumor stemness via activating the Hippo signaling pathway in hepatocellular carcinoma. [Abstract]

2023 Sep 16;11(4):101114. PMID: 38560500
Cell Commun Signal

Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD+ acute myeloid leukemia by inhibiting β-catenin activity via the PP2A-GSK3β axis. [Abstract]

2024 Aug 7;22(1):391. PMID: 39113090
Int J Biol Macromol

KIF20A drives epithelial cell proliferation and migration in gastric adenocarcinoma, facilitating macrophage M2 polarization and subsequent immune evasion. [Abstract]

2026 Mar:351:150982. PMID: 41713545
Int J Biol Macromol

The role of solute carrier family 16 member 3 protein in hepatocellular carcinoma and sorafenib resistance. [Abstract]

2025 Oct 9;330(Pt 3):148223. PMID: 41075888
Acta Pharmacol Sin

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]

2021 Jan;42(1):108-114. PMID: 32398685
Phytomedicine

Usenamine a potentiates anti-CRC activity of sorafenib by inducing autophagy and inhibiting YAP pathway through targeting SOD2. [Abstract]

2026 Jun:155:158086. PMID: 41861687
Phytomedicine

Arnicolide C induces ROS-mediated modulation of PI3K/Akt and MAPK pathways to suppress MYC in hepatocellular carcinoma. [Abstract]

2025 Oct 20:148:157423. PMID: 41138574
Phytomedicine

Picropodophyllin induces ferroptosis via blockage of AKT/NRF2/SLC7A11 and AKT/NRF2/SLC40A1 axes in hepatocellular carcinoma as a natural IGF1R inhibitor. [Abstract]

2025 May 10:143:156840. PMID: 40412057
Phytomedicine

Indole-3-carbinol inhibits PD-L1-mediated immune evasion in hepatocellular carcinoma via suppressing NF-κB p105 Ubiquitination. [Abstract]

2025 Apr 1:141:156692. PMID: 40215823
Phytomedicine

Stigmasterol: Remodeling gut microbiota and suppressing tumor growth through Treg and CD8+ T cells in hepatocellular carcinoma. [Abstract]

2024 Jul:129:155225. PMID: 38678948
Phytomedicine

The role of daurisoline treatment in hepatocellular carcinoma: Inhibiting vasculogenic mimicry formation and enhancing sensitivity to sorafenib. [Abstract]

2021 Nov:92:153740. PMID: 34600176
ACS Appl Mater Interfaces

Structure-Selective Polydopamine Coating on Drug Nanoparticles. [Abstract]

2026 Jan 25. PMID: 41582522
Free Radic Biol Med

The PGC1α/NRF1-MPC1 axis suppresses tumor progression and enhances the sensitivity to sorafenib/doxorubicin treatment in hepatocellular carcinoma. [Abstract]

2021 Feb 1;163:141-152. PMID: 33276082
Free Radic Biol Med

Ferritinophagy-mediated ferroptosis is involved in sepsis-induced cardiac injury. [Abstract]

2020 Nov 20;160:303-318. PMID: 32846217
ACS Appl Mater Interfaces

A New Spin on Antibody-Drug Conjugates: Trastuzumab-Fulvestrant Colloidal Drug Aggregates Target HER2-Positive Cells. [Abstract]

2017 Apr 12;9(14):12195-12202. PMID: 28319364
Drug Deliv

Andrographolide nanophytosomes exhibit enhanced cellular delivery and pro-apoptotic activities in HepG2 liver cancer cells. [Abstract]

2023 Dec;30(1):2174209. PMID: 36762548
Chemosphere

The influence of sunitinib and sorafenib, two tyrosine kinase inhibitors, on development and thyroid system in zebrafish larvae. [Abstract]

2022 Dec;308(Pt 2):136354. PMID: 36087734
Clin Sci

Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors. [Abstract]

2024 Sep 18;138(18):1131-1150. PMID: 39282930
Sens Actuators B Chem

2024 Nov 1.
Clin Sci

A novel epigenetic drug conjugating flavonoid and HDAC inhibitor confer suppression of acute myeloid leukemogenesis. [Abstract]

2021 Jul 30;135(14):1751-1765. PMID: 34282832
Br J Pharmacol

DGT, a novel heterocyclic diterpenoid, effectively suppresses psoriasis via inhibition of STAT3 phosphorylation. [Abstract]

2021 Feb;178(3):636-653. PMID: 33140855
Biomed Pharmacother

Decursin induces ferroptosis via the NRF2/GPX4/SLC11A2 axis and suppresses migration in hepatocellular carcinoma. [Abstract]

2026 Feb:195:118941. PMID: 41496356
Biomed Pharmacother

Inhibition of the PI3K/AKT signaling pathway contributes to the anti-renal cell carcinoma effects of deoxyelephantopin. [Abstract]

2025 May 8:187:118136. PMID: 40344699
J Transl Med

Endogenous protein S100A14 stabilizes glutaminase to render hepatocellular carcinoma resistant to sorafenib. [Abstract]

2025 Apr 11;23(1):435. PMID: 40217256
J Transl Med

RPL22L1 fosters malignant features of cervical cancer via the modulation of DUSP6-ERK axis. [Abstract]

2025 Feb 28;23(1):244. PMID: 40022129
J Transl Med

Mito-LND and (E)-Akt inhibitor-IV: novel compounds inducing endoplasmic reticulum stress and ROS accumulation against hepatocellular carcinoma. [Abstract]

2024 Aug 28;22(1):792. PMID: 39198815
J Transl Med

Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies. [Abstract]

2023 Jan 9;21(1):9. PMID: 36624452
Biomed Pharmacother

Advantage of clinical colchicine concentration to promote sorafenib or regorafenib anti-cancer effects on hepatocellular carcinoma. [Abstract]

2022 Sep:153:113540. PMID: 36076618
J Transl Med

RAF1 promotes lymphatic metastasis of hypopharyngeal carcinoma via regulating LAGE1: an experimental research. [Abstract]

2022 Jun 6;20(1):255. PMID: 35668458
Biomed Pharmacother

TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib. [Abstract]

2020 Jun;126:109862. PMID: 32120157
Biomed Pharmacother

Contrary influence of clinically applied sorafenib concentrations among hepatocellular carcinoma patients. [Abstract]

2017 Feb:86:27-31. PMID: 27936391
Cell Mol Gastroenterol Hepatol

Sorafenib Promotes Treg Cell Differentiation To Compromise Its Efficacy via VEGFR/AKT/Foxo1 Signaling in Hepatocellular Carcinoma. [Abstract]

2024 Dec 30:101454. PMID: 39743020
Oncogene

LINC-AC092535.5 regulates MICAL2 mRNA level to inhibit p53-mediated ferroptosis in nasopharyngeal carcinoma. [Abstract]

2026 Apr;45(14):1260-1274. PMID: 41832266
Stem Cell Res Ther

Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy. [Abstract]

2023 Apr 1;14(1):58. PMID: 37005657
Oncogene

PBLD inhibits angiogenesis via impeding VEGF/VEGFR2-mediated microenvironmental cross-talk between HCC cells and endothelial cells. [Abstract]

2022 Mar;41(13):1851-1865. PMID: 35140333
Oncogene

Antifungal agent Terbinafine restrains tumor growth in preclinical models of hepatocellular carcinoma via AMPK-mTOR axis. [Abstract]

2021 Aug;40(34):5302-5313. PMID: 34247189
Cell Death Discov

Engineered small extracellular vesicles loaded with miR-654-5p promote ferroptosis by targeting HSPB1 to alleviate sorafenib resistance in hepatocellular carcinoma. [Abstract]

2023 Sep 30;9(1):362. PMID: 37777559
Cell Death Discov

Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma. [Abstract]

2022 Aug 17;8(1):365. PMID: 35973992
Cell Rep

A shear stress-responsive pathway in monocytes drives cardiopulmonary bypass-induced inflammation via spectrin/RAF1/store-operated calcium entry. [Abstract]

2026 Jan 22;45(2):116903. PMID: 41579376
Cell Rep

Carbonic anhydrase 2 facilitates sorafenib resistance by counteracting MCT4-mediated intracellular pH dysregulation in HCC. [Abstract]

2024 Nov 27;43(12):114996. PMID: 39607826
Cell Rep

STUB1-mediated ubiquitination and degradation of NSUN2 promotes hepatocyte ferroptosis by decreasing m5C methylation of Gpx4 mRNA. [Abstract]

2024 Oct 24;43(11):114885. PMID: 39453812
Cell Rep

Intratumor Mycoplasma promotes the initiation and progression of hepatocellular carcinoma. [Abstract]

2023 Dec 12;42(12):113563. PMID: 38088929
Clin Transl Med

Oncofetal dual‑specificity phosphatase 9 drives stem-like properties through ERK1/2-PPARG-SCD axis-mediated lipid metabolism in hepatocellular carcinoma. [Abstract]

2025 Dec;15(12):e70550. PMID: 41383134
Clin Transl Med

USP22 promotes the proliferation and Sorafenib resistance of hepatocellular carcinoma cells via its deubiquitinase activity. [Abstract]

2025 May;15(5):e70324. PMID: 40341781
J Med Chem

Discovery of Highly Potent AKR1C3 Inhibitors Treating Sorafenib-Resistant Hepatocellular Carcinoma. [Abstract]

2025 Mar 27. PMID: 40143712
Clin Transl Med

Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation. [Abstract]

2023 Jun;13(6):e1300. PMID: 37337470
J Med Chem

Protein Stability Effects in Aggregate-Based Enzyme Inhibition. [Abstract]

2019 Nov 14;62(21):9593-9599. PMID: 31589047
Br J Cancer

Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer. [Abstract]

2017 Sep 26;117(7):974-983. PMID: 28850563

Sorafenib purchased from MedChemExpress. Usage Cited in: Br J Cancer. 2017 Sep 26;117(7):974-983. [Abstract]

The effect of the AKT inhibitor MK2206 (10 μM) on the expression levels of phosphor-AKT, AKT, and STMN1 in TKI-pretreated NCI-H460 cells. β-actin is used as a loading control.
Int J Nanomedicine

A Novel Triptolide Nano-Liposome with Mitochondrial Targeting for Treatment of Hepatocellular Carcinoma. [Abstract]

2024 Dec 3:19:12975-12998. PMID: 39654802
Comput Biol Med

Liquid-liquid phase separation-related lncRNA prognostic signature and ZNF32-AS2 as a novel biomarker in hepatocellular carcinoma. [Abstract]

2024 Feb:169:107975. PMID: 38199212
Cancer Cell Int

Establishment and characteristic analysis of a novel patient derived cell line of intrahepatic cholangiocarcinoma. [Abstract]

2025 Oct 15;25(1):357. PMID: 41094661
Biomater Adv

Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs. [Abstract]

2022 May:136:212761. PMID: 35929305
Cancer Cell Int

The deubiquitinating enzyme OTUD1 antagonizes BH3-mimetic inhibitor induced cell death through regulating the stability of the MCL1 protein. [Abstract]

2019 Aug 27;19:222. PMID: 31467488
Cell Biol Toxicol

Protocatechuic acid relieves ferroptosis in hepatic lipotoxicity and steatosis via regulating NRF2 signaling pathway. [Abstract]

2024 Nov 26;40(1):104. PMID: 39589556
Eur J Med Chem

Novel inhibitors targeting the PGK1 metabolic enzyme in glycolysis exhibit effective antitumor activity against kidney renal clear cell carcinoma in vitro and in vivo. [Abstract]

2024 Mar 5:267:116209. PMID: 38354523
Cell Biol Toxicol

The mtDNA-STING pathway plays an important role in both navitoclax- and S63845-induced autophagy and enhances cell death. [Abstract]

2023 Dec;39(6):2821-2839. PMID: 37002446
Int J Mol Med

STOML2 interacts with PHB to activate the MEK/ERK signaling pathway and mediates autophagy‑related proteins in the progression of hepatocellular carcinoma. [Abstract]

2026 Feb;57(2):38. PMID: 41347828
Chin Med

Polyphyllin I exerts anti-hepatocellular carcinoma activity by targeting ZBTB16 to activate the PPARγ/RXRα signaling pathway. [Abstract]

2024 Aug 24;19(1):113. PMID: 39182119
Biochem Pharmacol

Low Pi stress enhances the sensitivity of hepatocellular carcinoma to sorafenib. [Abstract]

2023 Jul:213:115593. PMID: 37196682
Biochem Pharmacol

ALOX5 Promotes Autophagy-dependent Ferroptosis by Activating the AMPK/mTOR Pathway in Melanoma. [Abstract]

2023 Jun:212:115554. PMID: 37080437
Biochem Pharmacol

Organic anion transport polypeptide 1b2 selectively affects the pharmacokinetic interaction between paclitaxel and sorafenib in rats. [Abstract]

2019 Nov:169:113612. PMID: 31437461
Mol Cancer Ther

Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma. [Abstract]

2020 May;19(5):1197-1209. PMID: 32220970
Lab Chip

A novel microfluidic self-perfusion chip (MSPC) for pumpless 3D cell, microtissue and organoid culture. [Abstract]

2025 Apr 10. PMID: 40206017
World J Gastroenterol

Y-box binding protein 1 augments sorafenib resistance via the PI3K/Akt signaling pathway in hepatocellular carcinoma. [Abstract]

2021 Jul 28;27(28):4667-4686. PMID: 34366628
J Ethnopharmacol

Modulation of the VEGF/AKT/eNOS signaling pathway to regulate liver angiogenesis to explore the anti-hepatic fibrosis mechanism of curcumol. [Abstract]

2021 Nov 15:280:114480. PMID: 34358654
J Enzyme Inhib Med Chem

Design, synthesis, and biological evaluation of novel substituted thiourea derivatives as potential anticancer agents for NSCLC by blocking K-Ras protein-effectors interactions. [Abstract]

2020 Dec;35(1):344-353. PMID: 31851852
Lab Chip

Development of a biomimetic liver tumor-on-a-chip model based on decellularized liver matrix for toxicity testing. [Abstract]

2018 Nov 6;18(22):3379-3392. PMID: 30298144
Cancer Immunol Immunother

Targeting ST3GAL1 to downregulate ligands for the glycoimmune checkpoint Siglec-7 and reverse immune escape in hepatocellular carcinoma. [Abstract]

2026 Apr 10;75(5):140. PMID: 41961075
Commun Biol

Isoacteoside alleviates hepatocellular carcinoma progression by inhibiting PDHB-mediated reprogramming of glucose metabolism. [Abstract]

2025 Feb 8;8(1):205. PMID: 39922943
Commun Biol

USP24 promotes autophagy-dependent ferroptosis in hepatocellular carcinoma by reducing the K48-linked ubiquitination of Beclin1. [Abstract]

2024 Oct 8;7(1):1279. PMID: 39379617
Drug Des Devel Ther

Identification of Potential Therapeutics for Infantile Hemangioma via in silico Investigation and in vitro Validation. [Abstract]

2024 Sep 12:18:4065-4088. PMID: 39286286
Int J Mol Sci

XON9-A Glyco-Humanized Polyclonal Antibody Effective Against Hepatocellular Carcinoma. [Abstract]

2025 Sep 20;26(18):9185. PMID: 41009747
Biol Direct

L-741626 inhibits hepatocellular carcinoma progression by targeting Ref-1 to suppress MAPK/ERK signalling pathway activity. [Abstract]

2025 Apr 16;20(1):54. PMID: 40241114
Biol Direct

Sorafenib-induced macrophage extracellular traps via ARHGDIG/IL4/PADI4 axis confer drug resistance through inhibiting ferroptosis in hepatocellular carcinoma. [Abstract]

2024 Nov 11;19(1):110. PMID: 39529192
Int J Mol Sci

The Potential of Congo Red Supplied Aggregates of Multitargeted Tyrosine Kinase Inhibitor (Sorafenib, BAY-43-9006) in Enhancing Therapeutic Impact on Bladder Cancer. [Abstract]

2023 Dec 23;25(1):269. PMID: 38203437
Int J Mol Sci

SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma. [Abstract]

2022 Sep 21;23(19):11092. PMID: 36232407
Chin J Nat Med

Two cardenolide glycosides from the seed fairs of Asclepias curassavica and their cytotoxic activities. [Abstract]

2022 Mar;20(3):202-209. PMID: 35369964
Front Pharmacol

Protein and metabolic profiles of tyrosine kinase inhibitors co-resistant liver cancer cells. [Abstract]

2024 May 21:15:1394241. PMID: 38835670
Front Pharmacol

Caryophyllene Oxide Induces Ferritinophagy by Regulating the NCOA4/FTH1/LC3 Pathway in Hepatocellular Carcinoma. [Abstract]

2022 Jul 11;13:930958. PMID: 35899120
Eur J Pharmacol

Neoprzewaquinone A suppresses hepatocellular carcinoma through promoting the ubiquitin-related degradation of EGFR and inhibiting PI3K-AKT pathway. [Abstract]

2025 Oct 21:1007:178274. PMID: 41130376
Bioorg Chem

Synthesis and evaluation of sulfonamide-chalcone hybrid compounds as inhibitors of VEGFR1/VEGFR2-mediated angiogenesis. [Abstract]

2025 Aug 21:164:108903. PMID: 40848708
Int Immunopharmacol

ASIC1a regulates ferroptosis in hepatic stellate cells via the Hippo/Yap-1 pathway in liver fibrosis. [Abstract]

2024 Sep 30;143(Pt 1):113226. PMID: 39353388
Eur J Pharmacol

Imatinib inhibits the malignancy of hepatocellular carcinoma by suppressing autophagy. [Abstract]

2021 Sep 5:906:174217. PMID: 34087223
Toxicology

Sorafenib induces intestinal toxicity by disturbing gut microbiota and activating the LPS/TLR4/NF-κB signaling pathway in mice. [Abstract]

2025 Jun 13:517:154220. PMID: 40518001
RSC Adv

Self-assembled nanoplatform-mediated co-delivery of brusatol to sensitize sorafenib for hepatocellular carcinoma treatment. [Abstract]

2025 Apr 14;15(15):11675-11687. PMID: 40230634
Hepatol Commun

Oxyberberine sensitizes liver cancer cells to sorafenib via inhibiting NOTCH1-USP7-c-Myc pathway. [Abstract]

2024 Mar 29;8(4):e0405. PMID: 38573832
Toxicology

Inhibitory effects of flavonoids on glucose transporter 1 (GLUT1): From library screening to biological evaluation to structure-activity relationship. [Abstract]

2023 Apr:488:153475. PMID: 36870413
Neuropharmacology

Sorafenib promotes sensory conduction function recovery via miR-142-3p/AC9/cAMP axis post dorsal column injury. [Abstract]

2019 Apr:148:347-357. PMID: 30710569
Molecules

Facilitating Anti-Cancer Combinatorial Drug Discovery by Targeting Epistatic Disease Genes. [Abstract]

2018 Mar 23;23(4). pii: E736. PMID: 29570606
RSC Adv

2018 8:6425-6435.
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Mol Oncol

Loss of GABARAPL1 confers ferroptosis resistance to cancer stem-like cells in hepatocellular carcinoma. [Abstract]

2022 Oct;16(20):3703-3719. PMID: 36062307
Clin Epigenetics

Decitabine regulates the resistance of HCC to sorafenib through demethylation. [Abstract]

2025 Jul 7;17(1):120. PMID: 40624511
Cancers (Basel)

Sorafenib Resistance Contributed by IL7 and MAL2 in Hepatocellular Carcinoma Can Be Overcome by Autophagy-Inducing Stapled Peptides. [Abstract]

2023 Nov 3;15(21):5280. PMID: 37958451
Cancers

CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-b Signaling. [Abstract]

2020 Jun 30;12(7):1737. PMID: 32629802
ACS Omega

Association Study of OATP1B3 Polymorphisms on Hepatic Uptake and Drug-Drug Interaction In Vitro. [Abstract]

2025 Oct 29;10(44):52562-52575. PMID: 41244417
FASEB J

Blocking the ADAM9/ITGAV Pathway Ameliorates Sepsis-Induced Acute Lung Injury by Promoting Macrophage Efferocytosis. [Abstract]

2025 Aug 15;39(15):e70845. PMID: 40736047
J Clin Transl Hepatol

HBx Facilitates Drug Resistance in Hepatocellular Carcinoma via CD133-regulated Self-renewal of Liver Cancer Stem Cells. [Abstract]

2025 Jan 28;13(1):15-24. PMID: 39801781
J Mol Med (Berl)

c-Met up-regulates the expression of PD-L1 through MAPK/NF-κBp65 pathway. [Abstract]

2022 Apr;100(4):585-598. PMID: 35122106
iScience

Phospho-JNK agonists show promising effects for the treatment of hepatocellular carcinoma. [Abstract]

2026 May 20;29(6):116005. PMID: 42211113
Oncol Res

Apatinib modulates sorafenib-resistant hepatocellular carcinoma through inhibiting the EGFR/JNK/ERK signaling pathway. [Abstract]

2025 May 29;33(6):1459-1472. PMID: 40486881
Transl Oncol

Targeting STK26 and ATG4B: miR-22-3p as a modulator of autophagy and tumor progression in HCC. [Abstract]

2024 Nov 27:51:102214. PMID: 39608212
iScience

SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma. [Abstract]

2023 May 29;26(7):106994. PMID: 37534166
Virol Sin

Identification of a receptor tyrosine kinase inhibitor CP-724714 inhibits SADS-CoV related swine diarrhea coronaviruses infection in vitro. [Abstract]

2023 Oct;38(5):778-786. PMID: 37406816
Sci Rep

Chemotherapy-derived DAMPs drive reprogramming of tumor-associated macrophages toward a pro-inflammatory phenotype in hepatocellular carcinoma. [Abstract]

2026 Apr 3;16(1):17440. PMID: 41933190
J Biotechnol

FRET two-hybrid assay-based target drug screening in living cells. [Abstract]

2025 Nov 12:410:1-9. PMID: 41238124
Sci Rep

SLC25A39 regulates Hedgehog signaling to promote tumor progression and sorafenib resistance in hepatocellular carcinoma. [Abstract]

2025 Oct 15;15(1):36061. PMID: 41093994
Sci Rep

Sorafenib-treated Th9 cells exhibit superior anti-tumor effect in lung metastasis. [Abstract]

2025 Aug 7;15(1):28871. PMID: 40775250
Sci Rep

Dimethyl fumarate abrogates hepatocellular carcinoma growth by inhibiting Nrf2/Bcl-xL axis and enhances sorafenib's efficacy. [Abstract]

2025 May 14;15(1):16724. PMID: 40369009
Sci Rep

Novel use of FDA-approved drugs identified by cluster analysis of behavioral profiles. [Abstract]

2022 Apr 21;12(1):6120. PMID: 35449173
Oncol Rep

EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer. [Abstract]

2021 Feb;45(2):776-785. PMID: 33416143
Oncol Rep

Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib. [Abstract]

2018 Sep;40(3):1525-1532. PMID: 30015938

Sorafenib purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Sep;40(3):1525-1532. [Abstract]

SMMC-7721 and HepG2 cells are treated with 4 µM Sorafenib and 100 µM Berberine alone or in combination (4 µM Sorafenib+100 µM Berberine) for 72 h, and the expression levels of apoptosis-associated proteins are measured by western blot analysis.
Sci Rep

Glycosylation-dependent galectin-1/neuropilin-1 interactions promote liver fibrosis through activation of TGF-β- and PDGF-like signals in hepatic stellate cells. [Abstract]

2017 Sep 8;7(1):11006. PMID: 28887481
Oncol Rep

Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1. [Abstract]

2017 Jan;37(1):273-280. PMID: 27878301
Dig Liver Dis

Tumor suppressor CLCA1 inhibits angiogenesis via TGFB1/SMAD/VEGF cascade and sensitizes hepatocellular carcinoma cells to Sorafenib. [Abstract]

2024 Jan;56(1):176-186. PMID: 37230858
J Pharmacol Exp Ther

Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis. [Abstract]

2017 Aug;362(2):219-229. PMID: 28515157

Sorafenib purchased from MedChemExpress. Usage Cited in: J Pharmacol Exp Ther. 2017 Aug;362(2):219-229. [Abstract]

The combination of sorafenib and CAI induces apoptosis in NSCLC. Effect of 10 μM CAI and/or 5 μM Sorafenib on the expression of cleaved PARP and cleaved caspase-. Protein levels of cleaved PARP and cleaved caspase-3 from treated cell lysates are normalized against GAPDH levels.
ACS Chem Biol

Internal Structure and Preferential Protein Binding of Colloidal Aggregates. [Abstract]

2017 Jan 20;12(1):282-290. PMID: 27983786
ACS Chem Biol

Stable Colloidal Drug Aggregates Catch and Release Active Enzymes. [Abstract]

2016 Apr 15;11(4):992-1000. PMID: 26741163
Bioengineering (Basel)

Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]

2025 Oct 19;12(10):1121. PMID: 41155119
Cell Signal

Natural exosome-like nanovesicles from Salvia chinensis Benth induce ferroptosis to suppress hepatocellular carcinoma progression via AMPK/Nrf2/xCT axis. [Abstract]

2025 Jun 6:111928. PMID: 40484104
Cell Signal

Sorafenib inhibits multiple sclerosis by regulating T cell differentiation. [Abstract]

2025 Sep:133:111872. PMID: 40389044
Biochim Biophys Acta Mol Cell Res

Salinomycin inhibits SREBP1 to sensitize ferroptosis and ameliorate sorafenib resistance in clear cell renal cell carcinoma. [Abstract]

2025 May 11:119989. PMID: 40360020
PLoS Genet

TRIM21 modulates stability of pro-survival non-coding RNA vtRNA1-1 in human hepatocellular carcinoma cells. [Abstract]

2025 Mar 17;21(3):e1011614. PMID: 40096176
Cell Signal

Nuclear export of PML promotes p53-mediated apoptosis and ferroptosis. [Abstract]

2024 Jun 27:111278. PMID: 38944257
Heliyon

Naringenin enhances the efficacy of ferroptosis inducers by attenuating aerobic glycolysis by activating the AMPK-PGC1α signalling axis in liver cancer. [Abstract]

2024 May 31;10(11):e32288. PMID: 38912485
Heliyon

Paeoniflorin increases the anti-tumor efficacy of sorafenib in tumor-bearing mice with liver cancer via suppressing the NF-κb/PD-l1 axis. [Abstract]

2024 Jan 13;10(2):e24461. PMID: 38312647
Biology (Basel)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2. [Abstract]

2023 Oct 16;12(10):1337. PMID: 37887047
Med Oncol

The natural medicinal fungus Huaier promotes the anti-hepatoma efficacy of sorafenib through the mammalian target of rapamycin-mediated autophagic cell death. [Abstract]

2022 Sep 29;39(12):221. PMID: 36175804
Exp Cell Res

12 T high static magnetic field suppresses osteosarcoma cells proliferation by regulating intracellular ROS and iron status. [Abstract]

2022 Aug 15;417(2):113223. PMID: 35643180
Exp Cell Res

Dichloroacetate enhances the anti-tumor effect of sorafenib via modulating the ROS-JNK-Mcl-1 pathway in liver cancer cells. [Abstract]

2021 Sep 1;406(1):112755. PMID: 34332981
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
NPJ Syst Biol Appl

Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma. [Abstract]

2019 Aug 16:5:29. PMID: 31452933
Eur J Med Res

Long non-coding RNA NORAD serves as a promoter of oncogenesis and inhibits ferroptosis via miR-144-3p-mTOR-ferritinophagy axis in cancer. [Abstract]

2025 Aug 4;30(1):704. PMID: 40760677
BMC Complement Med Ther

Therapeutic efficacy of sorafenib and plant-derived phytochemicals in human colorectal cancer cells. [Abstract]

2023 Jun 26;23(1):210. PMID: 37365571
Saudi Pharm J

Development and validation of a UPLC-MS/MS method for simultaneous detection of doxorubicin and sorafenib in plasma: Application to pharmacokinetic studies in rats. [Abstract]

2023 Jul;31(7):1317-1326. PMID: 37323919
J Hepatocell Carcinoma

Inhibitory Effects of Esculetin on Liver Cancer Through Triggering NCOA4 Pathway-Mediation Ferritinophagy in vivo and in vitro. [Abstract]

2023 Apr 11:10:611-629. PMID: 37069958
Phytochemistry

Five undescribed steroids from Talaromyces stipitatus and their cytotoxic activities against hepatoma cell lines. [Abstract]

2021 Sep:189:112816. PMID: 34087503
PLoS Negl Trop Dis

Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]

2019 Aug 20;13(8):e0007681. PMID: 31430351
BMC Cancer

Sphere-forming culture enriches liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as a potential therapeutic target. [Abstract]

2019 Aug 1;19(1):760. PMID: 31370822
Endocrinology

TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice. [Abstract]

2023 Aug 28;164(10):bqad135. PMID: 37702560
Front Oncol

Silenced LINC01134 Enhances Oxaliplatin Sensitivity by Facilitating Ferroptosis Through GPX4 in Hepatocarcinoma. [Abstract]

2022 Jul 8;12:939605. PMID: 35875091
Front Oncol

Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. [Abstract]

2021 Jul 13:11:704042. PMID: 34327143
J Cancer

SREBP1-SCD1 enhanced MUFAs Biosynthesis drives Nutrient Deprived Pancreatic cancer cell Ferroptosis Resistance. [Abstract]

2025 Sep 8;16(13):3960-3971. PMID: 41049011
NAR Cancer

Regulation of angiogenesis and cancer cell proliferation by human vault RNA1-2. [Abstract]

2025 Aug 30;7(3):zcaf028. PMID: 40918645
Mol Carcinog

CYP4F11, an NRF2 Target Gene, Promotes Hepatocellular Carcinoma Cell Growth. [Abstract]

2025 Jul;64(7):1264-1274. PMID: 40329467
Mol Carcinog

Transmembrane protein 147, as a potential Sorafenib target, could expedite cell cycle process and confer adverse prognosis in hepatocellular carcinoma. [Abstract]

2023 Sep;62(9):1295-1311. PMID: 37212496
Environ Toxicol

Tanshinone IIA inhibits gastric cancer cell stemness through inducing ferroptosis. [Abstract]

2022 Feb;37(2):192-200. PMID: 34661962
J Cancer

The Inhibitory Effects of Recombinant Hespintor Combined with Sorafenib on Transplanted Human Hepatoma in Nude Mice, and Transcriptional Regulation of Hespintor Based on RNA-Seq. [Abstract]

2021 Jan 1;12(2):343-357. PMID: 33391431
Int J Med Sci

LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells. [Abstract]

2021 Jan 29;18(6):1456-1464. PMID: 33628103
Am J Hypertens

Mineralocorticoid Receptor in Endothelial Cells Contributes to Vascular Endothelial Growth Factor Receptor Inhibitor-Induced Vascular and Kidney Damage. [Abstract]

2025 Jan 16;38(2):104-110. PMID: 39514632
Front Biosci (Landmark Ed)

Downregulation of MTHFD2 Inhibits Proliferation and Enhances Chemosensitivity in Hepatocellular Carcinoma via PI3K/AKT Pathway. [Abstract]

2024 Jan 19;29(1):35. PMID: 38287824
Kaohsiung J Med Sci

Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression. [Abstract]

2022 Feb;38(2):157-164. PMID: 35142429
Mol Immunol

Sophora tonkinensis reprograms tumor-associated macrophages to M1-like phenotype and exerts anti-hepatocellular carcinoma effects. [Abstract]

2026 Mar:191:49-59. PMID: 41666700
Curr Issues Mol Biol

Exploring the Molecular Mechanism of 1,25(OH)2D3 Reversal of Sorafenib Resistance in Hepatocellular Carcinoma Based on Network Pharmacology and Experimental Validation. [Abstract]

2025 Apr 29;47(5):319. PMID: 40699718
Diseases

Examining the Effects of Dasatinib, Sorafenib, and Nilotinib on Vascular Smooth Muscle Cells: Insights into Proliferation, Migration, and Gene Expression Dynamics. [Abstract]

2023 Oct 23;11(4):147. PMID: 37873791
Mol Cell Probes

Circular RNA ITCH increases sorafenib-sensitivity in hepatocellular carcinoma via sequestering miR-20b-5p and modulating the downstream PTEN-PI3K/Akt pathway. [Abstract]

2023 Feb:67:101877. PMID: 36442661
Discov Oncol

Activating the Hippo pathway by nevadensin overcomes Yap-drived resistance to sorafenib in hepatocellular carcinoma. [Abstract]

2023 May 27;14(1):83. PMID: 37243813

Sorafenib purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2023 May 27;14(1):83. [Abstract]

Sorafenib (0.25, 0.5, 1, 2, 4, 6 µM; 24 h) significantly inhibits the cell viability of HepG2 and Hep3B.

Sorafenib purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2023 May 27;14(1):83. [Abstract]

Sorafenib (3 µM; 24 h) significantly inhibits the cell proliferation of HepG2 and Hep3B.
Am J Cancer Res

Combination of sorafenib and Valproic acid synergistically induces cell apoptosis and inhibits hepatocellular carcinoma growth via down-regulating Notch3 and pAkt. [Abstract]

2017 Dec 1;7(12):2503-2514. PMID: 29312803

Sorafenib purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2017 Dec 1;7(12):2503-2514. [Abstract]

VPA potentiates anti-tumor effects of Sorafenib tosylate in vivo. The expression of cleaved caspase9, cleaved caspase3, cleaved PARP from tumor tissue homogenates are analyzed by western blot.
J Chromatogr B Analyt Technol Biomed Life Sci

Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients. [Abstract]

2024 Apr 15:1237:124100. PMID: 38547701
Int J Biochem Cell Biol

Valproic acid overcomes sorafenib resistance by reducing the migration of Jagged2-mediated Notch1 signaling pathway in hepatocellular carcinoma cells. [Abstract]

2020 Sep;126:105820. PMID: 32750425
J Chromatogr B Analyt Technol Biomed Life Sci

Investigation of the effect of plasma albumin levels on regorafenib-induced hepatotoxicity using a validated liquid chromatography-tandem mass spectrometry method. [Abstract]

2017 Sep 1:1061-1062:220-224. PMID: 28750235
Toxicol Mech Methods

A novel in vitro assay for rapid screening of embryotoxicity in multiple species. [Abstract]

2025 Sep 10:1-8. PMID: 40908820
Toxicol In Vitro

Increased effects of 2,5-dimethylcelecoxib on sensitivity of hepatocellular carcinoma cells to sorafenib via CYP3A5 expression and activation of AMPK. [Abstract]

2021 Oct:76:105226. PMID: 34293431
PLoS One

A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery. [Abstract]

2024 Nov 1;19(11):e0308647. PMID: 39485774
Clin Transl Oncol

FAT4 loss promotes tumor growth and ferroptosis resistance in hepatocellular carcinoma via PI3K/AKT pathway activation. [Abstract]

2026 Mar 14. PMID: 41832339
Fundam Clin Pharmacol

Valproic acid reverses sorafenib resistance through inhibiting activated Notch/Akt signaling pathway in hepatocellular carcinoma. [Abstract]

2021 Aug;35(4):690-699. PMID: 33015852
Prostate

MicroRNA181c inhibits prostate cancer cell growth and invasion by targeting multiple ERK signaling pathway components. [Abstract]

2018 Apr;78(5):343-352. PMID: 29341215
Can J Gastroenterol Hepatol

Hsa_circ_0006988 Promotes Sorafenib Resistance of Hepatocellular Carcinoma by Modulating IGF1 Using miR-15a-5p. [Abstract]

2022 Dec 24:2022:1206134. PMID: 36594050
Biomed Res Int

A Pharmacokinetic Interaction Study of Sorafenib and Iced Teas in Rats Using UPLC-MS/MS: An Illustration of Beverage-Drug Interaction. [Abstract]

2019 Nov 28;2019:2410845. PMID: 31871933
Biochem Biophys Res Commun

Natural exosome-like nanovesicles from Smilax China rhizome induce mitophagy-dependent ferroptosis in hepatocellular carcinoma via GPX4/ACSL4 axis. [Abstract]

2026 Feb 12:800:153270. PMID: 41529459
BMJ Open Ophthalmol

Impact of anticancer drugs on human Tenon's fibroblast proliferation: implications for glaucoma surgery. [Abstract]

2026 Jan 12;11(1):e002307. PMID: 41526033
Biochem Biophys Res Commun

Targeted co-delivery of PD-L1 monoclonal antibody and sorafenib to circulating tumor cells via platelet-functionalized nanocarriers. [Abstract]

2023 Sep 3:671:335-342. PMID: 37327705
Biochem Biophys Res Commun

The deubiquitinating enzyme USP20 regulates the stability of the MCL1 protein. [Abstract]

2022 Feb 19:593:122-128. PMID: 35063767
Biochem Bioph Res Co

Functional loss of TAGLN inhibits tumor growth and increases chemosensitivity of non-small cell lung cancer. [Abstract]

2020 Sep 3;529(4):1086-1093. PMID: 32819569
Liver Res

2025 Sep 22.
Endocr J

Effects of sorafenib and an adenylyl cyclase activator on in vitro growth of well-differentiated thyroid cancer cells. [Abstract]

2017 Nov 29;64(11):1115-1123. PMID: 28855436

Sorafenib purchased from MedChemExpress. Usage Cited in: Endocr J. 2017 Nov 29;64(11):1115-1123. [Abstract]

Effect of Sorafenib on phosphorylation of ERK and AKT. Thyroid cancer cells are treated for 30 minutes with 10 μM Sorafenib, 10 μM Forskolin, and combination therapy of 10 μM Sorafenib with 10 μM Forskolin. The levels of ERK and AKT phosphorylation are examined by immunoblot analysis. β-actin is used as the control. Sorafenib suppresses phosphorylation of ERK, but not of AKT.

Sorafenib purchased from MedChemExpress. Usage Cited in: Endocr J. 2017 Nov 29;64(11):1115-1123. [Abstract]

Effect of Sorafenib and Forskolin on expression of CDK4 and CDK regulatory proteins. Thyroid cancer cells are treated for 24 hours with 10 μM Sorafenib, 10 μM Forskolin, and combination therapy of 10 μM Sorafenib with 10 μM Forskolin. The expression of cyclin D1, CDK4, and phosphorylation of RB are examined by immunoblot analysis. β-actin is used as the control. The combination therapy suppresses expression of cyclin D1, and Forskolin monotherapy suppresses expression of cyclin D1 in TPC-1 and W
Int J Environ Health Res

Investigation of synergistic effects of silver nanoparticles with sorafenib on in vitro prostate and head and neck cancer models. [Abstract]

2025 Apr 24:1-9. PMID: 40270101
Clin Med Insights Oncol

Exploring the Clinical Implications of RPL3 Presence in BRCA-Associated Cancers: Unraveling the Interplay With Cancer Immunity. [Abstract]

2024 Oct 16:18:11795549241285387. PMID: 39429685
Ann Med Surg (Lond)

Synergistic mechanism of Shengyang Shiyiwei Pill in enhancing bevacizumab efficacy for hepatocellular carcinoma-associated ascites. [Abstract]

2025 Nov 25;88(1):290-302. PMID: 41496997
Scand J Immunol

IL-6 upregulates the expression of IL-6R through the JAK2/STAT3 signalling pathway to promote progression of hepatocellular carcinoma. [Abstract]

2023 Jul;98(1):e13271. PMID: 38441314
Am J Transl Res

ETS-1/c-Met drives resistance to sorafenib in hepatocellular carcinoma. [Abstract]

2023 Feb 15;15(2):896-913. PMID: 36915773
Am J Transl Res

Phenformin synergistically sensitizes liver cancer cells to sorafenib by downregulating CRAF/ERK and PI3K/AKT/mTOR pathways. [Abstract]

2021 Jul 15;13(7):7508-7523. PMID: 34377232
Am J Transl Res

CXCR3 confers sorafenib resistance of HCC cells through regulating metabolic alteration and AMPK pathway. [Abstract]

2020 Mar 15;12(3):825-836. PMID: 32269715
Braz J Med Biol Res

MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling. [Abstract]

2021 May 31;54(9):e10390. PMID: 34076140
Integr Biol (Camb)

Structural insights and influence of V599 mutations on the overall dynamics of BRAF protein against its kinase domains. [Abstract]

2018 Oct 15;10(10):646-657. PMID: 30229251
Int J Clin Exp Pathol

2017;10(3):3033-3042.
Int J Clin Exp Pathol

SOX9 was involved in TKIs resistance in renal cell carcinoma via Raf/MEK/ERK signaling pathway. [Abstract]

2015 Apr 1;8(4):3871-81. PMID: 26097571

Sorafenib purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]

The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/SU 11248 (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by Western blot (with GAPDH as internal control).

Sorafenib purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]

The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/SU 11248 (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by RT-PCR (with β-actin as internal control).
bioRxiv

2026 Jun 11.
chemRxiv

2026 May 17.
bioRxiv

2026 May 19.
bioRxiv

2026 Apr 16.
bioRxiv

2026 Apr 24.
chemRxiv

2026 Apr 6.
bioRxiv

2026 Mar 31.
Res Sq

2026 Mar 18.
bioRxiv

2025 Oct 15.
bioRxiv

Closing the loop: Teaching single-cell foundation models to learn from perturbations. [Abstract]

2025 Jul 12:2025.07.08.663754. PMID: 40672312
Res Sq

2025 Jul 13.
Res Sq

2024 Sep 16.
SSRN

2024 Oct 16.
Research Square Preprint

2023 Nov 11.
SSRN

2023 Apr 24.
Research Square Preprint

2023 Mar 29.
Research Square Print

2023 Feb 20.
SSRN

2023 Jan 27.
Research Square Print

October 3rd, 2022.
Evid Based Complement Alternat Med

Effects of Sensitized Sorafenib with a Paeoniflorin and Geniposide Mixture on Liver Cancer via the NF- κ B-HIF-2 α-SerpinB3 Pathway. [Abstract]

2022 Oct 15:2022:1911311. PMID: 36285158
Patent

US20220305013A1.
Research Square Preprint

2022 Jul.
Research Square Preprint

2022 May.
Research Square Preprint

2022 Jan.
Journal of Pharmaceutical Research International

33(47B): 274-279, 2021.
Research Square Preprint

2021 Aug.
Advances in Parkinsons Disease

2021, 10, 1-13.
Pak J Zool

2021 May.
bioRxiv

2021 Jan 25.
University of Toronto

2019 Aug.
Math Biosci Eng

Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinoma. [Abstract]

2019 Jul 8;16(6):6319-6334. PMID: 31698564
Personalized Medicine Universe

2019 May.
Patent

US20180263995A1.
Oncotarget

Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma. [Abstract]

2017 Oct 6;8(52):90185-90196. PMID: 29163820
Oncotarget

Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma. [Abstract]

2017 May 2;8(18):29771-29784. PMID: 28404959

Sorafenib purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 May 2;8(18):29771-29784. [Abstract]

Sorafenib inhibits Pin1 biosynthesis and accumulation in Huh7 and HepG2 cells. Cells are treated with 5 or 10 μM Sorafenib for indicated times. Pin1 protein expression is determined by Western Blot.
Chem Cent J

Simultaneous determination of newly developed antiviral agents in pharmaceutical formulations by HPLC-DAD. [Abstract]

2017 Jan 3:11:1. PMID: 28101128
Am J Dig Dis (Madison)

2015;2(2):95-99.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 45 mg/mL (96.81 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1513 mL

10.7566 mL

21.5132 mL

5 mM

0.4303 mL

2.1513 mL

4.3026 mL

10 mM

0.2151 mL

1.0757 mL

2.1513 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 2% DMSO 40% PEG300 5% Tween-80 53% Saline

Solubility: ≥ 3 mg/mL (6.45 mM); Clear solution

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (4.47 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 4

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (307 KB)
SDS (597 KB)
- English - EN (597 KB)
- Français - FR (597 KB)
- Deutsch - DE (597 KB)
- Norwegian - NO (597 KB)
- Español - ES (597 KB)
- Swedish - SV (597 KB)
- Italian - IT (597 KB)
- Portuguese - PT (597 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Wilhelm SM, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099-7109. [Content Brief]

[2]. Heim M, et al. The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs. 2005;16(2):129-136. [Content Brief]

[3]. Gu FM, et al. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World J Gastroenterol. 2011;17(34):3922-3932. [Content Brief]

[4]. El-Ashmawy NE, et al. Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor. Clin Exp Med. 2017;17(2):185-191. [Content Brief]

[5]. Li M, et al. Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer. Br J Cancer. 2017;117(7):974-983. [Content Brief]

[6]. Jin W, et al. Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1. Oncol Rep. 2017;37(1):273-280. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1513 mL	10.7566 mL	21.5132 mL	53.7831 mL
	5 mM	0.4303 mL	2.1513 mL	4.3026 mL	10.7566 mL
	10 mM	0.2151 mL	1.0757 mL	2.1513 mL	5.3783 mL
	15 mM	0.1434 mL	0.7171 mL	1.4342 mL	3.5855 mL
	20 mM	0.1076 mL	0.5378 mL	1.0757 mL	2.6892 mL
	25 mM	0.0861 mL	0.4303 mL	0.8605 mL	2.1513 mL
	30 mM	0.0717 mL	0.3586 mL	0.7171 mL	1.7928 mL
	40 mM	0.0538 mL	0.2689 mL	0.5378 mL	1.3446 mL
	50 mM	0.0430 mL	0.2151 mL	0.4303 mL	1.0757 mL
	60 mM	0.0359 mL	0.1793 mL	0.3586 mL	0.8964 mL
	80 mM	0.0269 mL	0.1345 mL	0.2689 mL	0.6723 mL

Sorafenib

292 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Sorafenib

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Anti-COVID-19 Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Targeted Therapy Drug Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cytokine Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radiosensitizer Library

Mitophagy Compound Library

Bioactive Compound Library Max

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library